Programme Friday, 11 April 2025 
	SP1	08:30 - 10:30	Hall 0 Special Session Antimicrobial Stewardship in Different Scenarios Chairs	Murat Akova (Ankara, Türkiye) Andre Fuchs (Augsburg, Germany) Maddalena Giannella (Bologna, Italy) Angela Huttner (Geneva, Switzerland) Benedikt Huttner (Geneva, Switzerland) Jose Ramon Pano-Pardo (Zaragoza, Spain) Galadriel Pellejero-Sagastizábal (Zaragoza, Spain) Holger Rohde (Hamburg, Germany) Oana Sandulescu (Bucharest, Romania) Jeroen Schouten (Nijmegen, Netherlands) Valentijn Schweitzer (Utrecht, Netherlands) Thomas Tängdén (Uppsala, Sweden) Suzanne Van Asten (Nijmegen, Netherlands) Dafna Yahav (Ramat-Gan, Israel) Co-organised with: ESCMID Education Subcommittee
	EW001	08:30 - 10:30	Hall 2 Educational Session Surgical site infections: principles and practice in the era of multidrug resistance Chairs	Gabriel Birgand (Nantes, France) Efthymia Giannitsioti (Athens, Greece)
	W0001	08:30	Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis?Camilla Rodrigues (Mumbai, India)
	W0002	08:50	Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance	Prasannakumar Palanikumar (Vellore, India)
	W0003	09:10	Screening for MDR GNR coloniSation: is there evidence for prophylaxis	Elisabeth Presterl (Vienna, Austria)
	W0004	09:30	Perioperative prophylaxis in special populations in the era of MDRDivyashree Shanthamurthy (Mumbai, India)
	EW002	08:30 - 10:30	Hall 3 Educational Session Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts Chairs	Shampa Das (Liverpool, United Kingdom) João Paulo Telles (Sao Paulo, Brazil)
	W0005	08:30	Pharmacokinetics 101: navigating the basics for optimal dosing	Linda Aulin (Leiden, Netherlands)
	W0006	08:50	The ABCs of population pharmacokinetic models	Erwin Dreesen (Leuven, Belgium)
	W0007	09:10	Looking into the crystal ball: exploring the fabulous world of PK-PD simulations	Vincent Aranzana-Climent (Poitiers, France)
	W0008	09:30	Decoding population pharmacokinetic papers: interpreting, comparing and discussing results	Iris K. Minichmayr (Vienna, Austria) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
	EW003	08:30 - 10:30	Hall 5 Educational Session Challenges in identification and relevance of slow-growing pathogens Chairs	Kerrie Davies (Leeds, United Kingdom) Yann Dumont (Nancy, France)
	W0009	08:30	Sampling and culturing anaerobes	Hugo Cruz (Porto, Portugal)
	W0010	08:50	I have an anaerobe: what is it and does it matter?Kathleen Boiten (Groningen, Netherlands)
	W0011	09:10	Actinomyces in clinical samples: when is it worth the trouble?Eija Inkeri Könönen (Turku, Finland)
	W0012	09:30	Nocardiosis: when to test and how to manage results?David Lebeaux (Paris, France) Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)
	EW004	08:30 - 10:30	Hall 6 Educational Session A hard nut to crack in HIV Chairs	Yoav Keynan (Winnipeg, Canada) Justyna Kowalska (Warsaw, Poland)
	W0013	08:30	Viral reservoir: what a physician should know	Ivailo Alexiev (Sofia, Bulgaria)
	W0014	08:50	Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians	Jose Arribas (Madrid, Spain)
	W0015	09:10	Chronic vascular and pulmonary disease and HIV: what can we do about it?Susanne Dam Poulsen (Copenhagen, Denmark)
	W0016	09:30	Opportunistic infections: most common and most deadly	Milena Stevanovikj (Sopje, North Macedonia, Republic of) Co-organised with: Euroguidelines in Central and Eastern Europe Network Group
	EW005	08:30 - 10:30	Hall 8 Educational Session Diagnostic parasitology in the XXIst century: is microscopy “+” still useful? Chairs	Miriam José Álvarez-Martínez (Barcelona, Spain) Caroline Rönnberg (Stockholm, Sweden)
	W0017	08:30	Artificial Intelligence for the diagnosis of parasitic infections	Bobbi Pritt (Rochester, United States)
	W0018	08:50	Histopathology of parasitic infections	Richard Bradbury (Townsville, Australia)
	W0019	09:10	Molecular diagnosis v	s. microscopy in the diagnosis of parasitic infections	Sitara Sr Ajjampur (Vellore, India)
	W0020	09:30	Paleoparasitology: what diagnostic tools?Ayman El- Badry (Cairo, Egypt) Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)
	EW006	08:30 - 10:30	Hall 9 Educational Session Vaccine hesitancy: from issues to solutions through developing communication skills Chairs	Monia Chemais (Soignies, Belgium) Petar Velikov (Sofia, Bulgaria)
	W0021	08:30	Vaccine hesitancy and its consequences	Noni Macdonald (Halifax, Canada)
	W0022	08:50	Why are patients and parents hesitant about vaccination?Eve Dube (Quebec City, Canada)
	W0023	09:10	Using social media to deal with vaccine hesitancy	Muge Cevik (St Andrews, United Kingdom) 
	W0024	09:30	Strengthening vaccine confidence in patients and parents	Tba Co-organised with: ESCMID Vaccine Study Group (EVASG)
	SP2	11:00 - 12:00	Hall 0 Special Session Principles of systematic reviews (with and without meta-analysis) Chairs	Chiara Iaria (Palermo, Italy) Miranda Langendam (Amsterdam, Netherlands) Blin Nagavci (Gjakove, Kosovo) Mical Paul (Haifa, Israel) Luigia Scudeller (Pavia, Italy) Co-organised with: ESCMID Education Subcommittee
	ME007	11:00 - 12:00	Hall 2 Meet-the-Expert How to interpret resistance patterns from antibiograms
	M0025	11:00	Tommaso Giani (Florence, Italy)
	M0026	11:12	Diaz Lorena (Santiago, Chile)
	ME008	11:00 - 12:00	Hall 3 Meet-the-Expert Children are not just small adults: interactive paediatric cases
	M0027	11:00	Julie Toubiana (Paris, France)
	M0028	11:12	Sanjay Patel (Winchester, United Kingdom)
	ME009	11:00 - 12:00	Hall 5 Meet-the-Expert How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections
	M0029	11:00	Kushlani Jayatilleke (Battaramulla, Sri Lanka)
	M0030	11:12	Walter Zingg (Zurich, Switzerland)
	ME010	11:00 - 12:00	Hall 6 Meet-the-Expert Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience
	M0031	11:00	Ecaterina Noroc (Chisinau, Moldova, Republic of)
	M0032	11:12	Fakhriddin Nizamov (Almaty, Kazakhstan) Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)
	ME011	11:00 - 12:00	Hall 8 Meet-the-Expert Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare
	M0033	11:00	Jaime Esteban (Madrid, Spain)
	M0034	11:12	Philippe Morand (Paris, France) Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC)
	ME012	11:00 - 12:00	Hall 9 Meet-the-Expert How to understand infectious disease risks in changing climates
	M0035	11:00	Kimberly Fornace (Singapore, Singapore)
	M0036	11:12	Rachel Lowe (Barcelona, Spain)
	SP3	13:30 - 14:30	Hall 0 Special Session Top five mistakes in Infection prevention and control Chairs	Maeve Doyle (Waterford, Ireland) Barbara Juliane Holzknecht (Copenhagen, Denmark) David Ong (Zoetermeer, Netherlands) Arjana Tambic Andrasevic (Zagreb, Croatia) Co-organised with: ESCMID Education Subcommittee
	ME013	13:30 - 14:30	Hall 2 Meet-the-Expert Orthopaedic implant infections: new approaches for improved outcomes
	M0037	13:30	Marjan Wouthuyzen-Bakker (Groningen, Netherlands)
	M0038	13:42	Trisha Peel (Melbourne, Australia) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)
	ME014	13:30 - 14:30	Hall 3 Meet-the-Expert Timing of antimicrobials in sepsis and septic shock - the sooner the better?
	M0039	13:30	Laura Evans (Seattle, United States)
	M0040	13:42	Evangelos Giamarellos-Bourboulis (Athens, Greece) Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)
	ME015	13:30 - 14:30	Hall 5 Meet-the-Expert Pr	EP in Europe: Current gaps and solutions
	M0041	13:30	Teymur Noori (Stockholm, Sweden)
	M0042	13:42	Milosz Parczewski (Szczecin, Poland) Co-organised with: European AIDS Clinical Society (EACS)
	ME016	13:30 - 14:30	Hall 6 Meet-the-Expert Short regimens for treating drug-susceptible and drug-resistant tuberculosis: Insights from guidelines 
	M0043	13:30	Daria Podlekareva (Copenhagen, Denmark)
	M0044	13:42	Raquel Duarte (Porto, Portugal) Co-organised with: European Respiratory Society (ERS)
	ME017	13:30 - 14:30	Hall 8 Meet-the-Expert How to navigate Risk Communication in Public Health
	M0045	13:30	Christina Rolfheim-Bye (Oslo, Norway)
	M0046	13:42	Marius Gilbert (Brussels, Belgium) Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)
	ME018	13:30 - 14:30	Hall 9 Meet-the-Expert Do we need antiviral stewardship in immunocompromised hosts? role of cellmediated immunity
	M0047	13:30	Michelle Yong (Melbourne, Australia)
	M0048	13:42	Genovefa Papanicolaou (New York, United States)
	SP4	14:45 - 15:45	Hall 0 Special Session Science Slam - How to Communicate Science with Clarity Chairs	Mary Horgan (Dublin, Ireland) Jaroslav Hrabak (Plzen, Czech Republic) Nina Khanna (Basel, Switzerland) Preeti Malani (Ann Arbor, United States) Emily G. Mcdonald (Montreal, Canada) Joshua Nosanchuk (Bronx, United States) Jesús Rodríguez-Baño (Seville, Spain) Co-organised with: ESCMID Education Subcommittee
	ME019	14:45 - 15:45	Hall 2 Meet-the-Expert Healthcare-associated CNS infections
	M0049	14:45	Diederik Van De Beek (Amsterdam, Netherlands)
	M0050	14:57	Alexandra Mailles (Paris, France) Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)
	ME020	14:45 - 15:45	Hall 3 Meet-the-Expert Translation of gut microbiome data to clinical practice: a guide for clinicians
	M0051	14:45	Aycan Gundogdu (Kayseri, Türkiye)
	M0052	14:57	Niranjan Nagarajan (Singapore, Singapore) Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)
	ME021	14:45 - 15:45	Hall 5 Meet-the-Expert How to make sense out of guidelines and scientific evidence
	M0053	14:45	Luigia Scudeller (Pavia, Italy)
	M0054	14:57	Blin Nagavci (Gjakove, Kosovo) Co-organised with: ESCMID Guidelines Subcommittee
	ME022	14:45 - 15:45	Hall 6 Meet-the-Expert Multidisciplinary management of bone and joint infections: is there a recipe for success?
	M0055	14:45	Natividad Benito (Barcelona, Spain)
	M0056	14:57	Tiziana Ascione (Naples, Italy) Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)
	ME023	14:45 - 15:45	Hall 8 Meet-the-Expert How to manage and prevent travellers' diarrhoea
	M0057	14:45	Tinja Laaveri (Helsinki, Finland)
	M0058	14:57	David Tribble (Bethesda, United States)
	ME024	14:45 - 15:45	Hall 9 Meet-the-Expert How to diagnose and treat infectious complications in critically ill patients receiving ECMO support
	M0059	14:45	Jordi Riera (Barcelona, Spain)
	M0060	14:57	Giacomo Grasselli (Besana In Brianza, Italy) Co-organised with: European Extracorporeal Life Support Organization (Euro	ELSO)
	SP5	16:15 - 18:15	Hall 0 Special Session Multidisciplinary approach to early sepsis management Chairs	Markus Bald (Lüdenscheid, Germany) Aleksandra Davidovic (Luedenscheid, Germany) Charalambos Dokos (Lüdenscheid, Germany) Co-organised with: ESCMID Education Subcommittee
	EW025	16:15 - 18:15	Hall 2 Educational Session AMR surveillance: current challenges and new perspectives Chair Tomislav Mestrovic (Varazdin, Croatia)
	W0061	16:15	The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden	Authia Gray (Washington, United States)
	W0062	16:35	Networks for surveillance of AMR in animal pathogens	Lucie Collineau (Lyon, France)
	W0063	16:55	Transition to genomic-based methodology for surveillance and outbreak detection to effectively combact AMRCamilla Wiuff Coia (Copenhagen, Denmark)
	W0064	17:15	Implementing and running hospital-wide genomic surveillance of pathogens	Alexander Mellmann (Münster, Germany) Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)
	EW026	16:15 - 18:15	Hall 3 Educational Session New insights into antifungal agents and resistance Chairs	Anuradha Chowdhary (New Delhi, India) Jon Salmanton-Garcia (Cologne, Germany)
	W0065	16:15	Emerging resistance in Candida tropicalis	Sharon Chen (Sydney, Australia)
	W0066	16:35	Mechanisms of resistance in Candida glabrata	David Perlin (Nutley, United States)
	W0067	16:55	Surveillance of resistance in Aspergillus species	Maiken Cavling Arendrup (Copenhagen, Denmark)
	W0068	17:15	Environmental surveillance for antifungal resistance	Eveline Snelders (Wageningen, Netherlands)
	EW027	16:15 - 18:15	Hall 5 Educational Session Going Viral! Phage Therapy Clinical rounds Chairs	Gregory German (Maple, Canada) Ameneh Khatami (Sydney, Australia)
	W0069	16:15	Clinical cases and lessons from the STAMP protocol	Holly Sinclair (Nsw, Australia)
	W0070	16:35	Difficult cases treated with phages	Ghady Haidar (Pittsburgh, United States)
	W0071	16:55	Challenging osteoarticular cases treated with phages	Tristan Ferry (Lyon, France)
	W0072	17:15	Treating urinary tract infections with phages: dream or reality?Saima Aslam (San Diego, United States) Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)
	EW028	16:15 - 18:15	Hall 6 Educational Session Addressing infection challenges in immunocompromised patients: a casebased exploration Chairs	Maddalena Giannella (Bologna, Italy) Asma Nasim (Karachi, Pakistan)
	W0073	16:15	Challenges in managing gastrointestinal infections in patients with primary immunodeficiency	Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)
	W0074	16:35	Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodies	Gemma Reynolds (Heidelberg, Australia)
	W0075	16:55	Mycobacterial infections in patients with HIV infection	Graeme Ayton Meintjes (Observatory, South Africa)
	W0076	17:15	Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation	Dimitrios P. Kontoyiannis (Houston, Tx, United States) Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)
	EW029	16:15 - 18:15	Hall 8 Educational Session Impact of diabetes on infectious diseases: what should we know? Chairs	Mark G. J. De Boer (Leiden, Netherlands) Suzanne Van Asten (Nijmegen, Netherlands)
	W0077	16:15	The impact of diabetes and host-pathogen interaction and gut microbiome	Reinout Van Crevel (Nijmegen, Netherlands)
	W0078	16:35	Diabetes and invasive fungal infections	Jochem Buil (Nijmegen, Netherlands)
	W0079	16:55	Viral infections and diabetes: is there a connection?Malin Flodström-Tullberg (Stockholm, Sweden)
	W0080	17:15	Pathogenesis of diabetic wound infection	Tba
	EW030	16:15 - 18:15	Hall 9 Educational Session Primer on infection prevention and control: the crucial support by clinical microbiology Chairs	Nico Tom Mutters (Bonn, Germany) Margreet C. Vos (Rotterdam, Netherlands)
	W0081	16:15	Microbial fundamentals: building blocks of infection prevention and control	Laurence Armand-Lefevre (Paris, France)
	W0082	16:35	Optimising environmental sampling in infection control: rational use of the microbiology laboratory	John E. Coia (Esbjerg, Denmark)
	W0083	16:55	The crucial role of molecular typing in infection control	Stefanie Kampmeier (Würzburg, Germany)
	W0084	17:15	How can we link diagnostic and antibiotic stewardship?Constantinos Tsioutis (Nicosia, Cyprus) Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee 
Saturday, 12 April 2025 
	SY036	08:30 - 10:30	Hall 15 2-hour Symposium The quality of antibiotics used in the communities of LMICs Chairs	Thi Thuy Nga Do (Ha Noi, Vietnam) Christina Obiero (Kilifi, Kenya)
	S0105	08:30	The quality of antibiotics and their potential impact on patient outcome and AMRPaul Newton (Oxford, United Kingdom)
	S0106	09:00	Community antibiotic access and use in Sub-Sahara Africa	Samuel Afari-Asiedu (Kintampo, Ghana)
	S0107	09:30	Encountered challenges and reflections on conducting multi-country medicine quality studies	Noudy Sengxeu (Vientiane Capital, Lao People's democratic republic)
	S0108	10:00	Confusion in appearance of common used antibiotics in LMICs	Heiman Wertheim (Nijmegen, Netherlands)
	SY031	08:30 - 10:30	Hall 6 2-hour Symposium To screen or not to screen prior to transplant? Chairs	Laura Alicia Barcan (Buenos Aires, Argentina) Oscar Len (Barcelona, Spain)
	S0085	08:30	HHV-8 Screening	Alessandra Mularoni (Palermo, Italy)
	S0086	09:00	TB screening and prevention in endemic regions	Rubina Naqvi (Karachi, Pakistan) 
	S0087	09:30	Screening for and prevention of chagas in immunocompromised hosts	Marcelo Victor Radisic (Buenos Aires, Argentina)
	S0088	10:00	Screening of lung donors for Molicutes	Michael G Ison (Derwood (MD), United States)
	EF003	08:30 - 09:30	Arena 1 e	Poster Flash Session On the frontiers of vaccine driven prevention Chair Maria Ganczak (Zielona Gora, Poland)
	E0021	Changes in dose interval can impact T cell responses but not antibody levels in individuals receiving the modified vaccinia Ankara Mpox vaccine	J. Parsons* (Liverpool, United Kingdom), K. Subramaniam, L. Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P. Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M. Carroll
	E0022	A phase 1 study with an innovative approach for an HIV-1 prophylactic vaccine	P. Garbes* (Newark, United States), C. Chang, H. Wraight, R. Norton, S. Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall, S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M. Giffear, K. Damjanoska, J. Li
	E0023	A Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein–based Vaccine Effectiveness for Preventing RSV Hospitalizations in Older Adults (DAN-RSV): Rationale & Trial Design	M. Lassen* (Copenhagen, Denmark), S. Christensen, N. Johansen, K. Skaarup, D. Modin, B. Claggett, C. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen
	E0024	Six-month Immunogenicity of m	RNA-1345 RSV Vaccine in Adults Aged ≥60 Years	M. Desai* (Cambridge, United States), E. Comstock, L. Lan, A. Kapoor, F. She, C. Reuter, J. Goswami, F. Priddy, R. Das
	E0025	Comparative Immune Responses to Homologous and Heterologous SARS-Co	V-2 Vaccination Using DNA and Protein Platforms	S. Prieto Martin Gil* (Madrid, Spain), S. Prieto Martín Gil, M. López Siles, J.A. Infantes Lorenzo, E. Lorente, D. Fousteris, B. Cano Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato, A. Pérez, M.J. Mcconnell
	E0026	Quantitative correlates of protection against SARSCo	V- 2 variants using individual-level reconstructed antibody kinetics	T. Russell* (London, United Kingdom), E.C. Wall, A.J. Kucharski, J. Hellewell, O. Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D. Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr
	E0027	Effectiveness of the 2023-24 seasonal influenza vaccine in UK healthcare workers: results from the SIREN prospective cohort study	L. Mcgeoch* (London, United Kingdom), S. Foulkes, H. Whitaker, K. Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall
	E0028	Immunogenicity and safety of second COVID-19 booster and Influenza vaccination coadministration	I. Wagenhäuser* (Würzburg, Germany), J. Reusch, J. Mees, A. Gabel, N. Petri, M. Krone
	E0029	The degree of immunization against the Measles virus of the infant population in Sibiu county, Romania	S. Cristea* (Sibiu, Romania), C. Grigore
	EF004	08:30 - 09:30	Arena 3 e	Poster Flash Session Pharmacology from bench to the bedside Chair Alina Karoline Nussbaumer-Pröll (Wien, Österreich, Austria)
	E0030	Enterococcus faecalis impairs Escherichia coli response to antibiotics in a dual-species intracellular infection model	F. Van Bambeke* (Brussels, Belgium), G. Wang
	E0031	In vitro investigations of ceftazidime-avibactam and fosfomycin against carbapenemase-producing Enterobacterales clinical isolates	M. Martens* (Hamburg, Germany), F.M. Docobo-Perez, C. Sauco Carballo, J. Rodriguez-Baño, S. Marchand, L. Keomany, I. Portillo-Calderon, M. Gianella, S. Ambretti, B. Secci, S.G. Wicha
	E0032	In vivo activity and PK of the novel siderophorecephalosporin AR-2126 in a lethal lung infection model in mice infected with a carbapenem-resistant Pseudomonas aeruginosa following subcutaneous administration	W. Wicha* (Bruck An Der Leitha, Austria), S. Paukner
	E0033	Synergistic Potency Unveiled: β-Lactam and β- Lactamase Inhibitor Combination against Mycobacterium abscessus with Dual Action of β- Lactamase Inhibition and Multi-Target Receptor Inactivation	E. Shin* (Cleveland, United States), K.M. Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J. Rubin, J.B. Bulitta, K. Barry, R.A. Bonomo
	E0034	Pharmacokinetic/pharmacodynamic evaluation of benzoxaborole MRX-5 in mouse pneumonia model with Mycobacterium abscessus infection	W. Wang* (Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q. Dai, G. Lamichhane
	E0035	Pharmacokinetic/pharmacodynamic modelling of immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models	R. Saporta* (Uppsala, Sweden), N. Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I. Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg
	E0036	Implementation of a model-based nomogram for amoxicillin precision dosing in patients suspected of infective endocarditis: preliminary results of the NOMOBA-AMX multicentre study	P. Le Turnier* (Cayenne, French Guiana), S. Jamard, A. Lorleac'h, C. Deschanvres, F. Andry, A. Coste, P. Danneels, T. Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R. Lamberet, A. Le Bot, M. Maillet, P. Petitgas, V. Rabier, S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M. Grégoire, A.G. Leroy, M. Wargny, R. Bellouard
	E0037	No time to waste: hospital-wide assessment of IVvial and line residuals and impact on target attainmen	t.D. Vanneste* (Leuven, Belgium), M. Gijsen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters, S. Desmet, E. Dreesen, I. Spriet
	E0038	Population pharmacokinetic modelling of colistin in critically-ill patients on sustained low-efficiency dialysis: implications for dose selection	D. Fuhs* (Parkville, Australia), A. Boonyasiri, T. Naorungroj, L. Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T. Visanu, C. Landersdorfer
	SY034	08:30 - 10:30	Hall 10 2-hour Symposium Endoscopy: infection risks and mitigation Chairs	Elisabeth Presterl (Vienna, Austria) Gordon Ramage (Glasgow, United Kingdom)
	S0097	08:30	Should we be concerned about infection from contaminated endoscopes?Claire Aumeran (Clermont-Ferrand, France)
	S0098	09:00	Prevention of multidrug-resistant infections from contaminated duodenoscopes	Margreet C. Vos (Rotterdam, Netherlands)
	S0099	09:30	Understanding the causes of medical device contamination: it is all biofilm!Roberto Rusconi (Milan, Italy)
	S0100	10:00	Does the European medical Device Regulation bring us safer duodenoscopes?Markus Hell (Salzburg, Austria) Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI) 
	OS002	08:30 - 10:30	Hall 11 2-hour Oral Session Translating metagenomics into clinical practice Chairs	Benjamin Peter Howden (Parkville (Victoria), Australia) Paula Mölling (Örebro, Sweden)
	O0011	Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational study	H.L. Nielsen* (Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B. Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen
	O0012	Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Was	h.J. Alexander* (Orlando, United States), A. Charles
	O0013	Implementing same-day respiratory metagenomic diagnostics in paediatric intensive care	R. Hammond* (London, United Kingdom), A. Kopec, J. Brown, J. Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. Snell, J. Breuer
	O0014	Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy	T. Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle
	O0015	Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomes	E. Siegel* (Mainz, Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. Hamm, D. Teschner, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. Hagge, S. Vieira-Silva, T. Sparwasser
	O0016	Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective study	L.B. Snell* (London, United Kingdom), A. Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J. Whitehorn, G. Nebbia
	O0017	Evaluation of the diagnostic efficacy of targeted nextgeneration sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICU	B. Ran* (Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Zhang, J. Hao, L. Jin, Z. Huang
	O0018	Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistence	C. Peng* (Shiyan, China), S. Qi, C. Jiachang, P. Chunyan, W. Taiquan, X. Xianru, Y. Jianying, Y. Qirong, Z. Pengyuan, L. Jun
	O0019	A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted nextgeneration sequencing (t	NGS)M.H. Nguyen* (Pittsburgh, United States), H. Badrane, B.A. Stevens, S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. Hao, E. Driscoll, W. Maynard, C. Clancy
	O0020	Implementation of Clinical Metagenomics in France: Insights from a Five-Years Study	M. Dutkiewicz* (Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Caméléna, J. Le Goff, M. Salmona
	SY035	08:30 - 10:30	Hall 12 2-hour Symposium Barriers to TB/HIV elimination in low- and high-incidence settings Chair Daria Podlekareva (Copenhagen, Denmark)
	S0101	08:30	HIV and TB epidemic: the storm hasn’t subsided yet	Tetiana Koval (Poltava, Ukraine)
	S0102	09:00	Approaches for latent and active TB screening in people living with HIV Raimonda Matulionyte (Vilnius, Lithuania)
	S0103	09:30	Integration of HIV and TB care to improve patient outcome in resource-limited settings	Akaki Abutidze (Tbilisi, Georgia)
	S0104	10:00	How researchers can influence policy and practice in HIV/TB care	Jens D. Lundgren (Copenhagen, Denmark) Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group
	EW041	08:30 - 10:30	Hall 13 Educational Session RSV infections: diagnosis, surveillance and treatment in the advent of vaccines Chair Monika Redlberger-Fritz (Vienna, Austria)
	W0126	08:30	Costs of RSV infection, compared to other respiratory viruses	Barbara Rath (Besançon, France)
	W0127	08:50	Virology and host interactions of RSV
	W0128	09:10	RSV surveillance in the EU/EEA in the vaccine era	Eeva Broberg (Solna, Sweden)
	W0129	09:30	RSV fusion inhibitors and monoclonals: current status and future developments	Peter Openshaw (London, United Kingdom) Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)
	EW042	08:30 - 10:30	Hall 14 Educational Session Traumatic wound infections: diagnosis and treatment options Chairs	Amparo Fernández-Rodríguez (Madrid, Spain) Veroniek Saegeman (Sint-Niklaas, Belgium)
	W0130	08:30	Multidrug-resistant infections after trauma in warzone	Shehan Hettiaratchy (Hampton, United Kingdom)
	W0131	08:50	Fungal infections during natural disasters	Anuradha Chowdhary (New Delhi, India)
	W0132	09:10	Bacteriophage therapy for multidrug-resistant wound infections in trauma	Tristan Ferry (Lyon, France)
	W0133	09:30	Infection of burn wounds	Nur Benzonana (Istanbul, Türkiye) Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades Infecciosas Microbiología Clinica), International Society of Antimicrobial Chemotherapy (ISAC)
	SY037	08:30 - 10:30	Hall 16 2-hour Symposium Unveiling the challenges: nosocomial infections in ECMO-supported patients Chairs	Antonios Katsounas (Bochum, Germany) Jordi Riera (Barcelona, Spain)
	S0109	08:30	Source of infection and pathogens	Christian Eckmann (Hannover, Germany)
	S0110	09:00	Prophylaxis and empiric treatment	Giacomo Grasselli (Besana In Brianza, Italy)
	S0111	09:30	Diagnostic criteria and definitions	Graeme Maclaren (Singapore, Singapore)
	S0112	10:00	Microbial films	Marta Hernández-Meneses (Barcelona, Spain) Co-organised with: European Extracorporeal Life Support Organization (Euro	ELSO) 
	EW039	08:30 - 10:30	Hall 2 Educational Session Are urinary tract infections still the same? Chairs	Suzanne Geerlings (Amsterdam, Netherlands) Agnes Maria Sonnevend (Pécs, Hungary)
	W0118	08:30	Update on paediatric UTI Michael Buettcher (Luzern, Switzerland)
	W0119	08:50	Diagnosis and treatment of UTI in the era of antimicrobial resistance	Jennifer Kranz (Aachen, Germany)
	W0120	09:10	Can UTI be prevented?Chris Harding (Newcastle Upon Tyne, United Kingdom)
	W0121	09:30	Fungal and parasitic infections of the urinary tract	Gladys Mbwanji (Mwanza, Tanzania, United republic of)
	EW040	08:30 - 10:30	Hall 3 Educational Session OPAT: from aged wine to new vintage Chairs	Birgit Koch (Rotterdam, Netherlands) Sonia Luque (Barcelona, Spain)
	W0122	08:30	OPAT: principles, practice and checklists	Charlotte Quintens (Leuven, Belgium)
	W0123	08:50	COPAT: complex outpatient parenteral antimicrobial therapy Ronald Andrew Seaton (Glasgow, United Kingdom)
	W0124	09:10	Antimicrobial stability and other challenges for OPAT practice? Mark Gilchrist (London, United Kingdom)
	W0125	09:30	New OPAT safety and efficacy data to guide practice	Matthew Rawlins (Murdoch, Australia) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)
	EW038	08:30 - 11:30	Hall 4 Educational Session EUCAST Educational Workshop Chairs	Marlene Amara (Le Chesnay Cedex, France) Alasdair P. Macgowan (Bristol, United Kingdom)
	W0113	08:30	EUCAST update	Sören G. Gatermann (Bochum, Germany)
	W0114	08:50	Setting clinical breakpoints, assessing evidence	Anouk Edwina Muller (The Hague, Netherlands)
	W0115	09:10	Benzylpenicillin susceptibility testing of S. pneumoniae by disk diffusion	Gunnar Kahlmeter (Tävelsås, Sweden)
	W0116	09:30	What to do when there are no breakpoints	Barbara Juliane Holzknecht (Copenhagen, Denmark)
	W0117	09:50	Detection of resistance mechanisms	Christian Giske (Stockholm, Sweden) Co-organised with: EUCAST Steering Committee
	OS001	08:30 - 10:30	Hall 5 2-hour Oral Session One Health means resistance everywhere Chairs	Alessandra Carattoli (Rome, Italy) Prasannakumar Palanikumar (Vellore, India)
	O0001	Decoding the role of bla	CPE-carrying plasmids on wings: A holistic view using the One Health approach	S.A. Martínez-Álvarez* (Logrono, Spain), P. Châtre, T. Cardona-Cabrera, P. François, U. Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres
	O0002	A novel isolation room model leveraging cultureindependent Hi-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs	V. Koh* (Singapore, Singapore), R. Cabrera, J. Chua, J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M. Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng
	O0003	Deciphering the pathogenic potentials and epidemiological identities of Staphylococcus pseudintermedius colonizing companion dogs in Sao Paulo	I.B. Moses* (Sao Paulo, Brazil), L. Sartori, D.A. Henriques, M.M. Marini, F.M. Lima, R.X. Espinosa, I. Orlandino Da Silva, F.F. Santos, L. Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales
	O0004	Recent progress towards integrated surveillance of antimicrobial resistance in France	L. Collineau* (Lyon, France), S. Bareille, G. Birgand, L. Lacmago, B. Lange, O. Lemenand, C. Chauvin
	O0005	Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: Insights into horizontal gene transfer and AMR dissemination	B. Timmer* (Debrecen, Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas- Kiss, L. Laczkó, G. Kardos
	O0006	Emergence of mobile colistin resistance in Klebsiella at human-animal-environment interface in Bangladesh	S. Rahman* (Oxford, United Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R. Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T. Walsh, R. Farzana
	O0007	Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective	I. Singh* (Chandigarh, India), R. Sharma, A. Arora, B. Mohan, N. Taneja
	O0008	Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples	E. Ouranou* (Heraklion, Greece), A. Psaroulaki, D. Chochlakis, M. Malliarou, K. Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos
	O0009	One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison	G. Knight* (London, United Kingdom), R. Booton, J.V. Robotham, K. Aluzaite, D. Belay, J. Guitian, M. Dione, E. Emes
	O0010	Clinically important sequence types and resistance genes in Enterobacteriaceae from coastal environments and gulls	V. Silva* (Lisbon, Portugal), M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G. Igrejas
	SY032	08:30 - 10:30	Hall 7 2-hour Symposium New insights into Candida pathogenesis Chairs	Aleksandra Barac (Belgrade, Serbia) Joshua Nosanchuk (Bronx, United States)
	S0089	08:30	Insights into the evolution of Candida under antifungal pressure	Attila Gacser (Szeged, Hungary)
	S0090	09:00	How do Candida extracellular vesicles modify virulence during disease?Leonardo Nimrichter (Rio De Janeiro, Brazil)
	S0091	09:30	The commensal to pathogen transition: kind to killer	Ilse D. Jacobsen (Jena, Germany)
	S0092	10:00	Fungal-bacterial interactions: who wins?Rebecca Hall (Canterbury, United Kingdom) 
	SY033	08:30 - 10:30	Hall 8 2-hour Symposium Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen population	s. Chairs	Christian Stephan Lentz (Tromsø, Norway) Annelies Zinkernagel (Zurich, Switzerland)
	S0093	08:30	Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infections	Christoph Ernst (Cologne, Germany)
	S0094	09:00	Single-cell imaging and heterogeneity in antimicrobial resistance	Stefano Pagliara (Exeter, United Kingdom)
	S0095	09:30	Single-cell RNAseq and heterogeneity in bacterial transcription	Anna Kuchina (Seattle, United States)
	S0096	10:00	Dissecting the function of individual bacteria in their spatial context	Knut Drescher (Basel, Switzerland)
	SY043	09:30 - 10:30	Hall 1 1-hour Symposium Year in infection control Chairs	Nico Tom Mutters (Bonn, Germany) Ermira Tartari (Msida, Malta)
	S0134	09:30	Andrew James Stewardson (Melbourne, Victoria, Australia)
	S0135	10:00	Kalisvar Marimuthu (Singapore, Singapore)
	EF005	09:30 - 10:30	Arena 2 e	Poster Flash Session It's all in the blood Chair Colin R. Mackenzie (Neuss, Germany)
	E0039	Limited delayed incubation of blood culture bottles has limited effect on yield and time-to-positivity	L. Hardy* (Antwerp, Belgium), A.S. Heroes, E. Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E. Corsmit, B. De Smet
	E0040	Unnecessary clinical interventions due to blood culture contamination in a large Canadian hospital network	C. Hall* (Hamilton, Canada), C. Fuller, S. Ramondino, C. Main
	E0041	Utility of sigmoidal growth curve when no organisms are seen on Gram stain in positive blood cultures	D. Crilly* (London, United Kingdom), A. Bapat, J. Youngs, G. Maloney, E. Drakes
	E0042	Clinical microbiology laboratory consultancy to optimize blood culture workflow: Analysis of results	C. Magri* (Rome, Italy), C. Magrì, G. Menchinelli, D. Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti
	E0043	Comparison of Syndromic Sepsis Panel and Standard Blood Culture Results: Contribution to Patient Management	S. Buyukberber* (Ankara, Türkiye), S. Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H. Dal, T. Kayan
	E0044	Predicting blood culture positivity using machine learning with complete blood and differential counts in a tertiary care hospital of TurkiyeÖ. Türkmen Recen* (Izmir, Türkiye), M. Kıplapınar, H. Özdemir, S. Kurutepe, H. Gazi
	E0045	Performance of direct pathogen and β-lactamase detection workflow using MALDI-TOF MS from positive blood culture specimens	K. Kosai* (Nagasaki, Japan), Y. Kawamoto, K. Yanagihara
	E0046	Waiting for follow-up blood cultures is not always necessary for diagnosis of central line-associated bloodstream infections	L. Van Balen* (Maastricht, Netherlands), R. Koeck
	E0047	Economic and health gains associated with the adoption of the 2-hour phenotypic antimicrobial susceptibility testing in patients with bloodstream infection in Europe	C. Pina-Vaz* (Oporto, Portugal), F. Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro, J.A. Paiva
	EF006	09:30 - 10:30	Arena 4 e	Poster Flash Session Emerging developments in antifungal pharmacology Chair Roger Brüggemann (Nijmegen, Netherlands)
	E0048	NATURE-US: the natural history of antifungal failure in invasive candidiasis	L. Ostrosky-Zeichner* (Houston, United States), P.G. Pappas, M.H. Miceli, A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E. Mc	Kie, M. Middle, M. Kordalewska, D.S. Perlin, D.P. Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo
	E0049	The antidepressant vortioxetine enhances resistance toward multiple azoles	S. Rizzo* (Rome, Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B. Posteraro, M. Sanguinetti, F. Bugli, R. Torelli
	E0050	Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate Exploration	A. Desai* (Northbrook, United States), L. Kovanda
	E0051	Identification of efflux inhibitors for Candida albicans through a drug repurposing strategy	D. Marques* (Lisbon, Portugal), S. Santos Costa, L. Rodrigues
	E0052	Clinical outcomes of micafungin 100 mg v	s. 150 mg daily for the treatment of Candida auris fungemia	J. Hou* (Chicago, Il, United States), Y. Wang, R. Burgos, L. Danziger, E. Drwiega
	E0053	Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: Re	STORE and STRIVE trial pooled analysis	G.R. Thompson* (Davis, California, United States), A. Soriano, M. Bassetti, P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely
	E0054	Ibrexafungerp is effective in treatment of patients with candidiasis, including candidaemia, caused by Candida auris: a multicentre, open-label study (CARES)M.H. Miceli* (Ann Arbor, United States), T.F. Patterson, D. Juneja, G.R. Thompson Ill, P. Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breedt, N. Yaddanapudi, R.S. Siebert, E. Mc	Kie, F. Lewis, M. Middle, M. Hoenigl
	E0055	High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosis	S. Wurster* (Houston, United States), N.D. Albert, N.P. Wiederhold, R.E. Lewis, D.P. Kontoyiannis
	E0056	Pharmacokinetics, pharmacodynamics, safety, and efficacy of innovative dosing schedules of liposomal amphotericin B for treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits	R. Petraitiene* (New York, United States), E. Naing, A. Garcia, V. Zigmantaite, R. Grigaleviciute, A. Pockevicius, M. Zimmerman, A.H. Groll, T.J. Walsh, V. Petraitis
	FO050	11:00 - 12:00	Arena 1 Open Forum HIV: a global ethical Conundrum Chair Seif Al-Abri (Muscat, Oman)
	F0147	11:00	HIV, from key population to general population: a Pandora's Box	Syed Faisal Mahmood (Karachi, Pakistan)
	F0148	11:10	Ethical considerations in preventing mother-to-child HIV transmission Glory Alexander (Bangalore, India)
	F0149	11:20	HIV drug trials in Africa: ethical concerns	Shah Reena (Nairobi, Kenya)
	F0150	11:30	HIV-related stigma and discrimination in the healthcare setting	Teymur Noori (Stockholm, Sweden) Co-organised with: ESCMID Ethics Advisory Committee (EEAC)
	EF014	11:00 - 12:00	Arena 2 e	Poster Flash Session Infection control and prevention around the World Chair Divyashree Shanthamurthy (Mumbai, India)
	E0092	WHO Global Survey on Infection Prevention and Control Minimum Requirements: Laying the Foundation for 2030 Global Targets	P. Bischoff* (Geneva, Switzerland), S. Tomczyk, G. Satta, E. Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R. Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh, B. Allegranzi
	E0093	Healthcare-associated infections in african intensive care units: A muliticentre prospective cohort study	B. Gaye* (Dakar, Senegal), N. Madani, J. Ben Khlil, A. Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M. Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T. Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. Elombila, W. Naija, M. Kahloul, R. Herch, R. Toumi, E. Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. Badis, L. Messaoud, A. Bouzid, S. Feki, H. Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. Faye, L. Ouanes Besbes, Z. Hammouda, M.S. Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy, M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B. Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N. Ben Slimane, F. Kaaniche Medhioub, R. Allala, C. Kaddour, N. Baffoun, R. Hammami, H. Allouche, H. Ghadhoune, S. Soui, H. Hmouda, R. Ben Dabebiss, A. Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O. Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj, H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, R. Abouqal, Y. Coulibaly
	E0094	Epidemiology of community-acquired versus hospital-acquired sepsis in acute hospitals in Ireland - 2016-2022.E. Liddy* (Dublin, Ireland), A. Vellinga, D. Amin
	E0095	Epidemiology of Central Line-Associated Bloodstream Infections (CLABSIs) in a Network of Ten Hospitals across Greece: A 30-Month Surveillance Study – GRIPP-SNF Network	I. Kopsidas* (Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Karaiiskou, D. Kaitelidou, T. Zaoutis, A. Koutsoukou
	E0096	Characterisation of plasmids disseminating antibiotic resistance in Klebsiella pneumoniae isolates from Pretoria, South Africa	T. Govender* (Pretoria, South Africa), A. Moultrie, M. Moodley, J. Featherston, M. Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Liknaitzky, K. Salvador-Oke, A. Smith, I. Arshad, M. Said, M. Ehlers, M. Kock
	E0097	Transmission dynamics of carbapenemaseproducing bacteria between hospital and household settings in Benin	K. Sintondji* (Abomey-Calavi, Benin), V. Dougnon, B. Legba, B.G. Hougbenou, K. Fabiyi, H. Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou
	E0098	Evaluating the impact of a rapid screening test for carbapenem-resistant organisms in Brazilian intensive care unit	s.M. Salomão* (Sao Paulo Sp, Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, G. Mahon, M. Westercamp, M. Chiarastelli Salomao
	E0099	Genomic Insights into the Rapid Rise of Pseudomonas aeruginosa ST463: A High-Risk Clone's Adaptive Strategy in China	X. Dong* (Hangzhou, China)
	E0100	Nanopore long-read only genome assembly for public health surveillance of Enterobacterales bloodstream infections and plasmid epidemiology in England: A pilot study	D. Nagy* (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pennetta, G. Rodger, K. Hopkins, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown
	EF015	11:00 - 12:00	Arena 3 e	Poster Flash Session Advances in the diagnosis and treatment of skin, bone, and joint infections Chair Norma Jung (Köln, Germany)
	E0101	Potential benefits of PET-CT in the management of bone and joint infections in infective endocarditis: a retrospective analysis from the Mayo Clinic	F. Petri* (Milan, Italy), F. Borgonovo, O.K. Mahmoud, R. Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone, A. Gori, E. Berbari
	E0102	Synovial fluid micro	RNA biomarkers enable accurate diagnosis of periprosthetic joint infection	B.J.H. Frank* (Vienna, Austria), T. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A. Diendorfer, M. Hackl, J. Hofstaetter
	E0103	Diagnostic accuracy of 16S r	DNA PCR, multiplex PCR and metagenomic Next-Generation Sequencing in periprosthetic joint infections: a systematic review and meta-analysis	F. Olearo* (Hamburg, Germany), S. El Zein, E. Portillo M, A. Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker
	E0104	Comparison of microbiology, management and outcome between patients with native and with post-surgical vertebral osteomyelitis: a 7-year retrospective study	G. Franceschi* (Modena, Italy), M. Pellegrino, M. Del Monte, A. Bedini, L. Benassi, A. Soffritti, A. Tili, E. Dema, M. Palmisani, A. Veroni, G. Pavesi, M. Cristina
	E0105	Cefiderocol real-life use in bone and joint infection: a retrospective French multicenter study	A. Diarra* (Tourcoing, France), V. Delastours, A. Bleibtreu, H. Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B. Valentin, M. Bermejo, P. Gazeau, A. Baldolli, B. Lefevre, A. Asquier, J. Courjon, R. Larcher, L. Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry, I. Eberl, M. Degrendel, P. Patoz, P.Y. Tortai, O. Robineau, E. Senneville
	E0106	Real-Life Experience with Dalbavancin as Suppressive Antibiotic Treatment in orthopaedic implant-related infection	s.R. Escudero-Sánchez* (Madrid, Spain), S. De La Villa Martínez, A. Rico Nieto, M. Sanchez-Somolinos, M. Tasias Pitarch, M. Salaver Lletí, M. Correa Ballester, R. Blanez Hernández, E. Calabuig Muñoz, M. Montero Alonso, L. Guio Carrion, J. Gomez Junyent, M.L. Sorli, F. Braojos Sanchez, A. Muñoz Gomez, M.J. Nuñez Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J. Perez-Somarribas Moreno, J.M. Barbero Allende, M.J. Garcia Pais, F.J. Martínez Marco, A. Galeote Rivas, B. De La Torre Escuredo, J. Cobo
	E0107	Short or Long Antibiotic Regimes in Orthopaedics: the SOLARIO multicentre randomised controlled trial	M. Dudareva* (Oxford, United Kingdom), M. Scarborough, M. Mcnally, M. Kumin, C. Scarborough, W. Vach, J. Ferguson
	E0108	Clinical and Antibacterial Diversity of Staphylococcal Phenotypes in Skin and Soft Tissue Infections: A Resource-Limited Country Perspectiv	e.F. Zeeshan* (Karachi, Pakistan), A. Naeem, F. Uddin
	E0109	Discrepancy between clinical-radiological diagnosis and surgical confirmation in 62 patients undergoing fasciotomy for suspected necrotizing fasciitis: a 11- year retrospective stud	y.F. Romani* (Modena, Italy), A. Bedini, A. Spadoni, G. Manzini, G. Franceschi, B. Fontana, M. Sarti, C. Mussini 
	EF016	11:00 - 12:00	Arena 4 e	Poster Flash Session Rising threats: antimicrobial resistance in STIs Chair Marcos Rust (Feldkirch, Austria)
	E0110	Important rise of antibiotic resistance of Mycoplasma genitalium, a sexually transmitted pathogen, in a French University hospital	F. Doucet Populaire* (Clamart, France), W. Ben Nejma, C. Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. Guillet-Caruba, N. Bourgeois-Nicolaos
	E0111	Molecular characterization of antimicrobial resistance and genotyping of Mycoplasma genitalium positive samples of the Lisbon area, Portugal	M. Barros* (Lisbon, Portugal), F. Pereira, L. Rodrigues
	E0112	Antimicrobial Resistance in Mycoplasma genitalium: Surveillance and Management in São Paulo, Brazil	V. Passarelli* (São Paulo, Brazil), F. Goldemberg, A. Freitas, C. Picone, C. Lazari, G. Carnevale, M. Thomazella, S. Chamarelli, D. Gennari, C. Pedrozo, G. Hughes, S. Costa
	E0113	Impact of genotypic substitutions on treatment failure for Mycoplasma genitalium infection	N.B. Bana* (Milan, Italy), A. Nava, D. Fanti, C. Vismara, G. Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. Mulè, L. Denti, M. Puoti, R. Rossotti
	E0114	Macrolide-resistant Mycoplasma genitalium: an emerging threat to public health?J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez- Ruiz, A. Valentín-Martín, A. Hernández-Cabezas, J.L. Lopez-Hontangas
	E0115	Comparison of carbapenem MIC in wild-type, MDR and XDR Neisseria gonorrhoeae isolates	J. Brousseau* (Paris, France), A. Braille, M. Mainardis, F. Meunier, M. Mérimèche, F. Caméléna, B. Berçot
	E0116	Unsettling surge in antimicrobial resistance patterns of Neisseria gonorrhoeae - A study from national reference centre in Indi	a.D. Sharma* (Delhi, India), S. Muralidhar, N. Joshi
	E0117	Surveillance of Neisseria gonorrhoeae antimicrobial resistance rate and treatment regimes in Singapore from 2014 to 2024M. Giovanni* (Singapore, Singapore), A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S. Goh, S.T. Koh, Y.E. Tan
	E0118	Molecular surveillance results of N. gonorrhoeae in Korea	K.H. Roh* (Goyang, Korea, Republic of), C. Liu, Y.H. Suh, H. Lee, K. Lee
	KN044	11:00 - 12:00	Hall 1 Keynote Lecture Asia: an AMR Hot Zone Chairs	Giulia De Angelis (Rome, Italy) Robert Leo Skov (Copenhagen, Denmark)
	K0136	11:00	David L. Paterson (Singapore, Singapore)
	OS010	11:00 - 12:00	Hall 10 1-hour Case Session Antimicrobial drugs in action Chairs	Katy Jeannot (Besançon, France) Timothy R. Walsh (Oxford, United Kingdom)
	O0072	In vivo cefiderocol resistance due to cir	A modification during treatment	E. Carretto* (Reggio Emilia, Italy), P. Pini, R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, M. Bardaro, N.C. Facciolongo, S. Mezzadri, T. Walsh
	O0073	Long-term outcomes in dalbavancin-treated patients with vascular graft infectio	n.A. Specklin* (Reims, France), T. Noël, M. Bonnet, A. Duprey, M. Hentzien
	O0074	Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant E.coli on peritonitis in a pediatric liver transplant recipient	R. Morales Junior* (Cincinnati, United States), V. Juodinis, C. Donini, J. Sampaio
	O0075	Early oral antibiotic treatment in patients with postneurosurgical brain abscesses caused by Cutibacterium acnes – a case series	M. Karolyi* (Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A. Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fischoeder, M. Ortler, C. Wenisch
	O0076	Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case report	s.G. Giuliano* (Siena, Italy), M. Sambo, P. Castellani, S. Benedetti, F. Tarantino, M. Tumbarello
	SY047	11:00 - 12:00	Hall 11 1-hour Symposium How long should contact isolation precautions be continued? Chairs	Cansu Cimen (Oldenburg, Germany) Kyriaki Tryfinopoulou (Heraklion, Greece)
	S0141	11:00	Contact isolation in patients with MDR organisms: Why, when, where?Gabriel Birgand (Nantes, France)
	S0142	11:30	Is discontinuation of contact precautions associated with an increase in infections?Daniel Diekema (Harpswell, United States) Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS
	ME048	11:00 - 12:00	Hall 12 Meet-the-Expert Cut a long story short: choosing NGS platforms
	M0143	11:00	Etienne Ruppe (Paris, France)
	M0144	11:12	Stefan Green (Chicago, United States)
	OS011	11:00 - 12:00	Hall 13 1-hour Oral Session Around the lab in 80 ways: a journey through innovative therapeutics Chairs	Zuzanna Drulis-Kawa (Wroclaw, Poland) Helena Zemlickova (Prague, Czech Republic)
	O0077	In vivo expression of an m	RNA encoded multimechanistic m	Ab combination against Staphylococcus aureus and protection in a disease model	C. Tkaczyk* (Gaithersburg, United States), N. Michael, P. Mun Mun, T. George, S. Martin, G. Adam, M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark, L. Ashley, D. Antonio, S. Bret
	O0078	Hijacking intrinsic resistance in Mycobacterium abscessus	G. Phelps* (Memphis, United States), S. Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E. Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L. Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O. Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A. Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S. Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander, R. Lee
	O0079	Tripartite bacteriophage-based strategy to combat human clinical pathogens	P. Kalatzis* (Copenhagen, Denmark), R. Ibarra-Chávez, H. Sampson, S. Michniewski, A. Shen, M. Ford, B. Petersen, P. Worning, P. Klement, H.P. Calum, U.M. Singh, A. Millard, M. Clokie, T. Sicheritz-Pontén 
	O0080	Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy	Y. Tekintas* (Cigli, Türkiye), P.B. Savage, M. Ucuncu
	O0081	Identification of compounds capable of removing established bacterial biofilms	T. Inzana* (Brookville, United States), A. Gates, W. Weng, J. Cusumano, Y.J. Lee, N. Vogelaar
	ME049	11:00 - 12:00	Hall 14 Meet-the-Expert How to perform clinical trials in mycoses?
	M0145	11:00	Monica Slavin (Melbourne, Australia)
	M0146	11:12	Nkechi Azie (Barrington, United States) Co-organised with: ESCMID Fungal Infection Study Group (EFISG)
	OS012	11:00 - 12:00	Hall 15 1-hour Oral Session Climate Impact and One Health Approaches Against Infectious Diseases Chair Chadia Wannous (Paris, France)
	O0082	Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective	C. Royo- Cebrecos* (Andorra, Andorra), N. Duran Torralbo, D. Vilanova Gonzalez, M. Clusas Antolin, L. Trapero
	O0083	Effects of climate change on Aedes aegypti abundance and dengue transmission	L. Geng* (Singapore, Singapore)
	O0084	Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia	M. Fereidouni* (Jahrom, Iran, Islamic Republic of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. Alhilfi, M. Keshtkar-Jahromi
	O0085	Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning	E. Athan* (Geelong, Australia), A. Hussain, K. Blaney, L. Cardamone, N. Clarke, M. Hayes, M. Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. O'brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear
	O0086	Turning disease surveillance into reality: Using metagenomic sequencing with piggery wastewater	M. Muralidhar* (St Lucia, Australia), L. Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni
	OS013	11:00 - 12:00	Hall 16 1-hour Oral Session Viral challenges in organ transplantation Chairs	Ghady Haidar (Pittsburgh, United States) Cristiana Oprea (Bucharest, Romania)
	O0087	Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cellmediated immunity in intermediate-risk kidney transplant recipients	I. Rodríguez-Goncer* (Madrid, Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, L.M. Allende, E. Paz-Artal, A. Andrés, F. López- Medrano, J.M. Aguado, I. Rodríguez-Góncer
	O0088	Real-world Use of Letermovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients	A. Mughrabi* (Rochester, Minnesota, United States), B. Bisono-Garcia, S. Chesdachai, N. Ranganath, R. Razonable
	O0089	Real-world administration of maribavir beyond the eight weeks established in the clinical trial	D. Martínez-Simón* (Barcelona, Spain), C. Ribera-Puig, M. Bodro, D. Campany, J. Esperalba, I. Los Arcos, P. Clèries-Rovira, A. Padullés, N. Sabé Fernández, M. Tuset, O. Len
	O0090	Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients	M. Solis* (Strasbourg, France), W. Fardi, I. Benotmane, F. Gallais, S. Caillard, S. Fafi-Kremer
	O0091	Dengue in solid organ transplant recipients	S.I. Galian* (Buenos Aires, Argentina), N. Pujato, N.S. Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustin, G. Werber
	SY045	11:00 - 12:00	Hall 2 1-hour Symposium What happens following TB infection? Chairs	Catherine Ong (Singapore, Singapore) Sean Wasserman (London, United Kingdom)
	S0137	11:00	Post-TB disease: burden and treatment strategies	Deborah Chong (London, United Kingdom)
	S0138	11:30	TB sequelae and fungal infection	Helmut Salzer (Linz, Austria) Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet YIA	11:00 - 12:00	Hall 3 Awards Young Investigator Award Session
	A001	11:00	Deciphering the pathogenic traits and epidemiological identities of Staphylococcus pseudintermedius: an emerging and underestimated zoonotic pathogen	Ikechukwu Benjamin Moses (Abakaliki, Nigeria)
	A002	11:12	Drugs for Vector-borne Infections: Facts and Fibrillations	Xin Hui Chan (Oxford, United Kingdom)
	A003	11:24	Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet? Matthaios Papadimitriou Olivgeris (Sion, Switzerland)
	A004	11:36	Finding a place for observational studies in infectious diseases research	Anthony Bai (Kingston, Canada)
	A005	11:48	Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis	Simon Feys (Leuven, Belgium)
	SY046	11:00 - 12:00	Hall 5 1-hour Symposium New frontiers in bacterial pathogenesis Chairs	Silvio Daniel Brugger (Zurich, Switzerland) Abdou Hachani (Melbourne, Australia)
	S0139	11:00	Bacterial infections and cellular immunity	Charlotte Odendall (London, United Kingdom)
	S0140	11:20	Immuno-metabolism in bacterial diseases	Tania Wong (New York, United States)
	OS007	11:00 - 12:00	Hall 6 1-hour Oral Session New developements in prophylaxis and treatment of COVID-19 Chairs	Gülsen Özkaya Sahin (Lund, Sweden) Snjezana Zidovec Lepej (Zagreb, Croatia) 
	O0057	Ensitrelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEP	F. Hayden* (Virginia, United States), N. Ohmagari, T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S. Lacey, G. Ichihashi, T. Uehara
	O0058	Efficacy of nirmatrelvir/ritonavir on overall COVID- 19 related symptoms in immunocompromised adult participants from the EPIC-IC trial	R. Mokgokong* (Tadworth, United Kingdom), P. Cislo, E. Tudone, E. Weinstein, J.C. Cappelleri
	O0059	COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approac	h.T.F. Aiello* (Barcelona, Spain), C. Teijón- Lumbreras, C. Garcia-Vidal, M. Chumbita, M. Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó- Gallo, A. Gallardo-Pizarro, A. Martinez-Urrea, R. Méndez, E. Calbo, M. Ballestero-Tellez, G. Cuesta- Chasco, M. Marcos, A. Soriano
	O0060	Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis	C. Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Coppola
	O0061	Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the Dis	Co	Ve	Ry trial	C. Massonnaud* (Paris, France), M. Hites, N. Peiffer- Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader
	OS008	11:00 - 12:00	Hall 7 1-hour Oral Session Advancing Malaria Research: From Molecular Insights to Clinical Challenges Chairs	Kamruddin Ahmed (Kota Kinabalu, Malaysia) Giri Shan Rajahram (Kota Kinabalu, Malaysia)
	O0062	Influence of second blood meals on Plasmodium vivax development and infectivity in mosquitoes	S. Bantuchai* (Bangkok, Thailand), W. Nguitragool, J. Sattabongkot, C. Kumpitak
	O0064	Severe imported Plasmodium falciparum malaria with hyperparasitaemia: evaluation of predictors for critical disease	T. Lingscheid* (Berlin, Germany), J. Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. Sander, M. Ramharter, F. Kurth
	O0065	The current status of Plasmodium falciparum chloroquine resistance transporter gene (K76T) and Plasmodium falciparum multi-drug resistance gene 1 (N86Y) in Cameroon	M. Fru* (Buea, Cameroon)
	O0066	SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewe	d.E. Savory* (Cambridge, United Kingdom), M. Routledge, B. Warne, E. Moore, D. Sparkes
	OS009	11:00 - 12:00	Hall 8 1-hour Case Session Osteoarticular uninvited guests Chairs	Tiziana Ascione (Naples, Italy) Jaime Esteban (Madrid, Spain)
	O0067	Antibiotic-refractory oligoarthritis in an adolescent caused by Borrelia bavariensis in Croatia	N. Krajcar* (Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Pažur, S. Roglić, R. Beck, G. Tešović
	O0068	Progression of vertebral echinococcosis despite radiotherapy treatment	M. González-Sanz* (Madrid, Spain), O. Martín, A. Romero-Alegría, M. Belhassen, S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, B. Monge Maillo, C. Crespillo-Andújar, M.D. Corbacho-Loarte, S. De La Fuente-Herranz, J. Cobo Soriano, J. Urbano, M. Martín Martín, J.A. Pérez- Molina
	O0069	Two cases of septic osteoarthritis of Cutibacterium acnes detected by 16S r	RNA gene sequencing in immunocompetent adolescents	H. Okuno* (Osaka, Japan), K. Shiota, K. Amo
	O0070	A UK case of Melioidosis with osteomyelitis two years after geographical exposure	C. Darlow* (Liverpool, United Kingdom), L. Swithenbank, R. Taggart, V. Owen, N. Wong, S. Woolley, W.D. Harrison, L. Ratcliffe, J. Lewis
	O0071	When Infection Masquerades as Malignancy: A Case of Disseminated Mycobacterium fortuitum complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN-γ Immunodeficiency Syndrome	N. Hiranburana* (Bangkok, Thailand), S. Khahakaew, K. Meesilpavikkai, M. Satja, G. Suwanpimolkul
	LB001	11:00 - 12:00	Hall 9 1-hour Oral Session Advances in vaccine effectiveness for viral respiratory infections Chair Jean Paul Stahl (Corenc, France)
	L0001	Immunogenicity of J	N.1- and K	P.2-encoding m	RNA COVID-19 vaccines against J	N.1 SARS-Co	V-2 sublineages in adult participants	A. Figueroa* (Cambridge, United States), D. Edwards, K. Johnson, D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt
	L0002	J	N.1-adapted vaccine effectiveness against COVID-19 hospitalisation in Europe: a test-negative case-control study using i	d.DRIVE	H.R. Volkman* (New York, United States), L. De Munter, J.L. Nguyen, T.M.P. Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite, S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E. Martro, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M. Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S. Otero-Romero, A. Riva, A. Torres, F. Martinon Torres, L. Jodar, J.M. Mclaughlin, K. Bollaerts
	L0003	Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults ≥65 years of age in the United States	A. Miles* (New York, United States), J.T. Vietri, S. Rosenstock, H. Li, J. Vojicic, L.R. Grant, A. Randall, B.D. Gessner, P. Balmer, A. Cane, P. Peyrani
	L0004	Safety and immunogenicity of the MERS vaccine, Ch	Ad	Ox1 MERS, in older adults with and without prior Ch	Ad	Ox1 exposure	D. Jenkin* (Oxford, United Kingdom), E. Sheehan, R. Huq, T. Lambe, S. Gilbert, A.M. Collins, M.N. Ramasamy, A. Mujati, R. Kenneil, N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi, S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O. Mazur, H.T. Belhadef, B. Stoilova, D. Pulido-Gomez, H. Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L. Mclellan, O. Hamilton, V. Simpson, J. Court, N. Murphy, M. Farrar, P. Saunderson
	L0005	Vaccination in pregnancy with RSVpre	F elicits Ig	G, Ig	A and total secretory antibody responses in milk of lactating individuals	J. Atwell* (New York, United States), R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan, S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B. Gessner
	SY051	13:30 - 14:30	Hall 1 1-hour Symposium Year in infectious diseases Chairs	Nur Benzonana (Istanbul, Türkiye) Evelina Tacconelli (Verona, Italy)
	S0151	13:30	Yoav Keynan (Winnipeg, Canada)
	S0152	14:00	Elisa Cordero Matia (Seville, Spain) 
	SY053	13:30 - 14:30	Hall 16 1-hour Symposium Developing guidelines with AI tools: are they ready for prime time? Chairs	Miranda Langendam (Amsterdam, Netherlands) Blin Nagavci (Gjakove, Kosovo)
	S0155	13:30	The PROs and CONs of using AI tools for developing guidelines	Holger Schuenemann (Milano, Italy)
	S0156	14:00	AI in action: validated tools for speeding up your systematic reviews and how to use them	Sara Fernandez (Oslo, Norway) Co-organised with: ESCMID Guidelines Subcommittee
	SY052	13:30 - 14:30	Hall 2 1-hour Symposium Exploring children's role in infection spread Chairs	Angelika Berger Sanjay Patel (Winchester, United Kingdom)
	S0153	13:30	Are children really super-spreaders of respiratory viruses?Emmanuel André (Leuven, Belgium)
	S0154	14:00	Should schools be closed at the start of the next pandemic?Vittoria Colizza (Paris, France) Co-organised with: European Society of Paedriatic Infectious Diseases (ESPID)
	EF021	13:30 - 14:30	Arena 1 e	Poster Flash Session Infections in hemato-oncological hosts: from bacterial to viral Chair Genovefa Papanicolaou (New York, United States)
	E0139	Vancomycin-resistant Enterococcus faecium bloodstream infection in patients with hematological malignancy and stem cell transplant: a case-control study	J. Fung* (Vancouver, Canada), K. Aldhaheri, C. Nishi, J. Lau, A. Mah, A. Wright, R. Stubbins, M. Charles, S. Belga
	E0140	Bacteremia secondary to urinary tract infection in oncology patients: risk factors and impact of multidrug-resistant Gram-negative bacill	i.I. Grafia* (Barcelona, Spain), A. Moll, S.J. Santillá, C. Rodrigo, E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, M. Espasa, D. Marco, S. Fernández, J. Marco- Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Viladot, A. Tuca, P. Puerta-Alcalde
	E0141	Rectal carriage of multidrug-resistant organisms and subsequent bloodstream infections in hematologic patients undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy	C. Charalampidis* (Athens, Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. Lazana, C. Chatzidimitriou, A. Zormpa, E. Mastrostamati, I. Grigoropoulos, D. Kavatha, S. Tsiodras, P. Tsirigotis, K. Thomas
	E0143	The RUSTIC Study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological Malignancy	B. Teh* (Melbourne, Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, P. Kinsella, N. Laundy, J. Wolfe, L. Cooley, M.K. Yong, M.A. Slavin
	E0144	Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity	P. Bono* (Milan, Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. Hejazifar, C. Biassoni, G. Giacomel, A. Valzano, M.R. Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti, A. Callegaro, C. Alteri
	E0145	Safety and tolerability of SYN-004 in allogeneic hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)E. Dubberke* (Saint Louis, United States), M. Schroeder, H. Sappington, G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E. Jeremy, M. Keller, A. Bristol, C. Le, S. Connelly, M. Moenk, V. Wacher, M. Kaleko, J. Kuti, M. Olsen
	E0146	Standardized gastrointestinal cytomegalovirus (CMV) tissue quantitative-nucleic-acid testing (QNAT) compared to immunohistochemistry in allogeneic hematopoietic cell transplant (HCT) recipients	S. De Aragón De La Cruz* (Basel, Switzerland), C.S. Walti, N. Khanna, K. Leuzinger, J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J. Vosbeck
	E0147	Real-life experience with maribavir for the treatment of cytomegalovirus infection in hematological patient	s.J. Boan Perez* (Madrid, Spain), J.M. Sánchez-Pina, C. Aizpurúa, I. Rodríguez-Goncer, F. López-Medrano, R. San-Juan, M. Fernández-Ruiz, E. Aparicio, M. Lizasoaín, J.M. Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado
	EF022	13:30 - 14:30	Arena 2 e	Poster Flash Session Syndromic testing is still coming of age Chair Tommaso Giani (Florence, Italy)
	E0148	Bacterial infections of the central nervous system: addressing the diagnostic gap in non- communityacquired meningitis	G. Menchinelli* (Rome, Italy), M. Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis, B. Posteraro, M. Sanguinetti
	E0149	Epidemiological surveillance of central nervous system infections through a rapid syndromic testing platform	M. Rey* (Barcelona, Spain), L. Pau, C. Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona
	E0150	Impact of Syndromic Panel Implementation on Meningitis/Encephalitis Diagnosis, Antimicrobial Use, Costs, and Hospital Stay in a Regional Australian Hospital	S. Subedi* (Brisbane, Australia), P. Harris, D. Paterson
	E0151	Performance evaluation of the Nx	TAG® GPP Panel for the detection of gastrointestinal pathogens by comparison with current routine methods in Nantes University Hospita	l.S. Gibaud* (Nantes, France), L. Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P. Lepape, S. Corvec
	E0152	Correct discrimination of Monkeypox virus clades by fast syndromic testing	S. Reister* (Hilden, Germany), L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S. Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla- Cámara, J. Michel, A. Puyskens, F. Van Deursen, D. Lueerssen
	E0153	Managing a Mycoplasma pneumoniae Outbreak: Impact of Syndromic Panels on Antimicrobial Prescriptions in Pediatric Emergencies	L. Brusca* (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés- Borrás, G. Santillana-Cernuda, M. Ballestero-Tellez, A. Boronat, J. Perez
	E0154	Performance of BIOFIRE® FILMARRAY® Pneumonia plus in general population, solid organ transplant recipients and patients with hematologic malignancies – Interim analysis	R. Riccardi* (Bologna, Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P. Viale, M. Giannella
	E0155	Impact of the molecular rapid diagnostic panel testing in adjustment of antimicrobial therapy in febrile neutropenic patients with bacteremia	S. Chantharasut* (Bangkok, Thailand), M. Chayakulkeeree, W. Kamolvit, A. Jitmuang, I. Thaipisuttikul
	E0156	Bacte	REVEAL: Analytical performance and contribution of Bio	Fire® BCID2 and Vitek® REVEALTM in intensive care patients with Gramnegative bloodstream infections	C. Roger* (Nimes, France), L. Oudiane, M. Benyahia, F. Salipante, A. Dubois, L. Muller, J.P. Lavigne, A. Pantel
	EF023	13:30 - 14:30	Arena 3 e	Poster Flash Session Effective microbiology for the management of sepsis Chair Maurizio Sanguinetti (Rome, Italy)
	E0157	Molecular epidemiology of Klebsiella bloodstream infection-causing isolates across England using Nanopore longread-only sequencing: An interim analysis of the NEKSUS study	D. Nagy* (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown
	E0158	Investigating seasonality of antibiotic resistance associated with E. coli and Klebsiella pneumoniae bloodstream infections	S. Lipworth* (Oxford, United Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, K. Turner
	E0159	Sensitivity of a host-protein test for microbiologically confirmed bacterial infections	R. Navon* (Tirat Carmel, Israel), E. Reiner, O. Shaham, A. Neuberger, S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P. Aufderheide
	E0160	Comparative genomics of Klebsiella pneumoniae from gut colonisation and bloodstream infections reveal novel genetic associations	M. Hetland* (Stavanger, Norway), K.L. Wyres, H.B. Cooper, A. Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger, A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr
	E0161	Conventional microbiology v	s. conventional microbiology + nucleic acid-based multiplex real-time polymerase chain reaction (MPCR) test kit in septic shock: results of a matched cohort study	G. Sanlidag Isbilen* (Izmir, Türkiye), G. Şanlıdağ İşbi̇len, B. Akkul, C. Tol, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli, B. Arda, O.R. Sipahi
	E0162	Contribution of Escherichia coli microbiological factors to the presentation as sepsis/septic shock in patients with bacteraemia: a matched case-control study	N. Maldonado* (Seville, Spain), I. López- Hernández, L.E. López-Cortes, P.M. Martínez Pérez- Crespo, A. García-Montaner, M. Alcade-Rico, A. Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á. Pulido-Navazo, C. Labayru Echeverría, A.I. Aller- García, L. Boix-Palop, A. Del Arco-Jiménez, A. Smithson-Amat, J.M. Sánchez-Calvo, C. Natera- Kindelán, J.M. Reguera Iglesias, C. Armiñanzas- Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea- Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T. Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual- Hernández, J. Rodríguez-Baño
	E0163	Simplified and rapid bacterial identification with antimicrobial resistance detection in bacteremia by on-chip multiplexed LAM	P.C. Treille* (Saclay, France), K. Perez-Toralla, H. Boutal, X. Garcia Velasquez, L. Pommies, S. Simon, H. Volland
	E0164	Community-onset bloodstream infection among people with opioid use disorders: A twenty-year population-based cohort study in Queensland, Australi	a.K. Laupland* (Herston, Australia), A. Stewart, F. Edwards, P. Harris, S. Coulter
	E0165	Microbiological diagnosis tools for primary and secondary abdominal aortic infections requiring surgery	S. Soueges* (Lyon, France), A. Blanco, A. Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della- Schiava, U. Huvelle, A. Millon, F. Valour
	EF024	13:30 - 14:30	Arena 4 e	Poster Flash Session A never-ending evolution of antimicrobial resistance Chair Antonio Oliver (Palma De Mallorca, Spain)
	E0166	Gfa, a novel integron-born fosfomycin resistance mechanism	N. Kieffer* (Madrid, Spain), L. Ortiz- Miravalles, A. Hipolito, J.A. Escudero
	E0167	Regulons of Ram	A, Rar	A and Sox	S mediated tigecycline resistance and oxidative stress among in vitro tigecycline resistant evolution trajectory of Klebsiella pneumonia	e.X. Wang* (Beijing, China), J. Kuai, Y. Zhao
	E0168	Assessing the impact of altered penicillin binding proteins on susceptibility to novel antimicrobials among clinical isolates of carbapenemase-producing Escherichia col	C. Tellapragada* (Stockholm, Sweden), P. Jonsson, C. Giske
	E0170	Enterococcus faecalis penicillin-binding protein-4 sequence differences based on penicillin minimum inhibitory concentration	O. Funk* (Brooklyn, United States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S. Brown, J. Cusumano
	E0171	Uncommon genomic rearrangements drive vancomycin resistance in van	B-positive Enterococcus faecium	K. Xanthopoulou* (Cologne, Germany), J. Mellüh, R. Arazo Del Pino, L. Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L. Maus, A. Klimka, P.G. Higgins
	E0172	Heteroresistance in Enterococcus faecalis: prevalence and mechanistic insights across clinically relevant antibiotics	S. Heidarian* (Uppsala, Sweden), S. Lohsen, A. Guliaev, K. Hjort, S. Satola, D. I. Andersson
	E0173	Side effects of rifampicin resistance: transcriptome modulation by rpo	B mutations in Staphylococcus aureus	M. Roch* (Geneva, Switzerland), R. Sierra, C. Colomer Winter, F. Bezrukov, O. Panasenko, A. Guisolon, U. Von Ah, M. Villanueva, P. Redder, K. Kline, J. Prados, W.L. Kelley
	E0174	Novel continuous experimental evolution methodology revealing rapid resistance development and cross-resistance	T. Echelmeyer* (Greifswald, Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H. Fickenscher, G. Maschkowitz, D. Nurjadi, R. Podschun, K. Schaufler, E. Eger
	OS018	13:30 - 14:30	Hall 11 1-hour Oral Session Battling the Spore: C. difficile epidemiology and management Chairs	Nicolas Benech (Lyon, France) Fidelma Fitzpatrick (Dublin, Ireland)
	O0124	Molecular epidemiology and antimicrobial resistome of Clostridioides difficile from private and public healthcare settings in three provinces in South Africa	H. Shirinda* (Pretoria, South Africa), A.M. Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M. Ehlers
	O0125	Screening for Clostridioides difficile colonization at admission and during hospitalization	N. Khanafer* (Lyon, France), S. Bennia, G. Martin-Gaujard, L. Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin, P. Vanhems
	O0126	Revolutionizing CDI treatment: Are shorter antibiotic regimens the future	M. Duricek* (Prague, Czech Republic), J. Benes, K. Halmova
	O0127	Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection	E. Rubio-Martín* (Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez Caballero, A.M. Rodríguez Benavente, S. De La Villa, J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez Gómez, E. Calabuig, M. Tasias, R. Blanes, M.Á. López Zúñiga, J. Rodríguez Granger, P. Merino Amador, A. Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G. Maestro De La Calle, J. Mateo Flores, J.B. Pérez Gilaberte, R.M. Martínez Álvarez, F. Martínez García, N. Cobos-Trigueros, J. Llenas-García, M. Solivella- Rodríguez, L. Ramos Merino, B. Castelo López, M.M. Montero, D. Echeverría-Esnal, J. López-Contreras, P. Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, A. Muriel García, S. Moreno Guillén, J. Cobo
	O0128	Gut phageome profiling in Clostridioides difficile infection and faecal microbiota transplantation	C. Chen* (Lausanne, Switzerland), T. Pillonel, J. Schaer, G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine
	OS019	13:30 - 14:30	Hall 12 1-hour Oral Session Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Potential Chairs	Mauricio Farfan (Santiago, Chile) Eija Inkeri Könönen (Turku, Finland)
	O0129	Multi-omics integrated analysis revealed the key role of Fusobacterium periodonticum in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxi	s.X. Chu* (Beijing, China), Q. Yang
	O0130	Exploring the respiratory microbiome in COPD patients: The role of Haemophilus sp	p. in disease pathogenesis	P. Camps-Massa* (Barcelona, Spain), L. Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara- Nuñez, F. Tubau, J. Burgos, M. Lopez, A. González- Díaz, C. Ardanuy, M. Dominguez, S. Santos, S. Martí
	O0131	Using the in vitro Mi	Gut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbes	I. Moura* (Leeds, United Kingdom), W. Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Wilcox, N. Kapur, A. Buckley
	O0132	Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: Insights into the impacts of Westernization on human health	M. Thorp* (Gent, Belgium), C. Callewaert, B. De Pessemier, D. Good, E. Allen-Vercoe, L. Paulino, L. Vereecke
	O0133	Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria?K. Villageois-Tran* (Bobigny, France), C. Emavivie, H. Skerdi, E.N. Saad, M. Julie, E. Ruppé
	ME055	13:30 - 14:30	Hall 14 Meet-the-Expert Long acting injectables to treat and prevent infections: an example from HIV field
	M0159	13:30	Monica Gandhi (Salt Lake City, United States)
	M0160	13:42	Pedro Cahn (Buenos Aires, Argentina)
	OS020	13:30 - 14:30	Hall 15 1-hour Oral Session How to evaluate AMS programs Chairs	Esther Calbo (Terrassa, Spain) Sabiha Essack (Durban, South Africa)
	O0134	Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD data	N. Nguyen* (Oxford, United Kingdom), K. Pouwels, J.V. Robotham, S. Yu, S. Wordsworth
	O0135	Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre study	B. Moshy* (London, United Kingdom), R. Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah, B. Gemma, I. Balakrishnan
	O0136	Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital	V. Huang* (Glendale, United States), T. Pham, A. Vogler, H. Chhen, C. Vandenberg
	O0137	Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting	A. Hopkins* (Livingston, United States), A. Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime
	O0138	Timing of Novel β-Lactams v	s. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (Lo	T) Analysis Preliminary findings	E. Yucel* (Rahway, United States), J. Min, Y. Wang, M. Vendetti, Y. Emre, R.K. Shields
	ME054	13:30 - 14:30	Hall 3 Meet-the-Expert How antimicrobial tolerance impacts polymicrobial biofilm-associated infections
	M0157	13:30	Hans Steenackers (Leuven, Belgium)
	M0158	13:42	Brian Conlon (Chapel Hill, United States)
	OS017	13:30 - 14:30	Hall 5 1-hour Case Session Bad bacteria Chairs	Maristela P. Freire (Sao Paulo, Brazil) Siegbert Rieg (Freiburg, Germany)
	O0119	Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug	R. Gupta (bagga)* (London, Canada), R. Gupta, A. Cabrera, A. Kanyua, F. Almutawa, J. Delport, K. Kavanoor Sridhar
	O0120	Whipple's disease: one of medicine's great imitators	S. Kesavan* (Nottingham, United Kingdom), F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos, R. Thomson
	O0121	Phage Therapy as a Rescue Treatment for Recurrent Pseudomonas aeruginosa Bentall Infection	V. Eiferman* (Paris, France), P.A. Vion, B. Rached, C. Granger, N. Hammoudi, A. Bleibtreu
	O0122	A clinical case of Legionella longbeachae pneumonia featuring unique epidemiological features in a major italian hospital	S. Guerriero* (Rome, Italy), M. La Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti, C. Torti
	O0123	Francisella tularensis – First autochthonous case in the UK	G. Vanstone* (Truro, United Kingdom), A. Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam, A. Ainarozidou
	ME061	14:45 - 15:45	Hall 3 Meet-the-Expert How to use large language models and machine learning for improving One Health
	M0170	14:45	Javier Fernández (Oviedo, Spain)
	M0171	14:57	Nicolas Radomski (Teramo, Italy) Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM) 
	FO063	14:45 - 15:45	Arena 1 Open Forum Science communication in a noisy world: podcasting and social media in ID/CM Chair Emily G. Mcdonald (Montreal, Canada)
	F0174	14:45	The ID:IOTS guide to creating a successful CM/ID podcast"Callum Mutch (Edinburgh, United Kingdom)
	F0175	14:55	Using social media for CM/ID education	Scott Jake (Oakland, United States)
	F0176	15:05	Podcasting and social media for antimicrobial stewardship and pharmacy	Erin Mccreary (Pittsburgh, United States) Co-organised with: CMI Communications Board of Editors
	EF029	14:45 - 15:45	Arena 2 e	Poster Flash Session Vaccination uptake-challenges and opportunities Chair Joanne M. Langley (Halifax, Canada)
	E0195	Electronic nudges to increase influenza vaccination uptake among patients with heart failure: insights from 3 nationwide randomized trials enrolling >2 million patients	N.D. Johansen* (Hellerup, Denmark), M. Vaduganathan, A.S. Bhatt, D. Modin, B.L. Claggett, K.H. Janstrup, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, E.L. Dueger, S. Samson, M.M. Loiacono, R.C. Harris, L. Køber, S.D. Solomon, P. Sivapalan, J.U.S. Jensen, T. Biering-Sørensen
	E0196	Psychological Predictors of Influenza Vaccination Intent Among Healthcare Workers in Bulgaria	P. Velikov* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva, Y. Tcholakov, V. Borisova-Nenovа, D. Ivanov, A. Zasheva, A. Hori
	E0197	Determinants of COVID-19 vaccine uptake in patients with hematologic malignancies: a nationwide cohort study	Q. Hofsink* (Amsterdam, Netherlands), T. Osmenaj, B.I. Lissenberg-Witte, S. Hahné, J. Heijmans, I.S. Nijhof, A. Goorhuis, M.D. Hazenberg, C.E. Rutten, S. Haggenburg, P. Den Tex, A. Dinmohamed, J. Kemmeren, H. De Melker, S. Van Den Hof
	E0199	Inequality in vaccine uptake among children in Denmark in the national childhood vaccination programme	A.C.M. Breschel* (Copenhagen, Denmark), A.V. Søndergaard, S.K. Nørgaard, B. Søborg, P.H. Andersend
	E0200	Prevalence and associated factors of parental refusal rates for routine immunisation: A cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan- 2024M. Hakim* (Hayat Abad Peshawar Kp Pakistan, Pakistan)
	E0201	Shingles Prevalence, Vaccine Awareness, and Acceptance in People Living with HIV	D. Yaman* (Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu, D. Gökengin
	E0202	Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden, 2018−2022A. Palmborg* (Stockholm, Sweden), F. Angulo, P. Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar
	E0203	Monkeypox (mpox) vaccination willingness and determinants among people living with HIV (PLWH) in turkey	C. Boşnak* (Altındağ, Türkiye), T.K. Şahin, E. Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal
	EF030	14:45 - 15:45	Arena 3 e	Poster Flash Session Viruses crossing the blood-brain barrier
	E0204	Clinical characteristics and outcome of Herpes simplex virus type 1 and varicella zoster virus encephalitis: A prospective population-based cohort study	L. Duerlund* (Aarhus, Denmark), L. Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G. Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø. Andersen, H. Nielsen, J. Bodilsen
	E0205	Arbovirus associated neurological disease in adults and children in Brazil: a multicentre case-control study	S. Lant* (Liverpool, United Kingdom), R. Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea Carrera, M. Tulius, P. Brasil, C. Miguelote, A. Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim Rodrigues, R. Braga, L. Pamplona, C. Spitz, F. Militao, A. Rosala Hallas, G. Burnside, R. Vivancos, S. Leonhard, L. Rodrigues De Mendonça-Vieira, B. Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R. Franca, A. Bispo, T. Solomon
	E0206	Challenges in managing Central nervous system infections: Battling the Unknown Enemy, West Nile virus vs unknown etiology	C. Marin* (Bucharest, Romania), A. Paun, E. Nedu, S. Tetradov, S. Lazar, M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu, S.M. Ruta, C.P. Popescu
	E0207	Spatial and temporal profiling of the immune responses induced by Japanese encephalitis virus in a mouse model	Z. Ou* (Shenzhen, China), Z. Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng
	E0208	Intrathecal immunoglobulin synthesis in tick-borne encephalitis	S. Grygorczuk* (Bialystok, Poland), P. Czupryna, D. Martonik, J. Dunaj-Małyszko, J. Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A. Moniuszko-Malinowska
	E0209	B and T cell responses to Tick-borne Encephalitis Virus	N. Mayola Danes* (Stockholm, Sweden), R. Varnaitė, N. Mayola Danés, K. Blom, H.G. Ljunggren, S. Gredmark-Russ
	E0210	Enterovirus infections in pediatric central nervous system (CNS) diseases: molecular epidemiology and neuroimaging insights	D. Sharma* (Chandigarh, India), R. Pathania, P. Bhattacharya, M. Gautam, A. Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh
	E0211	Neuroimaging findings and their correlation with autopsy findings: Prospective study on Rabies encephalitis	M. Mohata* (New Delhi, India), V. Suri, P. Singh, G.K. Mohi, A. Bhalla, R. Mohindra, R.K. Soni, K. Gupta
	E0212	Toxoplasma gondii Ig	G Screening and Central Nervous System Complications among People with HIV in the Combination Antiretroviral Therapy Era	T. Ou* (New Taipei City, Taiwan, China), T.Y. Tsai, S.H. Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C. Hung
	EF031	14:45 - 15:45	Arena 4 e	Poster Flash Session AMS around the world: know your data! Chair Eoghan De Barra (Dublin, Ireland)
	E0213	Duration of antibiotic treatment for respiratory tract infections in primary car	e.C. Llor* (Barcelona, Spain), M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H. Lindberg, I.K. Rebnord, R. Radzeviciene, L. Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk, C. Lionis
	E0214	Antibiotic prescribing for common acute infections in Pakistan - an analysis using IQVIA prescriber healthcare surveys	N. Nguyen* (Oxford, United Kingdom), K. Pouwels, M. Sharland, S. Mangla, A. Cook, M. Thorn, P. Stephens
	E0215	Antibiotic prescribing for common acute infections in Egypt - an analysis using IQVIA prescriber healthcare surveys	N. Nguyen* (Oxford, United Kingdom), S. Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels, M. Sharland
	E0216	Population based analysis of the impact of Japan's AMR national action plan and the COVID-19 pandemic on antimicrobial prescription	R. Koizumi* (Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N. Ohmagari
	E0217	Quality of antibiotic prescribing in Portuguese hospitals: a snapshot of the first National Antimicrobial Prescribing Surve	y.C. Palos* (Lisbon, Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky, P. Sousa
	E0218	Evaluating the impact on 28-day mortality of different empiric AWa	Re antibiotic treatment strategies for hospital-acquired infections across different hospital setting	s.C. Lim* (Oxford, United Kingdom), K.B. Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S. Walker, M. Sharland, B.S. Cooper
	E0219	Update on WHO's Global antibiotic use surveillance system (GLASS-AMU)B. Huttner* (Geneva, Switzerland), A. Muller, M. Escher, V. Ivanoska, D. Tong
	E0220	Harmonisation trajectory of Global-Point Prevalence Survey (Global-PPS) and WHO-PPS	A. Versporten* (Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe
	E0221	Implementation of prospective audit and feedback strategy in intensive care units: Analysis of antimicrobial prescription patterns in a Guatemalan tertiary care hospital	N. Sandoval* (Guatemala, Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa
	KN056	14:45 - 15:45	Hall 1 Keynote Lecture Defending against dengue: global epidemiology and strategies for prevention and control Chairs	Anu Kantele (Helsinki, Finland) Carlos Seas (Lima, Peru)
	K0161	14:45	Fernanda Boulos (São Paulo, Brazil)
	OS026	14:45 - 15:45	Hall 11 1-hour Oral Session Carbapenem resistance Gram-negatives, what's new in treatment? Chair Maria Milagro Montero (Barcelona, Spain)
	O0180	Ceftriaxone sulbactam disodium EDTA combination(CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be?Y. Verma* (Hisar, India), K. Narang, D. Bandlish, C. Sharma
	O0181	Sulbactam-durlobactam as an effective alternative option against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactamresistant isolates in Swizterland	C. Le Terrier* (Fribourg, Switzerland), P. Nordmann, A. Delaval, L. Poirel
	O0182	Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by in vitro Antibiotic Combination Testing	T. Lim* (Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa
	O0183	Management of infections caused by ST308 New Dehli metallo-ß-lactamase-producing Pseudomonas aeruginosa with in vitro-guided combination antibiotic therapy	J. Teo* (Singapore, Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa
	O0184	In vitro activity of cefepime/enmetazobactam against clinical isolates of Enterobacterales in Portugal: A multicentre retrospective study	H. Cruz* (Porto, Portugal), C. Chaves, L. Carneiro
	OS027	14:45 - 15:45	Hall 12 1-hour Oral Session Staphylococcus aureus: colonisation, virulence, and persistence Chair Stefano Giulieri (Melbourne, Australia)
	O0185	The nasal microbiome redefines and predicts Staphylococcus aureus nasal colonisation status	D. Aggarwal* (London, United Kingdom), K.L. Bellis, B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry, M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L. Sarkane, J. Brennan, S. Duthie, E. Johnson, M. Juhasz, S. Irvine, A. Mcmahon, A. Van Tonder, E. Di Angelantonio, A. Butterworth, J.A. Geoghegan, J. Danesh, J. Parkhill, S.J. Peacock, E. Harrison
	O0186	Development of a Staphylococcus aureus human nasal colonisation model	A. Hachani* (Melbourne, Australia), B. Tran, E. Cho, R. Guérillot, B. Howden, T. Stinear, E. Vincan
	O0187	Selection-free, virulence gene promoter-controlled CRISPR interference system for in vivo pathogenesis study of Staphylococcus aureus - A proof of concept	R. Miah* (Tromsø, Norway), M. Johannessen, M. Kjos, C. Lentz
	O0188	Placebo-controlled study of competitive exclusion using Lactococcus lactis to reduce transmission of LA-MRSA from pigs to humans	B. Duim* (Utrecht, Netherlands), A. Vlasblom, A. Rittscher-Fogg, R. Rattigan, L. Wajda, D. Crespo-Piazuelo, M. Broekhuizen-Stins, L. Portengen, G. Van Eijden, C. Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A. Zomer, J. Wagenaar
	O0189	Rifampicin-induced Staphylococcus aureus persister formation is driven by Cod	Y and oxidative stress level	N. Pordone* (Lyon, France), J. Guillemot, K. Rodriguez, N. Personnic, E. Botelho-Nevers, P.O. Verhoeven
	SY059	14:45 - 15:45	Hall 13 1-hour Symposium Value-based syndromic diagnostics in medical microbiology: Pro / Con debate Chairs	Hege Vangstein Aamot (Lørenskog, Norway) Eric Claas (Leiden, Netherlands)
	S0166	14:45	Pro: clinical benefit and potential for improved patient outcomes	Kirstine K. Søgaard (Aalborg, Denmark)
	S0167	15:15	Con: limitations, costs, and possible overuse of syndromic panels	Gilbert Greub (Lausanne, Switzerland) Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française
	SY060	14:45 - 15:45	Hall 14 1-hour Symposium We need to talk about toilets… Chairs	Stephanie J. Dancer (Glasgow, United Kingdom) Juliette Severin (Rotterdam, Netherlands)
	S0168	14:45	Infection risks from sanitation engineering	Davey Jones (Bangor, United Kingdom)
	S0169	15:15	Ventilation in toilets: how can we improve it?Michael Gormley (Edinburgh, United Kingdom) Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)
	OS028	14:45 - 15:45	Hall 15 1-hour Oral Session Unlocking the potential of the human microbiome for clinical diagnostics Chairs	John W. A. Rossen (Groningen, Netherlands) Maria Vehreschild (Frankfurt Am Main, Germany)
	O0190	Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions	O. Nalbantoglu* (Kayseri, Türkiye), A. Gundogdu, B.H. Ermis
	O0191	Comparison of Second-Generation and Third- Generation Sequencing technologies for 16S r	RNA amplicon-based gut microbiome analysis	E. Rubio García* (Barcelona, Spain), E. Rubio-García, A. Pulgarin, R. López-Aladid, L. Martínez-Priego, N. Palau, A. Mendoza, R. Isanta, A. Montalban, J.L. Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Reig, C. Casals-Pascual
	O0192	Donor for fecal microbiota transplantation: a challenging researc	h.B.S. Orena* (Milan, Italy), M.F. Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. Callegaro, L. Cariani
	O0193	Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy	N. Boutouchent* (Rouen, France), S. Kennedy
	O0194	Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology	A. Gundogdu* (Kayseri, Türkiye), O.U. Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Kelestimur, U. Ture
	ME062	14:45 - 15:45	Hall 16 Meet-the-Expert Untangling the web: antimicrobial dose adjustments in renal impairment
	M0172	14:45	Claire Roger (Nimes, France)
	M0173	14:57	Isabel Spriet (Leuven, Belgium) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)
	SY057	14:45 - 15:45	Hall 2 1-hour Symposium Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse? Chairs	Marc J.M. Bonten (Utrecht, Netherlands) Karin Thursky (Carlton, Australia)
	S0162	14:45	Pro: maximising outcomes with evidence-based use	Evangelos Giamarellos-Bourboulis (Athens, Greece)
	S0163	15:15	Con: the risks of routine (over)use	Aurélien Dinh (Garches, France)
	SY058	14:45 - 15:45	Hall 4 1-hour Symposium Top papers in transplant ID Chairs	Nicolas Mueller (Zurich, Switzerland) Alessandra Mularoni (Palermo, Italy)
	S0164	14:45	Top 10 papers in infections in SOTPatricia Munoz (Madrid, Spain)
	S0165	15:15	Top 10 paper in infections in HCT and cellular therapy	Joshua Hill (Seattle, United States)
	OS025	14:45 - 15:45	Hall 5 1-hour Oral Session Bacterial battles: a paediatric perspective on infections and interventions Chairs	Angelika Berger Julie Toubiana (Paris, France)
	O0175	Strong Alignment Between National Standard Treatment Guidelines and WHO AWa	Re Book Recommendations for Primary Care Pediatric Infections	D. Dona* (Padova, Italy), D. Donà, G. Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S. Mathur, M. Sharland, S.M.R. Esposito
	O0176	Correlation between antibiotic consumption and digestive colonization with multidrug-resistant Enterobacterales in a paediatric haematology department	S. Frigui Ep Oueslati* (Tunis, Tunisia), N. Fitouri, S. Frigui, Y. Chebbi, I. Fezaa, M. Ouederni, C. Drira, W. Achour
	O0177	Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a realworld cohort study	Sean Olann Whelan (Dublin, Ireland)
	O0178	Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center	E. Vaugon* (Los Angeles, United States), C. Costales, T. Barter, L. Posch, E. Orgel, J. Dien Bard
	O0179	Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre	M. De Luca* (Rome, Italy), R. Iacobelli, S. Samperi, S. Mercadante, L. Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti
	EW071	16:15 - 18:15	Hall 15 Educational Session The rare art of writing scientific articles: from conception to submission Chairs	Marlieke De Kraker (Geneva, Switzerland) Mical Paul (Haifa, Israel)
	W0205	16:15	Expressing yourself correctly: writing tips	Angela Huttner (Geneva, Switzerland)
	W0206	16:35	Constructing your manuscript for an original article	Jesús Rodríguez-Baño (Seville, Spain)
	W0207	16:55	The use of artificial intelligence tools for writing articles: what to do and not to do	Erlangga Yusuf (Rotterdam, Netherlands)
	W0208	17:15	Selecting the best journal for my manuscript	Andre Kalil (Omaha, United States) Co-organised with: CMI Board of Editors
	SY069	16:15 - 18:15	Hall 16 2-hour Symposium Controlled human infection models Chairs	Frederick Hayden (Charlottesville, United States) Nikolai Siemens (Greifswald, Germany)
	S0197	16:15	Updates on the dengue human infection model	Kirsten Lyke (Baltimore, United States)
	S0198	16:45	CHIM in endemic countries	Melissa Kapulu (Kilifi, Kenya)
	S0199	17:15	Controlled human infection models of parasitic infections	Meta Roestenberg (Leiden, Netherlands)
	S0200	17:45	Controlled human infection models of non-typhoidal Salmonella	Malick Gibani (London, United Kingdom) Co-organised with: British Infection Association (BIA) 
	EF033	16:15 - 17:15	Arena 2 e	Poster Flash Session Current treatment options for invasive fungal infections Chair Andreas H. Groll (Münster, Germany)
	E0232	The paediatric European Confederation of Clinical Mycology (ECMM) Quality (paed-EQUAL) Score for the management of candidaemia in children and neonates	Z.D. Pana* (Nicosia, Cyprus), A.H. Groll, A. Bal, R. Sprute, F. Carlesse, S. Mellinghoff, S. Butzer, D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A. Marek, U. Ristau-Schäfer, O. Cornely
	E0233	Prevalence rate, species distribution and antifungal susceptibility of bloodstream infections caused by rare yeasts of the Saccharomycetales order documented in 28 Brazilian medical centers	C. Palamin Buonafine* (São Paulo, Brazil), C.P. Buonafine, A.E. Dos Santos, L.M. Favarello, R.C. Cognialli, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T. Guimaraes, T.C. Sukiennik, F. Carlesse, P.T. Castro, C.C. Baqueiro, E.C. Francisco, A.L. Colombo
	E0234	Rezafungin showed high in vitro activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024J. Guinea* (Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, P. Muñoz
	E0235	Posaconazole Drug-Drug Interaction Potential is Similar Across Bodyweight	R.E. Wrishko* (Rahway, United States), P. Kothare, T.J. Bateman, M.G. Johnson, A. Stoch
	E0236	Phase 2, open-label, non-comparative clinical trial evaluating the safety and efficacy of posaconazole in paediatric patients 2 to <18 years old with invasive aspergillosis	H. Kang* (Seoul, Korea, Republic of), A.C. Arrieta, C. Dhooge, A. Kelemen, M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassis, S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H. Waskin, M.G. Johnson
	E0237	Activity of manogepix against a worldwide collection of mould isolates from 2023M. Winkler* (North Liberty, United States), S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira
	E0239	Candida auris displays an inoculum effect with multiple antifungal drug classes	R. Ben-Ami* (Tel Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi
	E0240	In vitro olorofim activity against Aspergillus spp clinical isolates collected as part as two national surveys on azole resistance conducted in Spain (ASPEIN II and III)J. Guinea* (Madrid, Spain), P. Escribano, J. Moraga, A. Gomez, P. Muñoz
	EF034	16:15 - 17:15	Arena 4 e	Poster Flash Session Surgical site infections: epidemiology, risk factors, and prevention strategies Chair Trisha Peel (Melbourne, Australia)
	E0241	Incidence of Surgical Site Infections (SSIs) from the automated patient-based surveillance system, SPICMI, France	P. Astagneau* (Paris, France), B. Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat- Trannoy, J. Auraix, K. Lebascle
	E0242	Beta-lactam versus non-beta-lactam antimicrobial prophylaxis and its association with the surgical site infection rate, a nationwide cohort study with 348 793 patients	S. Largiadèr* (Lucerne, Switzerland), D. Berthod, A. Widmer, N. Troillet, C. Perdrieu, S. Harbarth, R. Sommerstein
	E0245	Cutibacterium species in Neurosurgical Infections: Not Such a "Cute" Pathogen After All	J. Donnelly* (Dublin, Ireland), B. Dinesh, S. O'donnell
	E0246	The polymicrobial nature of wound infections in an emergency orthopaedic ward in Northern Nigeria - implications for treatment and patient outcome	K. Cook* (Oxford, United Kingdom), F.S. Mohd, M.Y. Ahmad, A. Aliyu, K. Iregbu, C. Achi, T. Walsh, K. Sands
	E0247	Efficacy of Octenidine Dihydrochloride Versus Chlorhexidine Gluconate Solutions in Reducing Surgical-Site Infections in Total Hip and Knee Arthroplasty: A Comparative Analysis	A. Abialevich* (Beer Sheva, Israel), V. Benkovich, G. Benkovich
	E0249	Impact on rates of surgical site infection of requiring pre-authorization of surgical antibiotic prophylaxis choice and post-operative antibiotic doses	C.M. Villavicencio* (Taguig, Philippines), M.C. Hufano, R.R. Gabunada, Z. Alano
	SY067	16:15 - 18:15	Hall 11 2-hour Symposium STIs: an ongoing crisis Chairs	Dagmar Heuer (Berlin, Germany) Tomislav Mestrovic (Varazdin, Croatia)
	S0189	16:15	STI treatment options are running out due to AMRMagnus Unemo (Örebro, Sweden)
	S0190	16:45	Genomic surveillance of Neisseria gonorrhoeae strains	Petra Wolffs (Maastricht, Netherlands)
	S0191	17:15	Evolutionary insights into syphilis and Treponema pallidum	Mathew Beale (Hinxton, United Kingdom)
	S0192	17:45	Challenges in chlamydial STI infections	Cecile Bebear (Bordeaux, France) Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie
	SY068	16:15 - 18:15	Hall 12 2-hour Symposium Tick-borne encephalitis: contemporary diagnosis and management Chairs	Joanna Maria Zajkowska (Białystok, Poland) Dace Zavadska (Riga, Latvia)
	S0193	16:15	Tick-borne encephalitis: immune response and clinical experience	Sara Gredmark Russ (Stockholm, Sweden)
	S0194	16:45	TBE immune responses and vaccine effectiveness	Karin Stiasny (Vienna, Austria)
	S0195	17:15	NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection	Gerhard Dobler (Munich, Germany)
	S0196	17:45	Treatment for TBE: where do we stand?Daniel Ruzek (Brno, Czech Republic)
	LB006	16:15 - 18:15	Hall 13 2-hour Oral Session The Trial Run: recent trials on S. aureus bacteraemia management Chairs	Julia Anna Bielicki (London, United Kingdom) Vance Fowler (Durham, United States)
	L0031	16:15	Introduction, Julia Anna Bielicki (London, United Kingdom), Vance Fowler (Durham, United States)
	L0032	16:20	Description of SNAP trial
	L0033	16:30	Benzylpenicillin versus (flu)cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia: a randomised controlled trial of the S. aureus network adaptive platform (SNAP)S. Tong* (Melbourne, Australia), S. Aureus Network Adaptive Platform Trial Group
	L0034	16:45	Cefazolin versus (flu)cloxacillin for the treatment of penicillin-resistant, methicillin-susceptible Staphylococcus aureus bacteraemia: a randomised controlled trial within the S. aureus network adaptive platform (SNAP)J. Davis* (Newcastle, Australia), S. Aureus Network Adaptive Platform Trial Group 
	L0035	17:00	Cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (Clo	Ce	Ba): a randomised, controlled, non-inferiority trial	X. Lescure* (Paris, France), F. Vandenesch, X. Duval, S. Tubiana, C. Burdet, N. Saïdani, A. Lemaignien, E. Canoui, L. Surgers, M. Esposito Farese, V. Le Moing, P. Tattevin
	L0036	17:15	Trial Discussion	Julia Anna Bielicki (London, United Kingdom)
	L0037	17:30	Trial Discussion	Vance Fowler (Durham, United States)
	L0038	17:45	Open Discussion and Q&A
	OS032	16:15 - 18:15	Hall 14 2-hour Oral Session Unraveling respiratory viruses, 2025 Chairs	Eeva Broberg (Solna, Sweden) Florian Krammer (New York, United States)
	O0222	Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France	P. Loubet* (Nimes, France), S. Guitton, R. Simon, L. Lefrancois, L.B. Luong Nguyen, P. Vanhems, F. Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. Lagathu, V. Foulogne, N. Houhou-Fidhou, A.S. L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay
	O0223	Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animalderived respiratory organoids	F. Tarrés-Freixas* (Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez- Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Moreno, C. López, J. Segalés, N. Majó, K. Kochanowski, J. Vergara-Alert
	O0224	Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infectio	n.B. Huckestein* (Memphis, United States), P. Thomas
	O0225	Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France	S. Fourati* (Créteil, France), A. Reslan, J. Bourret, Y. Rahou, L. Chollet, S. Pillet, P. Tremeaux, N. Candace Dossou, E. Gault, M. Salmona, B.M. Imbert, A. Mirand, S. Larrat, A. Moisan, S. Marot, A. Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, A. Henry, V. Stephan, S. Brichler, V. Avettand- Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Deroche, M.C. Jaffar, L. Mouna, C. François, A. Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. Rodriguez, G. Dos Santos, J. Buchrieser, O. Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti
	O0226	Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort	C. Geurts Van Kessel* (Rotterdam, Netherlands), M. Power, W. Rijnink, L. Gommers, T. Bestebroer, W. Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Geurtsvankessel
	O0227	Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems	J. Tan* (Singapore, Singapore), J.T. Lim, L.E. Wee, C. Chiew, B. Ong, D. Lye
	O0228	Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study	Stanislava Bratkovic (Copenhagen, Denmark)
	O0229	The burden of respiratory syncytial virus in children <3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study	E. Carter* (Liverpool, United Kingdom), H. Hill, D. Ferreira, A. Collins, C. Solórzano, L. Mclellan, L. Kerruish, F. Fyles, S. Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. Crozier, P. Saunderson, R. Kramer, M. Bangert, N. Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J. Bernatoniene, S. Bhowmik, J. Perry, P. Mottram, P. Mcnamara, D. Lewis, N. Van Kinnekan, A. Finn
	O0230	Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers	M. Knoll* (Hinxton, United Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego, D. Rajan, S. Frances Field, S. Thurston, A. Wong, B. Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin, B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick- Kretschmer, B. Dave, T. Maddison, S. Hopkins, S. Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison
	SY064	16:15 - 18:15	Hall 2 2-hour Symposium PK/PD to avoid emergence of resistance? Chairs	Anne-Grete Märtson (Leiden, Netherlands) Joseph Meletiadis (Athens, Greece)
	S0177	16:15	PK/PD and antibacterial therapy	Dolors Soy-Muner (Barcelona, Spain)
	S0178	16:45	PK/PD and antifungal therapy	Roger Brüggemann (Nijmegen, Netherlands)
	S0179	17:15	PK/PD and antiviral therapy	Joe Standing (London, United Kingdom)
	S0180	17:45	PK/PD considerations in anthelminthic treatment	Jennifer Keiser (Allschwil, Switzerland)
	EW070	16:15 - 18:15	Hall 3 Educational Session Malaria: when the drugs don’t work Management of treatment failure in nonendemic countries Chairs	Laura Nabarro (London, United Kingdom) Caroline Rönnberg (Stockholm, Sweden)
	W0201	16:15	Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure	Emmanuel Bottieau (Antwerp, Belgium)
	W0202	16:35	Malaria resistance mutations in the non-endemic setting: role of genomic surveillance	Anna Rosanas Urgell (Antwerp, Belgium)
	W0203	16:55	How to manage Plasmodium Knowlesi infection	Giri Shan Rajahram (Kota Kinabalu, Malaysia)
	W0204	17:15	Epidemiology and control of Plasmodium Knowlesi	Kimberly Fornace (Singapore, Singapore) Co-organised with: British Infection Association (BIA)
	SY065	16:15 - 18:15	Hall 4 2-hour Symposium Gram-positives, are they still going? Chairs	Diederik Bathoorn (Groningen, Netherlands) Stefania Stefani (Catania, Italy)
	S0181	16:15	The vanco chronicles: enterococci's global journey	Guido Werner (Wernigerode, Germany)
	S0182	16:45	Pitfall in susceptibility testing of Grampositives	Helena Zemlickova (Prague, Czech Republic)
	S0183	17:15	Drivers for daptomycin and linezolid resistance in Gram-positives	Glen Carter (Melbourne, Australia)
	S0184	17:45	What is new in treatment against MDR Grampositives? Alex Soriano (Barcelona, Spain)
	SY066	16:15 - 18:15	Hall 5 2-hour Symposium Biomarker testing to manage respiratory infections in primary care in low resource settings Chairs	Sonia Lewycka (Hanoi, Vietnam) Heiman Wertheim (Nijmegen, Netherlands)
	S0185	16:15	The Vietnamese experience with CRP testing in the community setting	Thi Thuy Nga Do (Ha Noi, Vietnam)
	S0186	16:45	The Nigerian experience with CRP testing in the community setting	Augustine Onwunduba (Awka, Nigeria)
	S0187	17:15	CRP testing in diagnosing tuberculosis in Zambia and South Africa	Helen Ayles (Lusaka, Zambia)
	S0188	17:45	The health economics of CRP testing in LMICs	Yoel Lubell (Bangkok, Thailand)
	EF035	17:15 - 18:15	Arena 1 e	Poster Flash Session Genomics in pathogen surveillance Chair Vítor Borges (Lisbon, Portugal)
	E0250	Genomic Surveillance of Invasive Group A Streptococcus in Argentina's 2023 Epidemic: Unveiling Hypervirulent emm1 Lineages and Pediatric emm12 Burden	L. Cipolla* (Buenos Aires, Argentina), A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto
	E0251	Understanding the population structure of Moraxella catarrhalis using core-genome multilocus sequence typing	I. Yassine* (Oxford, United Kingdom), K.A. Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel, A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J. Maiden, M.P. Nicol, A.B. Brueggemann
	E0252	Impact of the COVID-19 pandemic on the Streptococcus pyogenes clones causing adult invasive infections	M. Ramirez* (Lisbon, Portugal), A. Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt, M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For The Study Of Streptococcal Infections
	E0253	Unveiling the Hidden Complexity of Providencia: Genomic Insights into Species Reclassification and Antibiotic Resistance	X. Dong* (Hangzhou, China)
	E0254	Genomic description of outbreak of VIM-1 carrying Enterobacter in Switzerland suggests plasmid transmission between sequence types	H. Seth-Smith* (Zurich, Switzerland), M. Greutmann, C. Beckmann, E. Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin- Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte, L. Poirel, P. Nordmann, A. Egli
	E0255	Genomic epidemiology of Klebsiella pneumoniae bloodstream infections in a german tertiary centre: increased virulence in carbapenem-resistant strains	L. Knegendorf* (Hannover, Germany), M. Lindenberg, C. Baier, J. Erdmann, S. Häußler, D. Schlüter
	E0256	Phylogenetic mixing and undetected circulation of multiple Candida auris lineages following recognition of imported cases in Italy	V. Di Pilato* (Genoa, Italy), E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G. Daniele Roberto, M. Mikulska, B. Matteo, M. Anna
	E0257	Using Long-Read Sequencing for Core Plasmid Multilocus Sequence Typing to Investigate Plasmid Relationships Among Bacterial Species in German Hospital Wastewater	A.K. Bari* (Groningen, Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, T.T. Severs, M.J. Cardoso, M. Savin
	E0258	Screening for rectal colonization with multidrugresistant pathogens: usage of rapid metagenomic long-read technology	S. Purushothaman* (Zurich, Switzerland), A.M. Rooney, S. Moser, A. Egli
	EF036	17:15 - 18:15	Arena 3 e	Poster Flash Session Heads up! CNS infections Chair Jacob Bodilsen (Aalborg, Denmark)
	E0259	Central Nervous System Involvement by Mycobacterium avium Complex in Advanced HIV: A Rare and Underdiagnosed Challenge	E. Sienra Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A. Camiro Zuñiga, D.H. Martínez Oliva, A. Llamas Lopez, A.P. Rodriguez Zulueta
	E0260	Acute disseminated encephalomyelitis following bacterial meningoencephalitis – Two Case reports & Review of Literature	M. Priyadarshi* (Delhi, India), M. Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R. Bhatia
	E0261	Streptococcus equi Subspecies zooepidemicus Endocarditis and Meningitis in a 62-Year-Old Patient: A Case Report and Literature review	D. Chemello* (Modena, Italy), G. Franceschi, S. Alessandra, B. Andrea, S. Mario, M. Marianna, M. Cristina
	E0262	Breaking barriers: meropenem-vaborbactam as a game-changer for KPC central nervous system infections	F. Prataviera* (Udine, Italy), S. Giuliano, S. Flammini, J. Angelini, P.G. Cojutti, C. Tascini
	E0263	Multidrug-Resistant Klebsiella pneumoniae Meningitis in the Absence of Intracranial Devices: A Case Report	M. Chumbita* (Barcelona, Spain), E. Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A. Soriano
	E0264	Triple Threat: Sequential Meningitis Infections in an Immunosuppressed Patient with Morganella morganii, Acinetobacter baumannii, and Vancomycin-resistant Enterococcus faecium	Y. Çakir Kiymaz* (Sivas, Türkiye), Y. Çakır Kıymaz, E. Kıymaz, Z. Bulut, S.A. Büyüktuna, N. Elaldı
	E0265	Invasive pulmonary Arthrographis kalrae infection with cerebral abscesses in an immunocompromised child	B. Winkel* (Utrecht, Netherlands), J. Jans, M. Luesink, R.J. Nievelstein, F. Hagen, J. Buil, T. Wolfs, T. Van Der Bruggen
	E0266	Treatment of herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient	A. Birkmann* (Wuppertal, Germany), C. Lueck, C. Rautenberg, S. Bonsmann, A. Marini, M. Sumner, T. Schroeder, S. Voigt
	E0267	A case of influenza A (H1N1) encephalitis: Rare neurological implication in a healthy adult	N.K. Midha* (Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D. Kumar, G.K. Bohra 
Sunday, 13 April 2025 
	SY075	08:30 - 10:30	Hall 15 2-hour Symposium Diphtheria: from re-emergence to vaccine strategies Chairs	Helena Seth-Smith (Zurich, Switzerland) Julie Toubiana (Paris, France)
	S0221	08:30	Diphtheria: from clinical picture to medical management	Regina Oladokun (Oyo, Nigeria)
	S0222	09:00	The epidemiology of diphtheria worldwide over the last half-century: more than one comeback	Andreas Hoefer (Solna, Sweden)
	S0223	09:30	There’s more than one toxigenic Corynebacterium: the current genomics landscape of diphtheriaassociated strains	Sylvain Brisse (Paris, France)
	S0224	10:00	Diphtheria vaccination: a reappraisal Gayatri Amirthalingam (London, United Kingdom) Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Vaccine Study Group (EVASG)
	EF039	08:30 - 09:30	Arena 1 e	Poster Flash Session Novel approaches to antiviral therapy Chair Pinyo Rattanaumpawan (Bangkok, Thailand)
	E0288	Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infection	J. Pitts* (Foster City, United States), J.L.R. Zamora, S. Manhas, T. Aeschbacher, J. Chan, V. Cutillas, V. Nair, N. Riola, A. Vijjapurapu, M. Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S. Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H. Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V. Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T. Cihlar, S. Fletcher, J. Bilello
	E0289	EDP-323, a first-in-class, oral, RSV L-protein inhibitor reduces disease severity (respiratory mucus production) and accelerates viral clearance in a human viral challenge study	J. Devincenzo* (Watertown, United States), A. Ahmad, S. Chen, B. Löndt, A. Mann, J. Mori, A. Catchpole, S. Rottinghaus
	E0290	A Combined In Silico and In Vitro Pipeline for Optimizing Nanobodies Targeting Surface Proteins of Pathogens: Applications to SARS-Co	V-2, WNV, and Influenza A Virus	C.L. Pierri* (Bari, Italy), G.C.M. Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba, V. Scaglione, D.I. De Luca, F. Mastropirro, S. Spadone, L. Guerra, M. Volpicella, A. De Grassi
	E0291	Bemnifosbuvir and Remdesivir exhibit potent antiviral activity against tick-borne encephalitis virus in vitro	D. Grandgirard* (Bern, Switzerland), S. Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib
	E0292	Combinations of antiviral drugs demonstrating synergistic inhibition of multiple respiratory RNA viruses	S. Ellis* (London, United Kingdom), A.I. Jacobs, M. Woodall, S. Zhang, J.F. Standing, J. Breuer
	E0293	The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants	A. Gaggar* (South San Francisco, United States), E. Gane, C. Schwabe, G. Wang, J. Liu, S. Knox, K. Kitrinos, K. Zomorodi
	E0294	Efficacy of ganciclovir against CMV infection is dependent on treatment initiation time	L. Sudarsono* (Leiden, Netherlands), X. Liu, J.G.C. Van Hasselt, A.G. Märtson
	E0295	Efficacy of molnupiravir and baloxavir against influenza A H1N1 infection in vitro and in vivo	D. Liu* (Hong Kong, Hong-Kong SAR, China), K.Y. Leung, R. Zhang, Y. Fan, K.H. Chan, F.N.I. Hung
	E0296	Human defensin derived peptide showing broad antiviral activity against human adenoviruses	X. Wang* (Hongkong, China), H. Zhao 
	EF040	08:30 - 09:30	Arena 3 e	Poster Flash Session New frontiers in parasitic disease and migrant health research
	E0298	Targeting metabolic bioenergetics: the ‘Achilles' heel' of Leishmania	D. Sarkar* (Kolkata, India)
	E0299	Leishmaniasis in Southern Alicante (Spain): what is the new patient profile?M.D. Hernández Rabadán* (Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez López, D. López Parra, J. Llenas García
	E0300	Schistosoma haematobium infection is associated with oncogenic gene expression in cervical mucosa, with enhanced effects following treatment	Anna Mertelsmann (Zürich, Switzerland)
	E0301	Associations between water and sanitation service, risk of intestinal schistosomiasis, infection intensity, and liver fibrosis in selected households living near Lake Albert: a descriptive cross-sectional study?G. Lam* (London, United Kingdom), D. Dee, A. Edielu, E. Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P. Mawa, J. Friedman, A. Bustinduy
	E0302	Schistosomiasis detected by Screening of sub- Saharan African Unaccompanied Minor Refugees in Berlin between 2023 and 2024G. Equihua Martinez* (Berlin, Germany), A.K. Lindner, M.C. Moreno-Del Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T. Geppert, F. Mockenhaupt, B. Kampmann, F. Olgemöller
	E0303	NADPH oxidase of the mosquitoes and the antioxidant genes repertoire of the bacteria coordinate mosquito-bacteria interaction in midgut	B. Song* (Kowloon, Hong-Kong SAR, China), J. Zeb, N. Buchon, O. Sparagano, P. Butaye
	E0304	Molecular detection and sequencing of the genes encoding the predicted enzymes; Amidase, NADH ubiquinone oxidoreductase, and sodium neurotransmitter symporter in Onchocerca volvulus	A. Acheampong* (Sunyani, Ghana), J. Larbi, P.C. Kudzordzi, P. Nyarko, K.B. Otabil
	E0305	Tuberculosis outcomes among international migrants living in Europe compared to the non-migrant population: a systematic review and meta-analysis	G. Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R. Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di Franco, M. Affronti, E. Piccione, G. Gualano, F. Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F. Di Gennaro
	EW079	08:30 - 10:30	Hall 11 Educational Session New guidelines for management of brain infections Chairs	Jacob Bodilsen (Aalborg, Denmark) Kartika Maharani (Jakarta, Indonesia)
	W0237	08:30	Tuberculous meningitis: what can we learn from the first global guidelines?Joseph Donovan (Ho Chi Minh City, Vietnam)
	W0238	08:50	WHO guidelines on bacterial meningitis: change of clinical practice?Matthijs Brouwer (Amsterdam, Netherlands)
	W0239	09:10	ESCMID encephalitis guidelines 2024: what’s new?Tom Solomon (Liverpool, United Kingdom)
	W0240	09:30	WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation	Nelesh Govender (Johannesburg, South Africa) Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)
	SY073	08:30 - 10:30	Hall 12 2-hour Symposium Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship Chairs	Bhanu Sinha (Groningen, Netherlands) Annelies Verbon (Bosch En Duin, Netherlands)
	S0213	08:30	A broad spectrum of possibilities: spectrum scores as a unifying metric	Céline Pulcini (Nancy, France)
	S0214	09:00	Proxy indicators to estimate appropriateness of antibiotic prescriptions	Diane Ashiru-Oredope (London, United Kingdom)
	S0215	09:30	How to bridge the gap between surveillance and antimicrobial stewardship	Mark G. J. De Boer (Leiden, Netherlands)
	S0216	10:00	Health economics, surveillance and antimicrobial stewardship	Zhu Nina Jiayue (London, United Kingdom) Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)
	SY074	08:30 - 10:30	Hall 13 2-hour Symposium Difficile to treat: advanced management strategies in difficult to treat CDI Chairs	Frédéric Barbut (Paris, France) Kerrie Davies (Leeds, United Kingdom)
	S0217	08:30	Severe CDI: when standard protocols fail	Hynek Bartos (Prague, Czech Republic)
	S0218	09:00	Therapies for complicated CDIEmma Bishop (Clayton Vic, Australia)
	S0219	09:30	Recurrent CDI: Breaking the cycle	Andrea Marino (Catania, Italy)
	S0220	10:00	Live biotherapeutic products for Clostridioides difficile infection	Simon Goldenberg (London, United Kingdom) Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)
	OS038	08:30 - 10:30	Hall 14 2-hour Oral Session Making fast for making better: AMR rapid diagnostics Chairs	Giulia De Angelis (Rome, Italy) Onur Karatuna (Växjö, Sweden)
	O0278	Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infections	J. Rogers* (Bedford, United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch
	O0279	Evaluation of a new rapid Lateral flow immunoassay for the detection of DHA-producing Gram-negative bacteria	C. Moguet* (Guipry, France), S. Oueslati, A. Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas
	O0280	The Nitro	Speed Taniborbactam NP test; easy detection of β-lactamase sensitivity to taniborbactam	O. Raro* (Fribourg, Switzerland), S. Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poirel, P. Nordmann
	O0281	Rapid detection of β-lactamase-mediated resistance to aminopenicillins from urine	s.P. Nordmann* (Fribourg, Switzerland), N. Helsens, C. Duployez, L. Poirel, R. Dessein
	O0282	Rapid detection of antibiotic resistance in direct urine samples	M. Bot* (Arnhem, Netherlands), J. Flipse, S. Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, M. Van Meer
	O0283	Next-Generation Utilizer Dipsticks for direct-fromsample phenotypic Antibiotic Susceptibility Testing in UTIs	E. Iseri* (Stockholm, Sweden), W. Van Der Wijngaart, V. Özenci, R. Santini, A. Nakama, O. Ekelund, A. Van Belkum
	O0284	Screening for ceftriaxone-resistant Neisseria gonorrhoeae with the Urogenital and Resistance kit (Aus	Diagnostic)A. Braille* (Paris, France), M. Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Condamine, F. Caméléna, B. Berçot
	O0285	Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood cultures	D. Squitieri* (Rome, Italy), G. Menchinelli, C. Magrì, T. D'inzeo, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti
	O0286	Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapy	K. Chaudhary* (New Delhi, India), H. Gautam, P. Batra, S. Mohapatra, S. Sood, B. Dhawan, B. Das Kumar
	SY076	08:30 - 10:30	Hall 16 2-hour Symposium AMR Surveillance in low resource countries: insights into clinical and policy translation Chairs	Kwame Ohene Buabeng (Ho, Ghana) H. Rogier Van Doorn (Hanoi, Vietnam)
	S0225	08:30	New indicators in national monitoring and evaluation of AMR supported by improved data utilisation	Direk Limmathurotsakul (Bangkok, Thailand)
	S0226	09:00	Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections	Stephen Mshana (Mwanza, Tanzania, United republic of)
	S0227	09:30	A clinically-oriented AMR surveillance network: casebased surveillance and implementation	Paul Turner (Siem Reap, Cambodia)
	S0228	10:00	National prescribing guidelines based on AMR surveillance data	Vilada Chansamouth (Vientiane, Lao People's democratic republic) Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)
	EW077	08:30 - 10:30	Hall 2 Educational Session New tools in acute bacterial infections and sepsis: from machine learning to precision medicine Chairs	Benjamin Mcfadden (Perth, Australia) Rita Murri (Rome, Italy)
	W0229	08:30	Differentiating acute infection, sepsis and sepsis mimics in the ED?Lisa Mellhammar (Lund, Sweden)
	W0230	08:50	Machine learning for early recognition of sepsis	Karsten Borgwardt (Martinsried, Germany)
	W0231	09:10	How to avoid common mistakes in randomised clinical study design	Yin Mo (Singapore, Singapore)
	W0232	09:30	Improved clinical trials in community-acquired pneumonia using precision medicine	Lennie Derde (Utrecht, Netherlands) Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro
	SY072	08:30 - 10:30	Hall 3 2-hour Symposium Tackling the emergence of dengue and other Aedes-borne diseases in Europe Chairs	Fernanda Boulos (São Paulo, Brazil) Martin P. Grobusch (Amsterdam, Netherlands)
	S0209	08:30	How dengue, chikungunya and zika virus disease became emerging threats to Europe	Celine Gossner (Solna, Sweden)
	S0210	09:00	Surveillance of dengue in urbanised tropical regions	Vincent Junxiong Pang (Singapore, Singapore)
	S0211	09:30	Mosquito surveillance and control: opportunities and challenges	Tba
	S0212	10:00	Tracking autochthonous arboviral infection	Luisa Barzon (Padua, Italy) Co-organised with: European Centre for Disease Prevention and Control (ECDC)
	EW078	08:30 - 10:30	Hall 4 Educational Session Implementing metagenomics in my lab and mistakes to avoid Chairs	Hege Vangstein Aamot (Lørenskog, Norway) Claudio Neidhöfer (Bonn, Germany)
	W0233	08:30	Is metagenomics right for my lab?Paula Mölling (Örebro, Sweden) 
	W0234	08:50	Understanding the experimental and certification aspects of metagenomics	Mads Albertsen (Aalborg, Denmark)
	W0235	09:10	Navigating tools, techniques, and procurement	Basil Britto Xavier (Groningen, Netherlands)
	W0236	09:30	Setting realistic goals and outcomes for metagenomics integration	Claire Bertelli (Lausanne, Switzerland) Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee
	OS037	08:30 - 10:30	Hall 5 2-hour Oral Session Whole genome sequencing: tracking transmission and reservoirs in outbreaks Chairs	Eric Claas (Leiden, Netherlands) Paul G. Higgins (Cologne, Germany)
	O0268	From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting	N. Storey* (London, United Kingdom), E. Cloutman-Green, J. Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Hatcher, J. Brown, J. Breuer
	O0269	Why do routine genome-oriented surveillance for Pseudomonas aeruginosa?A. Rath* (Regensburg, Germany), L. Grancicova, B. Kieninger, A. Caplunik- Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert
	O0270	Tree	Time estimation depicts transmission dynamics of clinical and environmental Pseudomonas aeruginosa from common reservoirs in healthcare environment through whole genome sequencing (WGS)Ö. Yetis* (London, United Kingdom), Ö. Yetiş, F. Dyrkell, S. Ali, P. Wilson
	O0271	Understanding Serratia transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis	K. Jaakkola* (Lyon, France), C. Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. Colomb-Cotinat, S. Haÿs, J.P. Rasigade
	O0272	Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing	C. Shankar* (Ann Arbor, United States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin
	O0273	Genome-oriented analysis of the first outbreaks involving the novel Serratia sarumanii at a neonatal unit	A. Rath* (Regensburg, Germany), B. Kieninger, L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik- Pratsch, M. Kabesch, J. Kalinowski, W. Schneider- Brachert
	O0274	Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTIPE Study	J. Price* (Brighton, United Kingdom), I. Sey, A. Yeoh, D. Wlazly, A. Davies, O. Makanjuola, J. Leach, S. Mookerjee, M. Krutikov
	O0275	Outbreak of Carbapenem-Resistant Acinetobacter seifertii in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillanc	e.D. Pereira* (Porto Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, G. De Oliveira, L. Lutz, M. Mott, C. Constante, C. Wilhelm, L. Antochevis, R. Paiva, K. Tragnago, A. Barth, A. Martins
	O0276	Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant Klebsiella pneumoniae in the ICU environment	X. Han* (Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu
	O0277	Survey of Infection Prevention staff perception of WGS integration into routine IPC practice	D. Ling* (Melbourne, Australia), B. Baral, V. Madigan
	EF041	09:30 - 10:30	Arena 2 e	Poster Flash Session treatment of a cerebrospinal fluid drain infection caused by a multidrug-resistant Staphylococcus epidermidis strain	M.D. Di Trapani* (Bozen, Italy), T. Kamal Eldin, G. Spoladore, D. Drusiani, B. Ladinser, R. Aschbacher
	E0318	Timeline of early infections post porcine xenothymokidney transplant	H. Neumann* (New York, United States), M. Ringer, R. Alpizar-Rivas, J. Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A. Griesemer, R. Montgomery, S. Williams, S. Mehta
	E0319	Invasive Non-tuberculous mycobacteria Infection in children undergoing Cardiac Surgery at the specialized Cardiology Hospital of Peshawar	M. Khan* (Peshawar, Pakistan)
	E0320	Use of multiplex PCR assay analysis in patients with suspected implant-based breast reconstruction infection: a single center experience	A. Pagotto* (Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor, A. Colombo, P.C. Parodi, C. Tascini
	E0321	PET CT controls and Dalbavancin therapeutic drug monitoring can help guiding Dalbavancin treatment duration of complicated cardiovascular infections	C. Kujat* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank, A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewering, A. Friedrichs
	E0322	A complex case of pelvic bone infection caused by carbapenem-resistant Acinetobacter baumanii successfully treated with eravacycline	M. Zagarrigo* (Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro, A. Pozzi, E. Zamparini, P. Viale
	E0323	Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?M. Bongiovanni* (Lugano, Switzerland), B. Barda, E. Bernasconi
	KN080	09:30 - 10:30	Hall 1 Keynote Lecture Infections after solid organ transplantation: past, present and future Chairs	Nina Khanna (Basel, Switzerland) Priscilla Rupali (Vellore, India)
	K0241	09:30	Jay Fishman (Boston, United States)
	SY082	11:00 - 12:00	Hall 6 1-hour Symposium How to address anti-science in our community? Chairs	Tuba Dal (Ankara, Türkiye) Tyra Grove Krause (Copenhagen, Denmark)
	S0243	11:00	The rise of anti-science: lessons for the future scientist	Marion Koopmans (Rotterdam, Netherlands)
	S0244	11:30	Open science for public trust	Lisa Hansen (Ottawa, Canada)
	FO090	11:00 - 12:00	Arena 1 Open Forum European CM/ID exam: going forward Chair Siri Goepel (Tuebingen, Germany)
	F0259	11:00	View from medical microbiology	Maeve Doyle (Waterford, Ireland)
	F0260	11:10	view from infectious diseases	Eoghan De Barra (Dublin, Ireland)
	F0261	11:20	view from trainees (TAE)Christian Kraef (Copenhagen, Denmark)
	F0262	11:30	European exam - how to prepare?Annelies Verbon (Bosch En Duin, Netherlands) 
	E0367	Optimizing pretreatment for MALDI-TOF MS: Evaluating the dispersion method for filamentous fungal identification	R. Huang* (Shenzhen, China), Y. Li, Y. He, T. Ma, F. Lu
	E0368	Rapid detection of colistin resistance in Acinetobacter baumannii by a MALDI-TOF MS-based assay	E. Kırbaş* (Van, Türkiye), I.D. Nix, K. Sparbier, O. Drews, B. Oberheitmann, M. Kostrzewa, G. Hasçelik, B. Sancak
	E0369	Discrimination of clinical Pseudomonas strains at the species level using a large-scale genomically predicted protein mass database with MALDI-MS	K. Teramoto* (Kyoto, Japan), Y. Sekiguchi, L. Sellami, M. Tohya, T. Kirikae
	E0370	Automatic differentiation of Clostridioides difficile ribotypes using MALDI-TOF MS and web-based classification models	M. Blazquez Sanchez* (Madrid, Spain), M.C. Blazquez-Sanchez, J.M. Moreno, A. Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P. Muñoz, M. Marín, L. Alcalá, D. Rodriguez-Temporal, B. Rodriguez-Sanchez
	E0371	Identification of sepsis-causing bacteria using shotgun proteomics	L. Meekes* (Rotterdam, Netherlands), D. Rustad, C. Güzel, T.K. Jenssen, H. Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider, W. Goessens
	EF051	11:00 - 12:00	Arena 4 e	Poster Flash Session The enemy of my enemy: From jumbo phages to cocktails for difficult to treat infections Chair Paul G. Higgins (Cologne, Germany)
	E0372	Anti-K2 recombinant phage depolymerases as antivirulence agents against hypervirulent Klebsiella pneumoniae	M. Roch* (Geneva, Switzerland), R. Sierra, D. Andrey
	E0373	Jumbo Klebsiella bacteriophage demonstrates efficient multidrug-resistant Klebsiella pneumoniae killing and significant clinical potential	Y. Liu* (Singapore, Singapore), Y. Zhong, S. Thong, L.H.A. Kwa
	E0374	A new phage cocktail targeting at Klebsiella pneumoniae	X. Yin* (Chengdu, China), Y. Feng, H. Luo, Z. Zong
	E0375	Bacteriophages against pulmonary infection and colonization of the gut by multidrug-resistant Klebsiella pneumoniae in murine models	A.M. Örmälä- Tiznado* (Stockholm, Sweden), S. Patpatia, J. Bengoechea, C. Frantzen, A. Garcia Navarro, C. Giske
	E0376	A novel broad-spectrum phage cocktail effictive for carbapenem resistant Acinetobacter baumannii of capsular type 104/2/7 in vitro	L. Wei* (Chengdu, China), Y. Feng, Z. Zong
	E0377	Proteomic and Genomic Characterization of a Novel Bacteriophage of a New Genus Infecting Pseudomonas aeruginosa	S. Unlu* (Ankara, Türkiye), A. Uskudar Guclu
	E0378	Phages as innovative adjuvants of antibiotics therapy against S. aureus and P. aeruginosa in the context of Cystic Fibrosis	A. Glorieux* (Brussels, Belgium), S. De Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van Bambeke
	E0379	Evaluation of bacteriophages against Staphylococcus aureus strains isolated from orthopaedic infections	S. Patpatia* (Helsinki, Finland), A. Camporeale, S. Kiljunen, C. Giske, A.M. Örmälä-Tiznado
	E0380	Anti-Staphylococcus aureus phages: assessing the risk of bacterial resistance emergence through selective pressure	M. Degreze* (Lyon, France), M. Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent, C. Kolenda
	KN081	11:00 - 12:00	Hall 1 Keynote Lecture Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F. Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. Coppola, A. Mularoni
	O0350	Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers	M. Rinaldi* (Bologna, Italy), B. Miani, M. Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L. Alagna, E. Franceschini, P. Burra, A. Mularoni, M. Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. Caroccia, M. Di Chiara, P. Viale, M. Giannella
	O0351	Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donor	s.O. Fernandez Garcia* (Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. Doucette
	O0352	Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients	A. Dahl* (Københa	Vn V, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup, J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning, J. Lundgren, N. Mueller, M. Helleberg
	O0353	Burden of non-microbiologically confirmed infections in solid organ transplant recipients	M. Zou* (Basel, Switzerland), M. Koller, O.J. Manuel, N. Mueller, K. Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van Delden, D. Neofytos
	SY085	11:00 - 12:00	Hall 13 1-hour Symposium Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination Chairs	Mojca Maticic (Ljubljana, Slovenia) Snjezana Zidovec Lepej (Zagreb, Croatia)
	S0249	11:00	Role of reflex testing strategies in identifying patients with chronic viral hepatitis	Oana Sandulescu (Bucharest, Romania)
	S0250	11:30	Management and elimination of hepatitis in hard-toreach persons	Suda Tekin (Istanbul, Türkiye) Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS
	SY086	11:00 - 12:00	Hall 14 1-hour Symposium Impact on including a measure of viability in molecular diagnostic tests Chairs	Fusun Can (Istanbul, Türkiye) Denise O'sullivan (Teddington, United Kingdom)
	S0251	11:00	Viability markers in support of development of Chlamydia screening recommendations	Petra Wolffs (Maastricht, Netherlands)
	S0252	11:30	Measuring viability to improve the correlation of AMR markers and clinical outcomes in Neisseria gonorrhoeae	Tatum Mortimer (Athens, United States) Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)
	ME089	11:00 - 12:00	Hall 15 Meet-the-Expert How to teach Medical Mycology
	M0257	11:00	Katrien Lagrou (Leuven, Belgium)
	M0258	11:12	Mihai Mares (Iasi, Romania) Co-organised with: European Confederation of Medical Mycology (ECMM) Putoto, F. Di Gennaro, C. Severini, A. Saracino
	L0007	Investigation of an international pseudo-outbreak involving Paraburkholderia fungorum blood culture contamination	J. Moran-Gilad* (Jerusalem, Israel), J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Palavecino, P. Snippes Vagnone
	L0008	Evolving cluster of severe infective endocarditis with non-toxigenic C. diphtheriae amongst people experiencing homelessness and substance misuse in the UK	R. Cordery* (London, United Kingdom), T. Patel, T. Anwar, N. Utjesanovic, A. Aryee, E. Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Primus, S. Das, K. Paranthaman, G. Amirthalingham
	L0009	AI-driven live cough rate tracking for public health surveillance	M. Kågebäck* (Göteborg, Sweden), E. Carlsson
	OS044	11:00 - 12:00	Hall 5 1-hour Case Session Unusual presentations of unusual parasites Chairs	Emmanuel Bottieau (Antwerp, Belgium) Marcelo Victor Radisic (Buenos Aires, Argentina)
	O0329	Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resourcelimited setting	D. Ekwem Amarachi* (Gulu, Uganda), E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, R. Olum
	O0330	An itchy awakening due to Dermanyssus infestation	J. Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales, J.M. Bérenegr, S. Ranque
	O0331	Uterine Myiasis: A Rare Case of External Genitourinary Myiasis	R.L. Johnson* (Birmingham, United States), J.C.F. Nakazaki, P. Legua
	O0332	Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestatio	n.C. Norsungnern* (Bangkok, Thailand), J. Vinichanan, L. Paitoonpong
	O0333	If at first, you don't succeed… Treatment-resistant Fascioliasis: case report	W. Garr* (Leeds, United Kingdom), K. Woods, L. Nabarro
	SY083	11:00 - 12:00	Hall 7 1-hour Symposium Lyme neuroborreliosis: challenges in diagnosis and treatment Chairs	Alexandra Mailles (Paris, France) Joanna Maria Zajkowska (Białystok, Poland)
	S0245	11:00	Challenges in diagnosis of Lyme neuroborreliosis	Rick Dersch (Freiburg, Germany)
	S0246	11:30	Challenges in treatment of Lyme neuroborreliosis	Anne Marit Solheim (Kristiansand, Norway) Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)
	OS045	11:00 - 12:00	Hall 8 1-hour Oral Session Social behavioural dynamics of antibiotic use and AMR Chairs	Sonia Lewycka (Hanoi, Vietnam) Filippo Medioli (Milan, Italy)
	O0334	Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross- Sectional Survey	A. Abbara* (London, United 
	SY093	13:30 - 14:30	Hall 11 1-hour Symposium Immunosenescence and immune response to vaccination Chairs	Petar Velikov (Sofia, Bulgaria) Dafna Yahav (Ramat-Gan, Israel)
	S0267	13:30	How immunosenescence impacts vaccine response	Andrea Cossarizza (Modena, Italy)
	S0268	14:00	Strategies to tackle immunosenescence and improve immune response to vaccination in the elderly	Inna Ovsyannikova (Rochester, United States) Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)
	EW096	13:30 - 15:30	Hall 15 Educational Session Tools for successful development as a medical educator Chairs	Giorgia Caruana (Sion, Switzerland) Yoav Keynan (Winnipeg, Canada)
	W0273	13:30	Developing your educator professional identity	Todd Cassese (Bronx, United States)
	W0274	13:50	What do IPC doctors need to learn to be prepared	Simone Scheithauer (Göttingen, Germany)
	W0275	14:10	Communities of practice: successful experience of a transformative collaboration and roadmap	Erin Bonura (Portland, United States)
	W0276	14:30	The critical need for ongoing innovations in medical education	Clémentine Schilte (Paris, France) Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology
	FO097	13:30 - 14:30	Arena 1 Open Forum Essential diagnostics in Low-Resource Settings: why are we still talking? Chair Truls Michael Leegaard (Lørenskog, Norway)
	F0277	13:30	Training skilled personnel in LMIC and brain drain: is the solution the problem?Sipho Kenneth Dlamini (Observatory, South Africa)
	F0278	13:40	Leveraging surveillance networks to strengthen basic bacteriology	Dissou Affolabi (Cotonou, Benin)
	F0279	13:50	Clinical bacteriology laboratories in low-resource settings: considerations for sustainability	Makeda Semret (Montreal, Canada) Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity Commission,Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge d'Infectiolo
	FO098	13:30 - 14:30	Arena 2 Open Forum Best of ID Week Chair Tina Tan (Chicago, United States)
	F0280	, Seth Cohen (Seattle, United States), Erin Mccreary (Pittsburgh, United States), Ilan Youngster (Beer Yaakov, Israel) using whole genome analysi	s.M. Mansfield* (Dublin, Ireland), E. Roycroft, S. Mok, P. Flanagan, M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V. Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers
	E0403	Distinguishing relapse from reinfection in tuberculosis patients from Lithuania	L. Vasiliauskaite* (Vilnius, Lithuania), L. Vasiliauskaitė, A. Zinola, F. Di Marco, V.E. Davidavičienė, B. Nakčerienė, A. Vaitulionytė, D.M. Cirillo, T. Kačergius
	E0404	Rapid Resistance Profiling of Mycobacterium tuberculosis from Clinical Specimens using Targeted Next-Generation Sequencing: A Pilot Validation Study	P. Chheda* (Mumbai, India), S. Shivaprakash, T. Dama, G. Thandassery
	E0405	Inflammation precedes early respiratory worsening in HIV-negative tuberculosis patients during antituberculosis treatment	A. Van Laarhoven* (Nijmegen, Netherlands), L. Kurver, E. Klein Teeselink, A. Lemson, C. Bosteels, N. Carpaij, J. Van Ingen, E. Ardiansyah, C. Van Arkel, R. Vullinghs, C. Magis Escurra, W. Hoefsloot, R. Van Crevel
	E0406	Impact of fluoroquinolone resistance on the costeffectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis	C. Kim* (London, United Kingdom), S. Sweeney, H. Sohn, G.M. Knight, C.F. Mcquaid
	E0407	A longitudinal study on the evolution of drug resistance during tuberculosis treatment	E. Danso* (Accra, Ghana), P. Asare, P. Tetteh, A. Tetteh, A.A. Boadu, S. Osei-Wusu, A. Asante-Poku, Y. Klinogo, A. Sylverken, J. Afriyie-Mensah, A. Adjei, D. Yeboah- Manu
	E0408	Phase 1, randomized, double-blind, parallel-group, dose-escalation safety and tolerability of PLGA encapsulated first line antitubercular drugs nanoparticles in healthy volunteers	A.K. Pandey* (Chandigarh, India), N. Shafiq, S. Malhotra, C. Mothsara, G. Khuller, J. Verma, L. Verma SEL	13:30 - 15:30	Hall 1 Special Session Selective Pressure Chairs	Jacob Moran-Gilad (Beer Sheva, Israel) Joshua Nosanchuk (Bronx, United States) Jose Ramon Pano-Pardo (Zaragoza, Spain) Jesús Rodríguez-Baño (Seville, Spain) Anja Šterbenc (Ljubljana, Slovenia) Suzanne Van Asten (Nijmegen, Netherlands) David Van Duin (Chapel Hill, Nc, United States)
	JS1	13:30 - 14:30	Hall 12 Journal Session Late-breaker research from CMI and CMI Communications
	J001	13:30	Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023)Gaetan Gavazzi (Grenoble, France)
	J002	13:45	Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial	Thomas Holland (Durham, United States)
	J003	14:00	The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study	Elise Mitri (Heidelberg, Australia)
	J004	14:15	Efficacy and safety of mechanical thrombectomy in acute ischemic stroke secondary to infective endocarditis	Tba 
	O0382	Carba	Detector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase- Producing Enterobacterales Using Disk-Diffusion	L.K. Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht
	O0383	AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE)G. Danoe* (Groningen, Netherlands), M. Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A. Hamprecht, M. Brilman, L.L. Peters, M.S. Berends
	O0384	Predicting potentially infection-related findings in structured radiology reports	J. Xu* (Oxford, United Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P. Langlotz, D. Eyre
	O0385	Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections	H. Zhang* (Shanghai, China), X. Xu, J. Ai
	OS053	13:30 - 14:30	Hall 3 1-hour Oral Session Immune evasion and intracellular survival strategies Chairs	Juliane Bubeck Wardenburg (S	t. Louis, United States) Giovanni Delogu (Rome, Italy)
	O0386	Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in Acinetobacter baumannii	H. Wang* (Beijing, China), C. Jiang
	O0387	Intracellular lifestyle of Acinetobacter baumannii: Role of phospholipase	A2 and transcriptional factor EB (TFEB)Y. Smani* (Seville, Spain), C. Atalaya Rey, I. Molina Panadero, A. Lora González, A. Hmadcha
	O0388	The role of peg344 of hypervirulent Klebsiella pneumoniae on suppressing autophagy responses of macrophages	Z.E. Kuloğlu* (Istanbul, Türkiye), Ö. Albayrak, D. Güllü, G. Ekinci, F. Can
	O0389	c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection	C. Dollé* (Zurich, Switzerland), E. Sarti, R. Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander, G.S. Olson, J. Nemeth
	O0390	Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology	J. Kutschenreuter* (London, United Kingdom), D. Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman, J.S. Friedland, D.L.W. Chong
	SY091	13:30 - 14:30	Hall 4 1-hour Symposium Emerging infectious diseases: staying informed and prepared in a globalised world Chairs	Nitin Gupta (Manipal, India) Pikka Jokelainen (Copenhagen, Denmark)
	S0263	13:30	Lessons learnt from previous outbreaks	Tba
	S0264	14:00	Disease X: preparedness for the next pandemic	Yee Sin Leo (Singapore, Singapore) Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.
	SY092	13:30 - 14:30	Hall 5 1-hour Symposium Sex differences in management and outcome of patients with serious bacterial infections Chairs	Michele Bartoletti (Milan, Italy) Merel Lambregts (Leiden, Netherlands) 
	E0428	Invasive group A streptococcus infections is often preceeded by seasonal influenz	a.J. Westin* (Gothenburg, Sweden), M. Nygren, U. Snygg-Martin, L. Gustavsson, N. Sundell
	E0429	Impact of the COVID-19 Pandemic on Tuberculosis Transmission Rates	A. Cannas* (Rome, Italy), V. Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, E. Girardi, C. Fontana
	E0430	Treatment outcomes of bedaquiline-based longer oral regimens in Indian children above 5-years of age	D. Gandhi* (Mumbai, India), I. Shah, R. Ansari, H. Warse, S. Kalawadia, T. Yangchen, D. Shah, V. Puri, S. Mattoo, M. Bodhanwala
	E0431	Incidence of Invasive Escherichia coli Disease in the Northwestern United States (2002–2022): Insights from Electronic Health Records	M. Blum* (Leuven, Belgium), C. Onwuchekwa, M.A. Schmidt, J. Poolman, T. Verstraeten, J. Geurtsen
	E0432	A prospective controlled cross-sectional study demonstrates significantly higher Ig	G seroprevalence of leptospirosis among Munich's Eisbach river surfers	F. Voit* (München, Germany), D. Schult- Hannemann, M.H. Richter, L. Wagner, J. Ostermaier, K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider
	EF060	14:45 - 15:45	Arena 3 e	Poster Flash Session AMR in the community Chair Camilla Wiuff Coia (Copenhagen, Denmark)
	E0433	Socio-demographic factors associated with community-acquired extended spectrum β- lactamase producing E. coli urinary tract infections at intermunicipal level in France	M. Prime* (Nantes, France), O. Lemenand, S. Thibaut, T. Coeffic, B. Perrot, J. Caillon, D. Boutoille, E. Batard, G. Birgand
	E0434	Prolonged community outbreak of OXA-48- producing Escherichia coli linked to a food premises: Lower Hutt, New Zealand, 2018-2022C. Thornley* (Lower Hutt, New Zealand), M. Kelly, M. Bloomfield, A. Nesdale, R. White
	E0435	Low rates of macrolide resistance found in Mycoplasma pneumoniae cases in Australia	R. Rockett* (Westmead, Australia), J. Kok, K.G. Tam, T. Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, V. Sintchenko, S.C.A. Chen
	E0436	Epidemiology of antibiotic resistance associated with E. coli/Klebsiella pneumoniae bloodstream infections in England 2012-2023S. Lipworth* (Oxford, United Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, T. Katy
	E0437	The effect of long-term fluoroquinolone prophylaxis on carriage of antimicrobial resistant organisms in childre	n.C. Brand* (Cape Town, South Africa), R. Ocloo, D. Wilck, P. Dube, A. Hesseling, J. Seddon, A. Demers, M. Newton-Foot, A. Whitelaw
	E0438	Risk factors and prevalence of Anti	Microbial Resistant microbes In the English Community (AMRIC)D. Lecky* (Gloucester, United Kingdom), Z. Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S. Leaver, K. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown
	E0439	Risk factors for antimicrobial resistance in community commensal Staphylococcus aureus isolates, a subanalysis of the AMRIC projec	t.M. Joyce* (Manchester, United Kingdom), Z. Aiken, N. Zhu, A. Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown, D.M. Lecky
	E0440	Prevalence and risk factors for antimicrobial resistance in invasive pneumococcal disease in southern Ontario in the late post PCV13 era (2014- 2023)A. Mcgeer* (Toronto, Canada), A. Shigayeva, A. Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W. Cabed, V. García-López, A. Polo, J. Laporte-Amargos, G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. Galán, M. Chávez-Caballero, M.O. Mohamed- Balghata, S. Winderickx, J.M. García De Lomas, F.J. Martinez-Marcos, M. Giannella, M. Garzaro, M. Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. López Cardenas, E. Cendejas, A.V. Halperin Benito, A. Romero Palacios, M. Navarro, C.A. Alonso, A. Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E. Pachón-Ibáñez, E. Cordero-Matía
	SY100	14:45 - 15:45	Hall 12 1-hour Symposium The challenge of a healthy microbiota in neonates Chairs	Maria Vehreschild (Frankfurt Am Main, Germany) Walter Zingg (Zurich, Switzerland)
	S0283	14:45	Infant gut microbiome development	Debby Bogaert (Edinburgh, United Kingdom)
	S0284	15:15	Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates	Gautam Dantas (Saint Louis, United States) Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paedriatic Infectious Diseases (ESPID)
	OS058	14:45 - 15:45	Hall 16 1-hour Case Session In the field with fungi Chairs	Beatriz L. Gomez (Bogota, Colombia) Leonardo Nimrichter (Rio De Janeiro, Brazil)
	O0419	Fosmanogepix expanded access in patients with Fusarium infections	S. Dadwal* (Duarte, United States), A. Baluch, J. Dickter, J.R. Newman, M.H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner
	O0420	Voriconazole's hidden toll: unveiling periostitis in a heart transplant recipient and a hematologic patien	t.G. Motoa* (Boston, United States), A. Woolley, N. Issa
	O0421	Unveiling the Uncommon: Managing Geotrichum candidum in Pancreatic Necrosis	L. Kriegl* (Graz, Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Schlager, G. Zollner, K. Dichtl, R. Krause
	O0422	Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections	V. Havlicek* (Prague, Czech Republic), R. Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. Stevens
	O0423	Efficacy of novel antifungal therapies in refractory Candida and Aspergillus infections: insights from compassionate use and clinical trials	S. Sedik* (Graz, Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl, J. Prattes
	OS056	14:45 - 15:45	Hall 2 1-hour Oral Session Emerging trends in viral hepatitis across Europe Chairs	Federico Garcia (Granada, Spain) Neven Papic (Zagreb, Croatia)
	O0409	One of the largest outbreak of hepatitis A in the 21st century in Europe	I. Hockickova* (Košice, Slovakia), I. Hockicková, J. Hockicko, D. Javorská, Š. Zamba, A. Vasiľová, M. Ševčík, A. Cehelská, D. Hudáčková, P. Kristian
	O0410	Higher prevalence of Cytomegalovirus and Epstein– Movie Session	15:00 - 18:30	Hall 5 Special Session Behind the scenes: Contagion Chairs	William Hanage (Boston, United States) Luigia Scudeller (Pavia, Italy)
	SY107	16:15 - 17:15	Hall 15 1-hour Symposium Communicating (your) ID science for policy and societal impact Chairs	Leonard Leibovici (Petah-Tiqva, Israel) Ines Steffens (Solna, Sweden)
	S0297	16:15	Communicating to policy makers and for societal impact	Balázs Babarczy (Budapest, Hungary)
	S0298	16:45	Influencing behaviour through the media and a multichannel communications strategy	Charlotte Hutchinson (London, United Kingdom) Co-organised with: CMI Board of Editors
	EW109	16:15 - 18:15	Hall 2 Educational Session Infections in cancer patients: tips for daily practice Chairs	José Molina Gil-Bermejo (Seville, Spain) Stefan Schwartz (Berlin, Germany)
	W0301	16:15	Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi	Janne Vehreschild (Frankfurt, Germany)
	W0302	16:35	Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours	Tba
	W0303	16:55	The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patientsŞiran Keske (Istanbul, Türkiye)
	W0304	17:15	HTLV-1 and T-cell lymphoma - predict & prevent	Lucy Cook (London, United Kingdom) Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)
	EF065	16:15 - 17:15	Arena 1 e	Poster Flash Session The Antibiotic bakery: Novel compounds in the pipeline Chair Susanne Haeussler (Braunschweig, Germany)
	E0471	In vitro activity and in vivo proof-of-efficacy of epimutilin derivatives AR-7732, AR-7731, AR-9842 and AR-10058 against AMR bacterial pathogens	S. Paukner* (Vienna, Austria), W.W. Wicha
	E0472	SC5005 and DHA: A Novel, Rapid-Acting Combination Therapy for Biofilm Eradication in Catheter-Associated Infections	Y. Hui Hui* (Taipei, Taiwan, China), H.H. Yeo, H.N. Huang, Y.T. Huang, Y.S. Lu, H.C. Chiu
	E0473	In vitro potency of ceftibuten with xeruborbactam against β-lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme	O. Lomovskaya* (San Diego, California, United States), M. Castanheira, J. Lindley
	E0474	Effect of novel antimicrobial peptides SET-M33L and SET-M33L-PEG on Pseudomonas aeruginosa biofilm formatio	n.A. Fontanot* (Rotterdam, Netherlands), W. Unger, J. Hays, P. Croughs, A. De Bruijn, C. Falciani, A. Pini, R. Ecker, I. Ellinger e	Poster Flash Session Blood parasitology at its best Chair Miriam José Álvarez-Martínez (Barcelona, Spain)
	E0489	Unexepected P.malariae diagnosis in Italian woman with no history of travel to endemic areas	A. Busni* (Milan, Italy), L. Tartaglione, S. Torri, A. Longhi, E.M. Zavaroni, F. Crippa, C.S. Vismara
	E0490	A blue-hued mystery: Primaquine-induced methemoglobinemia in mixed infection with Plasmodium vivax and Plasmodium falciparum	U.A. Zainulabid* (Pahang, Malaysia), X.K. Cheong, P. Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W. Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris
	E0491	Trick or Treat? An unrelenting malaria case	C. Uhomoibhi* (Dublin, Ireland), E. De Barra, C. Leddy, A. Brown
	E0492	"64% Parasitaemia in Falciparum Malaria: Challenges in Managing Severe Infection and Delayed Haemolysis"F. Murphy* (Dublin, Ireland), A. Albadi, P. Coakley, C. Mcnally
	E0493	Benznidazole treatment in Chagas Disease: a case series in Luigi Sacco Hospital, Milan (Italy)F. Sabaini* (Milan, Italy), A. Giacomelli, M. Beltrami, L.R. Galimberti, S. Antinori
	E0494	The Challenge of Managing Visceral Leishmaniasis in Immunocompromised Patients	S. Vita* (Rome, Italy), A. D'abramo, A. Corpolongo, M.V. Tomassi, F. Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G. Maffongelli, E. Nicastri
	E0495	Diagnosis and management of visceral leishmaniasis in children in France : a national retrospective study	J. De Larminat* (Paris, France), N. Dahane, N. Argy, M. Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Pineau, P. Picherit Steinbrucker, S. Azohana, S. Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye
	E0496	Chronic cutaneous leishmaniasis following visceral leishmaniasis in a pediatric patient: a rare report of extensive facial involvement	A. Mohta* (Bikaner, India)
	E0497	Therapeutic challenges in the management of Disseminated leishmaniasis in a patient with HIV coinfection	N. T R* (Jodhpur, India), T. Kanagiri, S. Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit, G.K. Bohra
	EF068	16:15 - 17:15	Arena 4 e	Poster Flash Session A global perspective on antimicrobial resistance surveillance Chair Mirfin Mpundu (Lusaka, Zambia)
	E0498	Global, regional and country-level prevalence of antimicrobial resistance in human bacterial infections under surveillance in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS)E. Van Kleef* (Geneva, Switzerland), O. Tosas Auguet, S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S. Cooper, A.S. Dean, S. Bertagnolio
	E0499	Comparative analysis of antimicrobial resistance (AMR) burden across european countries	A. Dörre* (Berlin, Germany), A. Meinen, S. Haller, G. Robles Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns
	E0500	Setting up a regional AMR surveillance network in the Netherlands: challenges and opportunities	C. Van Rossum* (Nijmegen, Netherlands), C. Meijer, P. Koopman, D. Van Der Vegt, T. De Groot, M. Nabuurs- Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E. Bowles, A. Tostmann, C. Van Der Veer, S. Pas
	E0501	Bridging gaps in antimicrobial resistance surveillance: the CAESAR network's first decade	R. Janssen* (Bilthoven, Netherlands), S. Woudt, D. Boudville, C. Ruesen, W. Van Den Reek, J. Monen, O. Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M. 
	ME108	16:15 - 17:15	Hall 12 Meet-the-Expert Navigating travel medicine: expert tips for safe international travel
	M0299	16:15	Sophie Schneitler (Homburg, Germany)
	M0300	16:27	Andreas Neumayr (Basel, Switzerland)
	OS062	16:15 - 18:15	Hall 13 2-hour Oral Session Heterogeneity and complexity of sepsis Chairs	Despoina Koulenti (London, United Kingdom) Sylvain Meylan (Lausanne, Switzerland)
	O0451	A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium	A. Moore* (Emerald Hills, United States), T. Sweeney, A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin- Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B. Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I. Martin-Loeches, A. Garduno, J. Sevransky, D. Wright, R. Rothman, M. Atreya, L. Moldawer, P. Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. Meyer
	O0452	BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study	C. Genovese* (Milan, Italy), M. Offer, G. Tricella, G. Scaglione, E. Palomba, G. Montrucchio, F. Agostini, F. Dore, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri
	O0453	Deciphering the Dynamics of Klebsiella pneumoniae Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients	W. Yu* (Beijing, China)
	O0454	Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients	S. Taylor* (Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Papanicolas
	O0455	Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups	M.H. Øvre* (Herlev And Gentofte, Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. Hansen, T.S. Itenov, B.J. Holzknecht
	O0456	Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam – results from SPECTRA	E. Yucel* (Rahway, United States), A. Soriano, F. Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, J. Levy, H. Yang, S. Kaul
	O0457	Risk of myocardial infarction and stroke following bloodstream infection: a population-based selfcontrolled case series	J. Underwood* (Cardiff, United Kingdom), N. Reeve, V. Best, A. Akbari, H. Ahmed
	O0458	Is transthoracic echocardiography required in all patients with Staphylococcus aureus bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis	M. Verdejo Gómez* (Barcelona, Spain), D. Malano- Barletta, M.Á. Verdejo, G. Cuervo, C. Pitart, M. Hernández-Meneses, M. Bodro, S. Herrera, C. Garcia-Vidal, P. Puerta, A. Del Rio, M. Espasa, J.A. Martínez, L. Morata, A. Soriano
	O0459	DNA methylation changes in Sepsis: Potential use as biomarkers	I. López-Cruz* (Valencia, Spain), J.L. García-Giménez, L. Piles, M. Madrazo, G. Judit, M. López-Torres, A. Artero
	O0460	Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia	S. Doeleman* (Amsterdam, Netherlands), D. Susanne, E. Michels, J. Butler, F. Uhel, O. Cremer, T. Van Der Poll Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach Chairs	Robert A. Bonomo (Cleveland, United States) Arjana Tambic Andrasevic (Zagreb, Croatia)
	S0293	16:15	Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics	Anna Sramkova (Pilsen, Czech Republic)
	S0294	16:45	Clinical perspectives of novel beta-lactams and betalactamase inhibitors	Parikshit Prayag (Pune, India) Co-organised with: EUCAST Steering Committee
	LB004	16:15 - 18:15	Hall 9 2-hour Oral Session Trials in severe infections Chair Steven Tong (Melbourne, Australia)
	L0016	16:15	Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trial	F. Cogliati Dezza* (Seville, Spain), L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Peréz, V. Palomo Jiménez, S. De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. Lopéz-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. Lopez Cardenas, M.C. Goméz Sanchez, I. Peréz Camacho, S.M. Martin Ramos, E. Leon Jimenez, A.I. Aller García, M.T. Peréz-Rodríguez, A. Sousa, M.C. Fariñas, A.D.L.R.A. Fracisco, L. Gisbert Pérez, J. Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero Sanchez, S. De La Villa, J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz- Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez- Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño Álvarez, Z.R. Palacios Baena, L. López Cerero, J. Rodríguez-Baño
	L0017	16:27	HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study	M. Ju* (Shanghai, China), M. Wang, J. Yuan, H. Huang, G. Bi, J. Lyv, X. Lyv, L. Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q. Zhang
	L0018	16:39	Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilatorassociated bacterial pneumonia suspected or confirmed to be due to carbapenem resistant Acinetobacter baumannii	G. Dale* (Basel, Switzerland), F. Fratzeskaki, I. Tsagkaris, A. Armaganidis, M. Katsiashvili, D. Kazaishvili, T. Gaphrindashvili, K. Japaridze, E. Mouloudi, M. Kapanadze, T. Kachibaia, A. Sarkany, E. Zakynthinos, P. Delique, M. Davila, L. Husband, P. Timofeev, F. Jung, C. Kemmer
	L0019	16:51	Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trial	M. Canetti* (Tel Aviv, Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Magiel, N. Baharav, A. Belkin, I. Margalit, V. Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G. Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S. Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A. Wieder-Finesod, N. Maggio, D. Yahav
	L0020	17:03	Randomised placebo controlled trial of faecal microbiota transplantation to tackle antimicrobial resistance: inducing bacteriophage network remodelling and enteric pathogen reduction	L.A. Edwards* (London, United Kingdom), B. Auch, T. Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T. Tranah, J.M. Blanco, L. Meoli, A. Clavé Llavall1, V.T. Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I. Liachko, S. Goldenberg, D.L. Shawcross
	L0021	17:15	Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for patients mutations in Enterococcus sp	p. by using High Resolution Melting-q	PCR-typing analysis	R. Musumeci* (Monza, Italy), E. Giordano, M. Martinelli, M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P. Congedo, C.E. Cocuzza
	E0539	An automated pipeline to genotype bacteriophages using third generation sequencing	Z. Halász* (Debrecen, Hungary), E. Szoták, L. D	r. Laczkó, G. D	r. Kardos
	E0540	Novel approach for fast, automated strain typing and source tracking by Fourier-transform infrared spectroscopy	N. Mauder* (Bremen, Germany), M. Cordovana, M. Kostrzewa
	EF075	17:30 - 18:30	Arena 2 e	Poster Flash Session Healthcare (workers') safety revisited Chair Daniel Diekema (Harpswell, United States)
	E0541	Preparedness and cooperation throughout the chain of care during regional-level outbreaks with multidrug resistant organisms: a network analysis and interview study	B. Beishuizen* (Bilthoven, Netherlands), M. Stein, A. Tostmann, C. Rovers, A. Timen
	E0542	Preparing First-Line health care workers for 'Virus X' through targeted training (Fi	Li-Vi-X)A. Mondelaers* (Antwerp, Belgium), Y. Somers, K. Vanden Driessche, I. Brosius, L. Liesenborghs, C. Rovers, L. Zweers, M. Wieland, E. Vlieghe
	E0543	Analysis of the current situation of hospital inspection practices by German health authorities	A. Schwabe* (Bonn, Germany), J. Dannenberg, A.D. Wollkopf, F. Droop, S. Engelhart, N.T. Mutters
	E0544	A nationwide survey on the status and implementation of infection prevention and control practice on behalf of INSIEME Project (Italian National project for contrast antibiotic resistance a cooperation between Simit (Italian society of infectious diseases) E (&) Ministry of h	Ealth)M. Meschiari* (Modena, Italy), F.V. Segala, E. Ricchizzi, A. Gallerani, V. Scaglione, R. Castoldi, F. Almerigogna, I. Spalliera, A. Parente, S. Coladonato, P. Grimaldi, C. Camaioni, M. Abbott, A. Carretta, S. Audagnotto, A. Pan, C. Fanelli, S. Cicalini, P. Tanzili, E. Ponatali, I. Gentile, R.F. Del Vecchio, A. Oliva, A. Mularoni, M. Lichtner, F. Di Gennaro, A. Marino, R. Murri, C. Mussini
	E0545	High level of measles immunity among Dutch healthcare workers with self-reported “unknown” measles immunity statu	s.C. Meijer* (Nijmegen, Netherlands), J. Leijser, M. Mccall, C. Rovers, E. Bowles, N. Van Der Geest, A. Tostmann
	E0546	Factors associated with positive latent TB screening results in healthcare workers at two tertiary referral hospitals in Ireland	C. Anderson* (Dublin, Ireland), D. Mcgee, M. Coleman, A. Hehir, L. Dolan, N. Noonan, V. Tormey, C. Bergin, C. Fleming, L. Townsend
	E0547	Systematic review of determinants of vaccine hesitancy among healthcare workers	V. Gabellone* (Lecce, Italy), F. Nuccetelli, R. Prato, E. Gabrielli, P.L. Lopalco
	E0548	Post-pandemic questions on vaccine usage: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines	P. Shamsrizi* (Hamburg, Germany), S. Eitze, D. Heinemeier, A. Tänzer, M.A. Jenny
	E0549	Do healthcare professionals working in acute healthcare settings identify infection prevention and control related knowledge deficits?A. Kearney* (Dublin, Ireland), H. Humphreys, D. Fitzgerald Hughes
	EF076	17:30 - 18:30	Arena 3 from a multicenter questionnaire study in Western Japan	R.M. Sada* (Osaka, Japan), S. Yamamoto, T. Toyokawa, T. Takahashi, A. Yamanaka, M. Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Tanizaki, K. Iwata, S. Kutsuna
	E0563	Post-Acute Sequelae and Excess Healthcare Utilization Following Dengue Infection: A Population-Based Cohort Study	J.T. Lim* (Singapore, Singapore), I. Wee, W.Z. Tan
	E0564	Challenges of dengue in haematological malignancy patients: Analysis from the DANGO registry during the 2023-2024 outbreak in Argentina	G.A. Méndez* (Posadas, Argentina), J. Salmanton-García, C. Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Bernard, C.P.L. Fernández, M.F. Tosin, M.F. Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely
	E0565	Key predictors of critical illness and mortality in Crimean-Congo haemorrhagic fever	D. Yigci* (Istanbul, Türkiye), D. Güllü, N. Baykam, A. Kocagül Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan Sarıkaya, İ. Hasanoğlu, H.R. Güner, E. Doğan, F. Karakeçili, H. Alay, Z. Türe Yüce, E. Eryılmaz Eren, A. Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. Yetişgen, M. Özgüler, A. Şenol, Ö. Gündağ, M. Çağlar Özer, F. Soyak, B. Tanır, I.D. Alıravcı, G. Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkucu, Ö. Ergönül
	E0566	Kyasanur Forest Disease in 2024: A Retrospective Cohort Study from a tertiary care centre in South India	P. Venkata Swathi Kiran* (Udupi, India), P.K. Tirlangi, N. Gupta, R. Bhat, P. Ravindra, S.K. Pothumarthy
	E0567	Unravelling the aetiology of summer flu-like illness in Czechia	M.F. Kříha* (Ceske Budejovice, Czech Republic), V. Hönig, J. Kamiš, M. Dvořáková, L. Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek
	SY112	17:30 - 18:30	Hall 1 1-hour Symposium Year in public health Chairs	Ziad A. Memish (Riyadh, Saudi Arabia) Catherine Moore (Cardiff, United Kingdom)
	S0309	17:30	Li Yang Hsu (Singapore, Singapore)
	S0310	18:00	Rita Oladele (Lagos, Nigeria)
	SY111	17:30 - 18:30	Hall 11 1-hour Symposium PK/PD in drug development: what’s in it for me? Chairs	Sandrine Marchand (Poitiers, France) Sebastian Wicha (Hamburg, Germany)
	S0307	17:30	PK/PD from the EUCAST/regulatory perspective: what tools do we need?Joseph Meletiadis (Athens, Greece)
	S0308	18:00	PK/PD for new anti-TB drugs Elin Svensson (Uppsala, Sweden) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
	OS070	17:30 - 18:30	Hall 12 1-hour Oral Session What’s new in antifungal guidelines and management Chairs	Sharon Chen (Sydney, Australia) Helmut Salzer (Linz, Austria)
	O0512	Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid, M. Thy, N. Peiffer-Smadja
	O0523	Large language model in real-world clinical infectious diseases: are we there yet?G. Carra* (Switzerland, Switzerland), M. Van Singer, A. Cancela Costa, P.A. Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Papadimitriou-Olivgeris, M. Plebani, V. Suttels, P. Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann, N. Boillat-Blanco
	O0524	Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3S. Ahmad* (Tampere, Finland)
	O0525	A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines	J. Molina Gil-Bermejo* (Seville, Spain), J. Molina, J.R. Paño-Pardo, B. Nagavci, M. Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. Tacconelli, S. Tschudin-Sutter, M. Zervos, L. Scudeller
	O0526	Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult - a rare manifestation of tuberculosis	S. Angirekula* (Jodhpur, India), R. Modi, R. Bora, R. Lohiya, S.K. Shivtarkar, S. Jagennath, D. Kumar, S. Tiwari, G.K. Bohra
	OS073	17:30 - 18:30	Hall 16 1-hour Case Session Still going viral Chairs	Ursula Hofer (London, United Kingdom) Yee Sin Leo (Singapore, Singapore)
	O0527	Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusion	s.A. Tessitore* (Trieste, Italy), N. Maximova, S. Braidotti, M. Granzotto, R. Simeone
	O0528	Histopathological proof of herpes simplex pneumonitis in a patient with severe COVID-19 pneumonia	J. Heylen* (Leuven, Belgium), B. Lopuhaa, L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K. Lagrou, G. Hermans, M. Peetermans, E. Van Wijngaerden, P. Meersseman, A. Wilmer, G. De Hertogh, G. Verjans, J. Von Der Thüsen, J. Van Kampen, J. Wauters
	O0529	Transmission of dengue virus from donors to recipient after solid organ transplantatio	n. Case series in Argentin	a.L. Barcan* (Buenos Aires, Argentina), S. Villamandos, R. Gago, M. Aguirre, A. Martinoia, A. Patterer, M. Uranga, C. Sarkis, E. Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. Nyveyro, M. Martinez, A. Smud, P. Giorgio, L. Barcán
	O0530	Rash without borders: waning immunity in a travelling physician	R. Ville Benavides* (Mexico City, Mexico), R. Ville-Benavides, I. Avendaño-Gutiérrez
	O0531	A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient	A. Kaya* (Izmir, Türkiye), G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Karaaslan, M. Taşbakan
	SY110	17:30 - 18:30	Hall 3 1-hour Symposium Immune reconstitution syndrome in infectious diseases: Wh	o. Ar	e. You? Chairs	Elisa Borghi (Milan, Italy) Justyna Kowalska (Warsaw, Poland)
	S0305	17:30	IRIS in HIV immunocompromised hosts: a failure of Uren* (Lviv, Ukraine), N. Aliieva, O. Voitovych
	S0305	17:30	IRIS in HIV immunocompromised hosts: a failure of success	Paola Maria Cinque (Milan, Italy)
	S0306	18:00	Dysregulated host responses to infection	Michal Holub (Praha, Czech Republic) OS069 17:30 - 18:30 Hall 4 1-hour Oral Session Determining new and revising old breakpoints Chairs	Jaroslav Hrabak (Plzen, Czech Republic) Erika Matuschek (Växjö, Sweden)
	O0507	EUCAST disk diffusion testing of ten additional species of anaerobic bacteria	J. Ahman* (Växjö, Sweden), J. Åhman, E. Matuschek, B.J. Holzknecht, P.C. Lindemann, H. Marchandin, S. Copsey-Mawer, T. Morris, G. Kahlmeter
	O0508	Standardised antimicrobial susceptibility testing protocol for Legionella pneumophila validated across ten European reference laboratorie	s.M. Sewell* (Cardiff, United Kingdom), C. Farley, A.V. Krøvel, M. Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B. Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M. González-Rubio, F. González-Camacho, M. Petzold, M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L. Jones, O.B. Spiller
	O0509	Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods	L. Chan* (Kennedy Town, Hong-Kong SAR, China), D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung, V.C.Y. Chow
	O0510	Determination of optimal disk diffusion mass for zosurabalpin	M. Castanheira* (North Liberty, United States), J. Maher, Y. Edah, A. Trauner
	O0511	The clinical significance of aminoglycoside susceptibility breakpoints modification	O. Henig* (Tel Aviv, Israel), M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben- Ami 
Monday, 14 April 2025
	SY116	08:30 - 10:30	Hall 15 2-hour Symposium Climate Change: changing risks and adaptation strategies for a world on the move Chairs	Rachel Lowe (Barcelona, Spain) Giacomo Stroffolini (Lausanne, Switzerland)
	S0323	08:30	Vector-borne diseases in Europe and clinical consequences	Tuba Dal (Ankara, Türkiye)
	S0324	09:00	Rising temperatures and risks of fungal disease	Anuradha Chowdhary (New Delhi, India)
	S0325	09:30	Strategies for climate prevention and adaptation in a moving world	Kristie Ebi (Seattle, United States)
	S0326	10:00	AMR in climate change-affected countries	Esmita Charani (London, South Africa) Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM) EF079 08:30 - 09:30 Arena 1 e	Poster Flash Session AMS around the world: what we can learn from each other Chair Benedikt Huttner (Geneva, Switzerland)
	E0578	Battlefield Stewardship: Implementing Antimicrobial
	E0579	Evaluating a Tailored Antimicrobial Stewardship Strategy to Optimise IV to Oral Conversion: A Pre and Post-intervention Study	M. Alyazji* (Abudhabi, United Arab Emirates), A. Sadeq, J. Shamseddine, Z.O.E. Babiker, A. Almansoori, M. Alhindasi, A. Abadi, S. Alhebsi, S. Alawlaqi, F. Aljasmi, A. Aitamimi, S. Shaabani, A. Alhosani, S. Shawish, R. Ali
	E0580	Antimicrobial stewardship program for antibiotic use in the community: impact of multidisciplinary local guidelines during the 2023-2024 influenza a H1N1 season in northern Italy	R. Corsini* (Reggio Emilia, Italy), P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, S. Mezzadri
	E0581	Effectiveness of Clinical Algorithms combined with Point-of-Care testing to improve Antibiotic Prescribing practices of physicians in outpatient setting of low middle-income country	S. Qureshi* (Karachi, Pakistan), S. Ahmed, N. Nasir, F.N. Qamar
	E0582	Antibiotic prescribing behaviour in a public Bangladeshi hospital: a snapshot from BALANCE study	M.S. Kabir* (Dhaka, Bangladesh), R. Farzana, S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Humayra, M. Sultana, M.N. Haque, T.R. Walsh
	E0583	Tailored response to antimicrobial resistance emergence: remote-created stewardship program in a low/middle-income country pediatric hospital	P. Favier* (Valencia, Spain), M.A. Aguilera, G. Rapetti Salik, M. Quipildor, M.M. Maresca, I.A. Falco
	E0584	Weekly interdisciplinary antimicrobial stewardship rounds at two surgical wards show notable potential in optimising antimicrobial treatment	M. Krauss* (Vienna, Austria), C. Labut, G. Brunhofer-Bolzer, G. Laml-Wallner, B. Unterkoefler, M. Andtisch, E. Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. Starzengruber, F. Loetsch, H. Lagler
	E0585	Antimicrobial stewardship programmes may improve patients' outcome and hospitalization: a sub-analysis of the CASAS (CArbapenem Sparing Antimicrobial Stewardship) Project	M. Bongiovanni* (Lugano, Switzerland), B. Barda, L. Elzi, P. Bellini, C. Di Benedetto, N. Ramponi, M. Mombelli, N. Centemero, A. Colombo, D. Destefani, M. Bissig, E. Bernasconi
	E0586	“Prescribing antibiotics is a gamble…”: A mixedmethods approach to current practices and implementation challenges of antimicrobial stewardship in a Ugandan tertiary care hospital	L. Jung* (Leipzig, Germany), L. Atikoro, D. Owachi, A. Schneider, S. Schönherr, A. Von Braun, C. Kabugo
	EF080	08:30 - 09:30	Arena 3 e	Poster Flash Session Acinetobacter baumannii, still a strong knight to be knocked Chair Parikshit Prayag (Pune, India)
	E0587	Evaluation of the Antibacterial Activity of New Dermaseptin Derivatives against Acinetobacter baumannii	H. Haddad* (Sousse, Tunisia)
	E0588	Clonal dissemination of highly resistant Acinetobacter baumannii ST2: Insights from the BALANCE study	C. Abdellaoui* (Oxford, United Kingdom), R. Farzana, M.N. Haque, M. Sultana, A. Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S. Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh
	E0589	Prevalence and genomic characterization of Sulbactam-Durlobactam-resistant and Carbapenem-resistant Acinetobacter baumannii in ICU Patients in a tertiary hospital in Hanoi, Northern Vietnam	D. Nurjadi* (Luebeck, Germany), S. Boutin, Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K. Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P. stewardship in long-term care facilities Chairs	Gaetan Gavazzi (Grenoble, France) Giusy Tiseo (Pisa, Italy)
	S0319	08:30	The burden of nosocomial infections in long-term facilities Virginie Prendki (Genève-Thônex, Switzerland)
	S0320	09:00	Pneumonia in the elderly: management and prevention	Marcos Restrepo (San Antonio, United States)
	S0321	09:30	Challenges in the clinical diagnosis of infection in the elderly	Maheen Abidi (Denver, United States)
	S0322	10:00	Challenges in implementing antimicrobial stewardship in long-term care facilities	Elena Carrara (Verona, Italy) Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee
	SY117	08:30 - 10:30	Hall 16 2-hour Symposium Survival of the parasites: is treatment failure due to antimicrobial resistance? Chairs	Hanne Brekke (Oslo, Norway) Jaco J. Verweij (Tilburg, Netherlands)
	S0327	08:30	Nitroimidazole refractory Giardia intestinalis infection	Pavla Tůmová (Praha, Czech Republic)
	S0328	09:00	Treatment failure in scabies	Francisco Bravo (Lima, Peru)
	S0329	09:30	Recurrent Enterobius infections	Sarah Eisen (London, United Kingdom)
	S0330	10:00	Recent advances in the treatment of Visceral Leishmaniasis and PKDLShyam Sundar (Varanasi, India) Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)
	EW118	08:30 - 10:30	Hall 2 Educational Session How can we infer and track plasmid outbreaks? Chairs	Alessandra Carattoli (Rome, Italy) Jacob Moran-Gilad (Beer Sheva, Israel)
	W0331	08:30	Evolutionary modelling of plasmids	Manuel Ares Arroyo (Paris, France)
	W0332	08:50	How plasmids shape the emergence of nosocomial pathogens	Jukka Corander (Oslo, Norway)
	W0333	09:10	Understanding the complexity of plasmid outbreaks using bioinformatics	Torsten Seemann (Melbourne (VIC), Australia)
	W0334	09:30	Plasmid transmission at the One Health interface	Nicole Stoesser (Oxford, United Kingdom) Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)
	SY113	08:30 - 10:30	Hall 3 2-hour Symposium Haemorrhagic viral infections Chairs	Önder Ergönül (Istanbul, Türkiye) Catherine Houlihan (Porton Down, United Kingdom)
	S0311	08:30	Filovirus disease: evolving therapeutic strategies	Ian Crozier (Frederick, United States)
	S0312	09:00	Jack in the box: Re-emergence of Kyasanur Forest Disease in India	Kavitha Saravu (Manipal, India) 
	EF081	09:30 - 10:30	Arena 2 e	Poster Flash Session Clinical features and outcome of invasive fungal infections Chair Marcus De Melo Teixeira (Brasília, Brazil)
	E0596	Management, outcomes and predictors of mortality of Cryptococcus infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand	J. Coussement* (Melbourne, Australia), C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. Crawford, S.J. Crawford, B.J. Smith, A.P. Gador- Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Walls, G.M. O’kane, M.T. Broom, C.L. Keighley, O. Bupha-Intr, L. Cooley, J.A. O’hern, J.D. Jackson, A.J. Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade, V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. Slavin, S.C.A. Chen
	E0597	Incidence of invasive fungal infections in hospitalised paediatric patients in England	A. Warris* (Exeter, United Kingdom), L. Ferreras-Antolin, G. Kiely, Z. Riaz, M. Czachorowski, M. Gerino, K.K. Rai, Z. Akhter, J. Owczarek, C. Castillo, I. Jimenez
	E0598	Invasive fungal disease in critically ill patients with cirrhosis: an autopsy study	L. Maessen* (Leuven, Belgium), A. Wilmer, P. Meersseman, J. Wauters, J. Heylen, S. Feys, C. Jacobs, H.M. Lauwers, K. Lagrou, M. Peetermans, G. Hermans, Y. Debaveye, E. Van Wijngaerden, S. Van Der Merwe, G. De Hertogh
	E0599	Non-Aspergillus mould infections in Australia and New Zealand: a multi-centre study on epidemiology and clinical outcomes	C.F. Neoh* (Melbourne, Australia), S.C.A. Chen, A.J. Morris, C.H. Heath, S.J. Tan, R. Lane, S.Y. Tio, M.B. Roberts, S.Y. Tay, K. Kennedy, S. Van Hal, H. Murray, R. Pickles, A. Douglas, K. Urbancic, M. Menon, A. Stewart, P. Simos, N.M. Vaselli, J. Howard, C. Keighley, S. Miyakis, R. Beresford, L. Cooley, O. Smibert, M. Sehu, K.Y. Yong, A. Crowe, M. England, O. Robinson, S. Lynar, K. Daveson, C. Halliday, S. Kidd, D.C.M. Kong, T. Spelman, L. Worth, M. Slavin
	E0600	Leveraging natural language processing (NLP) for early detection of aspergillosis: A retrospective study	L. Nwankwo* (London, United Kingdom), N. Pinnock, A. Shek, C. Hemsley, J. Periselneris, S. Schelenz, D. Armstrong-James
	E0601	How often does Mucormycosis (MCM) contribute to mortality in Hematologic Malignancy (HM) patients? Analysis of 103 patients over 20 years	S. Wurster* (Houston, United States), T.M. John, J. Ying, D.P. Kontoyiannis
	E0602	Emergence of Wickerhamomyces anomalus invasive infections in injecting drug users	M. Lefranc* (Bordeaux, France), M. Desnos-Ollivier, P. Baudino, K. Boukris-Sitbon, C. Plaisant, F. Dalle, F. Lanternier, S. Imbert
	E0603	Prevalence and risk-factors for secondary localizations during candidemia in intensive care unit patients: the French Candid	ICU multicenter study	J.P. Gangneux* (Rennes, France), F. Reizine, J. Henry, L. Desmedt, C. Camus, V. Coirier, F. Arrive, E. Burban, G. Eustache, T. Belleville, A. Marc, J. Malherbe, P. Bouju, P. Jaubert, O. Lesieur, M. Leclerc, P. Fillâtre, A. Frérou, R. Prével, A. Cady, F. Morio, M. Pihet, G. Nevez, L. Delhaes, S. Imbert, H. Guegan, J. Bonhomme, E. Perraud, C. Dupin, D. Du Cheyron, Y. Launey, C. Aubron
	E0604	Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance	A. Stewart* (Boston, United States), K. Laupland, F. Edwards, S. Koo, S. Hammond, P. Harris, D. Paterson, M. Slavin, S. Chen 
	EF090	11:00 - 12:00	Arena 3 e	Poster Flash Session Addressing the need for speed: advances in point-of-care testing Chair Jennifer Dien Bard (Los Angeles, United States)
	E0649	Rapid respiratory microbiological POCTs and antibiotic use in primary care: the RAPID-TEST RCT	E. Brown* (Bristol, United Kingdom), A.D. Hay, S. Abbs, M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G. Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke, M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P. Mitchell, L. Zhu, L. Yardley, C. Metcalfe
	E0650	Evaluation of the prototype BIOFIRE® nasal HR panel (n	HRP) in children with acute respiratory illness, a nasal swab-based rapid ho	St gene expression test	G. Storch* (Saint Louis, Missouri, United States), M. Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin
	E0651	Evaluation of the analytical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit in the diagnossis of bacterial intestinal infections	P. Lehours* (Bordeaux, France), Q. Beaufils, L. Benejat, A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain
	E0652	Development and Validation of a Novel Rapid Antigen Test for Norovirus Detection: A Comparative Performance Analysis	N. Younes* (Doha, Qatar), G. Nasrallah
	E0653	A Rapid Molecular POCT System for Detection of Carbapenem-Resistant Enterobacterales (CRE)S.Y. Choi* (Daejeon, Korea, Republic of), C. Lee, H.O. Park
	E0654	Validation of an ultra-rapid, point-of-care, antibiotic susceptibility testing device	A. Van Der Linden* (Eindhoven, Netherlands), Y. Deurloo, N. Doomen, D. Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko
	E0655	Development of a frugal multiplexed paper sensor for rapid detection of sepsis-causing pathogens	C. Singhal* (Faridabad, India), S. Chatterjee, S. Gupta, M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, A. Tyagi, N. Kumar, S. Chaudhuri
	E0656	Multianalyte POCT device for a sample-to-result detection of nucleic acid and protein	L. Pommiès* (Gif Sur Yvette, France), H. Boutal, D. Fras, H. Volland
	E0657	A smartphone app for point-of-care quantification of lateral flow assays	R. Armiger* (London, United Kingdom), R. Reid, P. Georgiou, A. Holmes, J. Herberg
	KN121	11:00 - 12:00	Hall 1 Keynote Lecture HIV: from needle parks to injectables Chairs	Mary Horgan (Dublin, Ireland) Gülsen Özkaya Sahin (Lund, Sweden)
	K0341	11:00	Huldrych Günthard (Zürich, Switzerland)
	OS085	11:00 - 12:00	Hall 10 1-hour Oral Session Planes, Pains, and Pathogens: The Perils of Travel Medicine Chairs	Anu Kantele (Helsinki, Finland) Carlos Seas (Lima, Peru)
	O0620	Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiology	S. Caronni* (Milan, Italy), M. Pieruzzi, A. Rizzo, A.H. Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, A. Mancon, D. Mileto, S. Antinori
	O0621	Tracing the itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease data	S. Gupta* (Auckland, New Zealand), S. Thornley, G. Sundborn, C. Grant 
	SY126	11:00 - 12:00	Hall 13 1-hour Symposium Why is the concept of complicated UTI so complicated? Chairs	Gernot Bonkat (Basel, Switzerland) Maeve Doyle (Waterford, Ireland)
	S0350	11:00	The concept of complicated UTI: underlying conditions matter	Suzanne Geerlings (Amsterdam, Netherlands)
	S0351	11:30	The concept of complicated UTI: the site of infection matters most	Jesús Rodríguez-Baño (Seville, Spain) Co-organised with: ESCMID Education Subcommittee
	ME128	11:00 - 12:00	Hall 14 Meet-the-Expert How to apply organoid models to study infectious disease
	M0354	11:00	Jennifer Rohn (London, United Kingdom)
	M0355	11:12	Nathalie Sauvonnet (Paris, France)
	OS087	11:00 - 12:00	Hall 15 1-hour Oral Session Antimicrobial resistance around birth Chairs	Julia Anna Bielicki (London, United Kingdom) Surbhi Malhotra-Kumar (Antwerp, Belgium)
	O0630	Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairs	A. Sharma* (Chandigarh, India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Ray
	O0631	Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilk	A. Chakraborty* (Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. Kumar, P. Kumar, A. Pal, A. Arora
	O0632	Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units	A. Braspenning* (Antwerp, Belgium), L. Timbermont, L. Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar
	O0633	Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gut	V. Pettersen* (Tromsø, Norway), A. Bargheet, G.H. Bø, C. Klingenberg
	O0634	Dynamics of gut resistome and mobilome in early life: A meta-analysis	V. Pettersen* (Tromsø, Norway), A. Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K. Korpela, M. Valles-Colomer, J. Debelius, A. Kurilshikov
	OS088	11:00 - 12:00	Hall 16 1-hour Oral Session Advancing diagnostics and preventive measures in hemato-oncological patients Chairs	Dina Averbuch (Jerusalem, Israel) Malgorzata Mikulska (Genoa, Italy)
	O0635	Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapy	M. Freire* (Sao Paulo, Brazil), A. Villan	i. Jr, M. P. Freire, F. Lazzar Neto, L.A. De Padua Covas Lages, M. Salaroli De Oliveira, E. Abdala, F. L.S. Nunes, A.S. S. Levin 
	S0342	11:00	The lung microbiome of people with cystic fibrosis receiving modulator therapy	Sebastien Boutin (Lübeck, Germany)
	S0343	11:30	Tackling chronic infections in people with cystic fibrosis receiving modulator therapy: is it still necessary?Alessandra Bragonzi (Milano, Italy) Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology
	SY123	11:00 - 12:00	Hall 4 1-hour Symposium Infection prevention and control and intensive care: challenges and solutions Chairs	Antonios Katsounas (Bochum, Germany) Claire Roger (Nimes, France)
	S0344	11:00	Intensive care unit (ICU) and infection: two sides of a coin	Reto Schuepbach (Zurich, Switzerland)
	S0345	11:20	Ventilator- associated pneumonia (VAP) and ICU enviroment: how can we improve practices?Despoina Koulenti (London, United Kingdom) Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), EUCIC Steering Committee
	OS083	11:00 - 12:00	Hall 5 1-hour Oral Session Don't 'rash' it Chairs	Heli Harvala (Turku, Finland) Catherine Moore (Cardiff, United Kingdom)
	O0610	Current Prevalence of Parvovirus B 19 Infections: Ankara Bilkent City Hospital Experience 2019- 2024B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kırca, A. Toyran, S. Aydoğan, B. Dinç
	O0611	Managing an outbreak of parvovirus	B19 infection in pregnancy: clinical outcomes from a single-centre study	M. Melchio* (Genoa, Italy), E. Ricci, E. Cristina, E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. Mesini, M. Mariani, C. Russo Artimagnella, C. Saffioti
	O0612	The dark side of the „fifth disease” endemic: human parvovirus	B19 infections transmitted through blood transfusions in adults with malignant hematological diseases	B.G. Szabo* (Budapest, Hungary), D. Korozs, P. Remenyi, J. Sinko
	O0613	Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024A.M. Murray* (Dublin, Ireland), G. Larkin, D. Hickey
	O0614	Measles virus in the context of subacute sclerosing panencephalitis (SSPE)J. Dina* (Caen, France), S. Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous
	SY124	11:00 - 12:00	Hall 6 1-hour Symposium Antimicrobial prescribing: myths or pearls? Chairs	Massimo Fantoni (Roma, Italy) Spyros Pournaras (Athens, Greece)
	S0346	11:00	Why treat IV when PO is possible?Bradley Spellberg (Los Angeles, United States)
	S0347	11:30	De-escalation of antibiotic therapy to narrowspectrum IV drugs	Flaminia Olearo (Hamburg, Germany) Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee 
	M0367	13:30	Maheen Abidi (Denver, United States)
	M0368	13:42	Alaa Atamna (Petah-Tikva, Israel) Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)
	SY131	13:30 - 14:30	Hall 2 1-hour Symposium Vaccines and antimicrobial resistance Chairs	Iva Butic (Zagreb, Croatia) Zitta Barrella Harboe (Hillerød, Denmark)
	S0361	13:30	The impact of current and future vaccines on AMR: from pneumococcal to COVID-19Mateusz Hasso- Agopsowicz (Geneva, Switzerland)
	S0362	14:00	Can vaccines against AMR be translated into policy?William Hausdorff (Washington DC, United States) Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)
	EW135	13:30 - 15:30	Hall 3 Educational Session Transforming your research idea into an appropriate study design Chairs	Casandra Bulescu (Bucharest, Romania) Mary Horgan (Dublin, Ireland)
	W0369	13:30	Designing high-quality research studies: methodological skills and knowledge	Mical Paul (Haifa, Israel)
	W0370	13:50	How to design and run scientific studies using AI agents as research assistants	Alyssa Bilinski (Cambridge, United States)
	W0371	14:10	Designing your first study: how to construct a workable project when your work environment may not help	Thomas Tängdén (Uppsala, Sweden)
	W0372	14:30	Bridging early-career professionals with partners and seniors	Giorgia Caruana (Sion, Switzerland) Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee
	FO136	13:30 - 14:30	Arena 1 Open Forum Diversity in CM and ID: gender gaps and policy traps Chair Andre Fuchs (Augsburg, Germany)
	F0373	13:30	How to avoid parity traps in ID/CM research?Muge Cevik (St Andrews, United Kingdom)
	F0374	13:40	Gender gaps in visibility at scientific conferences	Sarah Delliere (Paris, France)
	F0375	13:50	Psychological determinants of empowerment at individual and societal level	Tba Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission
	EF093	13:30 - 14:30	Arena 2 e	Poster Flash Session Real world experience with modern HIV treatment: the art of ART
	E0668	Use of long-acting cabotegravir/rilpivirine in HIVviraemic individuals: a metanalysis	M. Bongiovanni* (Lugano, Switzerland), B. Barda, G. Barilaro, E. 
	E0681	Pathobiome characterization and role in disease severity in children under 5-years with respiratory infection symptoms	L. Terranova* (Milan, Italy), L. Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna, M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchì, M. Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A. Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri
	E0682	Viral viability markers of SARS-Co	V-2: A Comparison of cell culture genomic RNA RT-PCR and subgenomic RNA RT-PCR	C. Cuesta Chasco* (Barcelona, Spain), S. Alex, M. Mª Ángeles, C.C. Genoveva, A. Francesco, R. Cristina, V. Anna, H. Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N. Mireia, G. Ignacio, B. Marta, G.V. Carolina
	E0683	Diagnostic performance of Hepatitis B virus surface antigens in the Netherlands using type-specific external quality assessment	E. Vanhulle* (Bilthoven, Netherlands), M. Simões, H. Ten Bruin, G. Boland, A. Brandenburg, K. Benschop
	E0684	Low utility of parallel testing by multiplex and individual real-time PCR assays for the diagnosis of viral meningitis and encephalitis at a large public hospital in the United State	s.A. Cuber* (Los Angeles, United States), S. Butler-Wu
	E0685	Plasma Separation Card as an alternative sampling method for quantitative HCV RNA testing with high comparability to EDTA plasma	F. Garcia* (Granada, Spain), A. Fuentes López, A. Rando Segura, R. Carracedo, A. Kessler, A. De Salazar González, S.Z. Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, A. Carrasco Durán, A. Aguilera, F. García, M. Buti Ferret
	KN130	13:30 - 14:30	Hall 1 Keynote Lecture Infectious disease challenges in an ever-changing environment Chairs	Jacob Moran-Gilad (Beer Sheva, Israel) Annelies Zinkernagel (Zurich, Switzerland)
	K0360	13:30	Pamela Rendi Wagner (Stockholm, Sweden)
	PM3	13:30 - 14:30	Hall 12 Meet-the-Innovators Future prospects of electronic clinical decision support systems in stewardship programs
	L007	13:30	Opportunities for clinical decision support systems in infectious disease management	Nathan Peiffer- Smadja (Paris, France)
	L008	14:00	CDSS and AMS programs: the Lumed example	Valiquette Louis (Sherbrooke, Canada)
	SY132	13:30 - 14:30	Hall 13 1-hour Symposium Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art Chairs	Werner Ruppitsch (Vienna, Austria) Balaji Veeraraghavan (Vellore, India)
	S0363	13:30	Impact of the WHO’s developed catalogue of mutations on rapid TB diagnosis and treatment	Thomas Schön (Kalmar, Sweden)
	S0364	14:00	Antimicrobial resistance prediction using whole genome sequencing	Patricia Simner (Rochester, United States) Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee Türkiye), S. Unlu
	O0662	Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitis	R. Mändar* (Tartu, Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk
	EF099	14:45 - 15:45	Arena 1 e	Poster Flash Session Infection Prevention in Action: Innovations, Insights, and Global Intervention Chair Allison Mcgeer (Toronto, Canada)
	E0706	A Candida auris cg	MLST Scheme for Enhanced Outbreak Surveillance and Global Epidemiological Tracking	C. Harless* (Silver Spring, United States), J. Stam, B. Corey, E. Horishny, A. Ong, Y. Kwak, J. Bennett, P. Mcgann, F. Lebreton
	E0707	Machine Learning-Augmented Clinical Scoring System for Predicting KPC Infections in Healthcare Crisis Scenarios	A. Rearte* (Buenos Aires, Argentina), F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi
	E0708	Incident infections with respiratory syncytial virus in a hospital-based healthcare worker cohort, 2023-2024 winter season	C. Savulescu* (Paris, France), M. Rojas, K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. Hrisca, M. Cisneros, M. Latorre-Millán, J. Mcgrath, L. Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Nardone
	E0709	Evaluation of the efficiency of reusable terminal filters for showers for nosocomial legionellosis prevention in a French university hospital	N. Khanafer* (Lyon, France), A. Regard, L. Beraud, R. Sintes-Tissot, Q. Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Chaboud
	E0711	Emerging uncommon non-fermenters and their decreasing antibiotic susceptibility in patients with prolonged hospital stay	V. Khillan* (New Delhi, India), V.G. Nag P, P. Kale, A. Paul, A. Saran
	E0712	Air and surface sampling around mpox Clade 1b in hospitals in the UK	S. Gould* (Liverpool, United Kingdom), B. Atkinson, B. Hack, T. Williams, J. Otter, Y. Ceesay, A. Alsonso, G. Nebbia, S. Blundell, W. Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. Dunning
	E0713	Utilization of a healthcare facilities rapid assessment tool to define infection prevention and control and Water, Sanitation and Hygiene baseline criterion met during Democratic Republic of Congo mpox outbreak from August to November 2024A. Baller* (Geneva, Switzerland), N.R. Okum, G. Nsambi, K. Kabamba, Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton Hurwitz, M. Moon
	E0714	The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonization	M. Colaneri* (Milano, Italy), P. Giordani, S. Lerta, A. Sangani, V.A. Villano, A. Gori, M. Rettani, S. Milanesi, G. De Nicolao, R. Bruno
	EF100	14:45 - 15:45	Arena 2 e	Poster Flash Session Cefiderocol: an efficient Trojan horse? Chair Anna Sramkova (Pilsen, Czech Republic)
	E0715	Acceleration of Emergence of Cefiderocol Resistance in Microfluidic Evolution System	B. Li* (Beijing, China), S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang
	E0716	The hidden link between cefiderocol resistance and increased virulence in Klebsiella pneumoniae: Insights from a Tra	DIS-based investigation	E. Eger* 
	E0729	Impact of BCG vaccination on adaptive immune responses to mycobacterial and non-mycobacterial antigens in HIV-exposed, uninfected infant	s.R. Namakula* (Bergen, Norway), V. Nankabirwa, S. Cose, O. Namugga, M.G. Netea, H. Steinsland, H. Sommerfelt, K. Hanevik
	E0730	Immune signature against Klebsiella pneumoniae proteins in a mother-baby cohort from Blantyre, Malawi	E. Heinz* (Glasgow, United Kingdom), J. Campo, O. Pearse, A. Zuza, A. Teng, J. Pablo, A. Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey
	E0731	A comprehensive computational mapping of B-cell epitopes in the Klebsiella pneumoniae porinome	S. Prieto Martin Gil* (Madrid, Spain), S. Prieto Martín Gil, E. Gato, A. Pérez, M.J. Mcconnell, A.J. Martín Galiano
	E0732	Chronic infection induces a broadly neutralizing antibody response to Elastase B of Pseudomonas aeruginosa	A. Albus* (Cologne, Germany), D. Kolling, K. Rox, D. Holzmann, K. Mundry, M. Sánchez Agut, C. Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Klein, J. Koehnke, J. Rybniker, A. Simonis
	KN137	14:45 - 15:45	Hall 1 Keynote Lecture Staphylococcus aureus host-microbe interaction: ecology, disease, and vaccine development Chairs	Werner Ruppitsch (Vienna, Austria) Annelies Zinkernagel (Zurich, Switzerland)
	K0376	14:45	Juliane Bubeck Wardenburg (S	t. Louis, United States)
	ME140	14:45 - 15:45	Hall 11 Meet-the-Expert Bioinformatic tools from start to finish
	M0381	14:45	Vítor Borges (Lisbon, Portugal)
	M0382	14:57	Clare Sloggett (Melbourne, Australia)
	ME141	14:45 - 15:45	Hall 13 Meet-the-Expert AI use in antimicrobial stewardship
	M0383	14:45	Shruti Gohil (Irvine, United States)
	M0384	14:57	Jose Ramon Pano-Pardo (Zaragoza, Spain)
	OS097	14:45 - 15:45	Hall 14 1-hour Oral Session Update on zoonotic and enteric infections Chairs	Steen Ethelberg Kavitha Saravu (Manipal, India)
	O0696	A large-scale epidemiological study of Campylobacter employing whole genome analysis reveals the evolution of highly virulent and multidrugresistant clones in the U	K.B. Lopes* (Middlesbrough, United Kingdom), A.S. Boaitey-Biko
	O0697	Population dynamics and evolution of multidrug resistant clones of Shigella sonnei in Metropolitan France	C. Silva Nodari* (Paris, France), I. Carle, M. Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Pardos De La Gandara, F.X. Weill acquired pneumonia in hospitalized adults in Germany	D. Karssen* (Utrecht, Netherlands), L. Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T. Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten, C. Prat-Aymerich
	O0688	Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis	J. Wei* (Oxford, United Kingdom), K. Yuan, A. Luk, S. Walker, D. Eyre
	O0689	Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumoni	a.F. Al-Zergani* (Hvidovre, Denmark), C. Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard, L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. Benfield
	O0690	Oropharyngeal carriage of gut-derived Enterobacterales increases RTI risk in long-term aged care residents	S. Miller* (Adelaide, Australia), F. Zhang, S. Taylor, A. Shoubridge, E. Vasil, R. Woodman, L. Papanicolas, G. Rogers
	SY138	14:45 - 15:45	Hall 4 1-hour Symposium Global clones and evolving resistance mechanisms towards newer betalactams: Where are we heading? Chairs	Yesim Besli (Istanbul, Türkiye) Spyros Pournaras (Athens, Greece)
	S0377	14:45	Carbapenemase-producing Enterobacterales: the not so good, the bad and the ugl	y.Arjana Tambic Andrasevic (Zagreb, Croatia)
	S0378	15:15	The P. aeruginosa frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome	Katy Jeannot (Besançon, France) Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)
	OS096	14:45 - 15:45	Hall 5 1-hour Oral Session Trends in antifungal resistance Chairs	Alexandre Alanio (Paris, France) Ana Alastruey-Izquierdo (Madrid, Spain)
	O0691	Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies	K. Schmidlin* (Tempe, United States), K. Geiler- Samerotte
	O0692	Role of the C2585G substitution in the MRR1 gene in the development of azole resistance in Candida parapsilosis sensu strict	u.I. Franconi* (Pisa, Italy), P. Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, M. Falcone
	O0693	Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years	J. Guinea* (Madrid, Spain), P. Escribano, G. Jesús, M. Machado, A. Burillo, P. Muñoz
	O0694	A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against Candida auris with EUCAST broth microdilution reference methodology	J. Meletiadis* (Haidari, Greece), J. Guinea, S. Arikan- Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup
	O0695	Decoding Candida auris Resistance in Latin America: Candid	a.app v	s. Pathogenwatch	J. Acosta España* (Quiro, Ecuador), P. Eduarda, J.D. Acosta-España, A. Allam* (Paris, France), S. Agsous, P. Baylac, K. La, N. Godron, F. Mougari, Z. Awad, E. Cambau
	E0753	Pseudomonas aeruginosa rapidly kills Mycobacterium abscessus in dual-species biofilms in vitro	M. Mcdaniel* (Nijmegen, Netherlands), J. Scoffield, J. Van Ingen
	E0754	Distribution of contezolid in different tissues of mice and human patients infected with Mycobacterium abscessus	W. Nie* (Beijing, China), N. Chu
	E0755	Exploration of clofazimine and bedaquiline activity against clinical strains of Mycobacterium abscessus to advance innovative therapeutic strategies	C. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, J.J. Aguilera-Correa, M.C. Muñoz-Egea
	E0756	Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria	S. Sarkar* (Parkville, Australia), K. Strumila, S. Yu, R. Werder, T. Johanssen, A. Hidalgo Gonzalez, E. Stanley, S. Ranganathan
	E0757	Recovery of Non-Tuberculous Mycobacteria and Detection of Dominant Circulating Clones in Indoor Water Samples from Germany	N. Wetzstein* (Frankfurt, Germany), M. Diricks, D. Frank, I. Friesen, S. Niemann, T. Wichelhaus
	E0758	Deciphering the Epidemiology of Mycobacterium chimaera: Genetic Lineages, Environmental Sources, and Infection Prevention Insights	G. Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. Casadei, C. Scarparo
	E0759	Evaluation of a novel media for susceptibility testing of Mycobacterium avium-intracellulare complex isolates	T. Grams* (Salt Lake City, United States), S. Shakir
	E0760	Emerging cases of Mycobacterium chelonae endocarditis associated with Bio	Integral bioprostheses	J. Kikhney* (Berlin, Germany), F. Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, A. Moter
	EF106	16:15 - 17:15	Arena 3 e	Poster Flash Session The ABC (allergy, bloodstream infections and clinical decision support) in AMS Chair Céline Pulcini (Nancy, France)
	E0761	Evaluation of the allergy fact checker, a clinical decision support system to promote non-invasive delabeling of incorrect penicillin allergy labels: a mixed-methods study	D. Wets* (Leuven, Belgium), R. Schrijvers, I. Spriet, G. Van De Sijpe, L. Gilissen, C. Breynaert, T. Ieven, P. De Munter
	E0762	Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled tria	l.J. Sandoe* (Leeds, United Kingdom), S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P. Howard, D. Howdon, S. Mort, R. Mujica-Mota, A. Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, L.M. Yu, S. Pavitt
	E0763	Stewardship interventions reduced blood culture utilization by 40% during BD BACTEC™ Blood Culture media shortage	X. Li* (Toronto, Canada), K. Katz, A. Ceentavida, R. Kozak, C. Vermeiren, P. Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R. Lovinsky
	E0764	Prescriptive Impact of Rapid Microbiological Diagnostics in Bloodstream Infections Caused by Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus (PRIMEKA): A Retrospective Single-Center Cohort Stud	y.F. Salvati* (Rome, Italy), F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo, R. Murri, C. Torti 
	ME145	16:15 - 17:15	Hall 15 Meet-the-Expert Fungal meningitis: recognition and current status of management
	M0393	16:15	Olivier Lortholary (Paris, France)
	M0394	16:27	Janis Blair (Phoenix, United States)
	JS2	16:15 - 17:15	Hall 16 Journal Session Late-breaker research from the Lancet group: new interventions for familiar and new infectious diseases Chairs	Syeda Saleha Hassan (London, United Kingdom) Ursula Hofer (London, United Kingdom)
	J011	16:15	TBA
	J012	16:30	The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America	Jan Felix Drexler (Berlin, Germany)
	J013	16:45	The WHO Bacterial Priority Pathogens List: guiding research and development, and informing innovative public health strategies to address antimicrobial resistance	Hatim Sati (Geneva, Switzerland)
	J014	17:00	Efficacy, safety, and immunogenicity of the AS01Eadjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPre	F3 OA) in older adults over three RSV seasons: a randomized trial	Alberto Papi (Ferrara, Italy) Co-organised with: The Lancet group
	OS102	16:15 - 17:15	Hall 2 1-hour Oral Session AI tools empowering AMR prediction in WGS and MALDI-TOF Chairs	Oliver Nolte (Zürich, Switzerland) Patricia Simner (Rochester, United States)
	O0733	A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing data	Y. Zhong* (Liverpool, United Kingdom), A. Gerada, A. Howard, P. Green, W. Hope
	O0734	Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for Klebsiella pneumoniae from Clinical NGS Data	J. Xinmiao* (Beijing, China), X. Jia, J. Zhang, J. Chen, Q. Yang
	O0735	AI-Powered Real-Time Plasmid Prediction Using Nanopore Sequencing	E. Sauerborn* (Munich, Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. Foster-Nyarko, L. Urban
	O0736	MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 highvirulence K. pneumoniae	L. Dortet* (Le Kremlin- Bicêtre, France), L. Mancera Pascual, M.J. Arroyo
	O0737	Predicting rifampicin resistance in Mycobacterium tuberculosis complex with a machine learning based MALDI-TOF MS approche	Y.W. Sun* (Taichung, Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W. Lu, C.C. Chen, J. Yu
	LB005	16:15 - 17:15	Hall 3 1-hour Oral Session Emerging pathogens in humans, animals and vectors
	L0026	Genome-wide association study identifies ABCG1 as a susceptibility locus for tick-borne encephalitis	P. Gampawar* (Graz, Austria), M. Sagmeister, D. Ruzek, on Pseudomonas aeruginosa and its molecular interactions	S. Kansal* (Chandigarh, India), U. Dutta, A. Angrup, P. Ray
	O0741	Intra- and interspecific antagonism inhibits growth of Staphyloccous aureus in human nasal microbial communities	L. Brülisauer* (Zurich, Switzerland), M. Boumasmoud, S. Brugger, A.R. Hall
	O0742	Combination therapy against drug resistance biomimetic dual-species biofilm model of Pseudomonas aeruginosa and Staphylococcus aureus	P. Mojarrad* (Helsinki, Finland), P. Tammela, T. Laaksonen, Z. Gounani
	EF110	17:30 - 18:30	Arena 1 e	Poster Flash Session Advancing diagnostics and treatment of endocarditis Chair Benoît Guery (Lausanne, Switzerland)
	E0785	18F-FDG-PET/CT improves source control of extracardiac complications in infective endocarditis	J.M. Prins* (Amsterdam, Netherlands), S. Douiyeb, W. Van Gameren, D. Buis, T. Van Der Vaart, M. Boekholdt, J. Selder, D. Robbers-Visser, H. Verberne, H. Van Werkhoven, K. Sigaloff
	E0786	Comparing Duke criteria updates: Advancing IE diagnosis in patients with prosthetic intracardiac materials	M. Papadimitriou Olivgeris* (Sion, Switzerland), M. Papadimitriou-Olivgeris, B. Ledergerber, N. Fourré, V. Zimmermann, N. Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, O. Dzemali, J. Epprecht, B. Guery, B. Hasse
	E0787	In vivo Dalbavancin efficacy against methicillinresistant Staphylococcus aureus (MRSA) and highlevel aminoglycoside resistant (HLAR) Enterococcus faecalis (EFAE) experimental endocarditis mode	l.C. Garcia De La Maria* (Barcelona, Spain), C. García De La Mària, M.A. Cañas, M. Brunet, J. García-González, G. Cuervo, M. Espasa, M. Hernandez-Meneses, C. Falces, A. Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. Llopis, A. Moreno, J.M. Miro
	E0788	Identification and validation of clinical phenotypes in Staphylococcus aureus blood stream infection and their association with mortality (FEN-AUREUS study)J. Rodríguez-Baño* (Seville, Spain), B. Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M. Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita- Santos, Á. Cano, R. Palacios, S. López-Cárdenas, M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E. Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata- Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez, L. Romero-Calderón, A. Alemán-Rodríguez, E. Recacha, J. Torre-Cisneros, N. Merchante, Á. Pascual, L.E. López-Cortés
	E0789	Enterococcal Infective Endocarditis: demographics, comorbidities, diagnostic evaluation and mortality outcomes	M. Singh* (London, United Kingdom), C. Watkins, H. Bristowe, M. Gunning, J. Galloway, R. Dworakowski, M. Arias
	E0790	Health related quality of life of patients with infective endocarditis – preliminary data of the DERIVE cohort	C. Meyer-Schwickerath* (Cologne, Germany), K. Schmidt-Hellerau, J. Camp, K. Last, I. Joost, S. Rieg, N. Jung
	E0791	The optimal management of Enterococcus faecium catheter-related bloodstream infections: a gap to bridge	I. Rancan* (Florence, Italy), M. Rinaldi, F. Malerba, B. Profiti, L. Ancillotti, M. Tumbarello, P. Viale, M. Giannella
	E0792	Ceftobiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant Enterococcus faecalis	O. Funk* (Brooklyn, United States), I. Khan, J. Li, J. Cusumano
	E0793	Risk factors for in- hospital mortality in 500 cases of infective endocarditis	C. Lamas* (Rio De Janeiro, Brazil), G. Pompeo, T. De Almeida, M. De Carvalho, Infection: A randomized controlled trial	K. Angkanavisan* (Bankgkok, Thailand), B. Sakboonyarat, C. Ungthammakhun
	E0808	Oral switch v	s. intravenous antibiotics treatment for serious carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa infections on hospital discharge: the next frontier for oral switch?C. Arena* (Detroit, United States), A. Abed, R. Kenney, G. Suleyman, A. Shallal, S. Davis, M. Veve
	E0809	Metallo-β-lactamase colonization and subsequent risk of infection: a retrospective stud	y.C. Lee Luna Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato, S. Castelbuono, G. Di Martino, F. Cardinale, F. Monaco, A. Cona, A. Mularoni
	E0810	Polymyxin including therapy versus colistin including therapy in the therapy of carbapenemresistant Gram-negative infections: A retrospective matched cohort study	M. Mert Vahabi* (Van, Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yeniyol, G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkara, M. Ceylan, C. Bulut Avşar, U. Önal, S. Ketentzi, A. Uyan Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Vatansever, C. Tol, Ş. Aydemir, D. Akdağ, H.A. Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi
	E0811	Prognostic factors and role of clinical management in carbapenem-resistant Acinetobacter baumannii bacteraemia: results from a prospective, international, multicentre cohort (EURECA)F. Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, S. Benea, D. Tomescu, A. Meda Vasiesiu, L. Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H. Goosens, M.J.M. Bonten, J. Rodríguez-Baño
	SY147	17:30 - 18:30	Hall 11 1-hour Symposium Avian influenza in mammals: jumps under the radar Chairs	Patricia Antunes (Porto, Portugal) Ana Vale (Dublin, Ireland)
	S0399	17:30	Threat of highly pathogenic avian influenza to nontraditional hosts, including humans	Thijs Kuiken (Rotterdam, Netherlands)
	S0400	18:00	Recent changes in the epidemiology of avian influenza in relation to human health risks	Ron Fouchier (Rotterdam, Netherlands) Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific Working group on Influenza (ESWI)
	SY148	17:30 - 18:30	Hall 15 1-hour Symposium Echinococcosis: neglected but expanding Chairs	Daniel Grupel (Jerusalem, Israel) Francesca Tamarozzi (Negrar-Verona, Italy)
	S0401	17:30	Expansion and diversity of cystic echinococcosis	Pedro Legua (Lima, Peru)
	S0402	18:00	Management of echinococcosis: evidence, eminence and new developments	Beate Grüner (Ulm, Germany) Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM) 
	O0774	Aggregated summary of immunogenicity and safety for the chikungunya virus virus-like particle (VLP) vaccine development programme	L. Tindale* (Toronto, Canada), J. Richardson, D. Anderson, J. Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. Ajiboye, L. Bedell
	OS108	17:30 - 18:30	Hall 5 1-hour Oral Session Novel approaches to preventing device-related infections Chairs	Natividad Benito (Barcelona, Spain) Preeti Malani (Ann Arbor, United States)
	O0775	Clinical and microbiological impact of antibioticimpregnated catheters in ventriculoperitoneal shunt infections in adult	s.M. Sanz De Mena* (Barcelona, Spain), I. Pelegrín Senent, J. Gómez Junyent, J. Poblet Florentin, C. Iglesias, A. Siverio Parés, S. Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Horcajada
	O0776	Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial Anti	Red	Men	S. Scheithauer* (Goettingen, Germany), O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K. Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, A. Beste, N. Kucheryava, M. Baehr
	O0777	Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis	A. Mahajan* (Melbourne, Australia), C. Robson
	O0778	A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients	J. Guerrero* (Scarborough, Canada), A. Garga, S. Paramalingam, R. Lovinsky, F. Go
	O0779	Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89'709 patients	N. Imhasly* (Lucerne, Switzerland), A. Widmer, C. Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. Wicki, M. Beck, R. Sommerstein 
Tuesday, 15 April 2025 
	SY152	08:30 - 10:30	Hall 12 2-hour Symposium Out of the spotlight or out of reach? Vaccination of hard-to-reach groups Chairs	Olivier Epaulard (Grenoble, France) Justyna Kowalska (Warsaw, Poland)
	S0413	08:30	Ukrainian war refugees and vaccination attitudes: experience from Poland	Maria Ganczak (Zielona Gora, Poland)
	S0414	09:00	Vaccination in migrants in Latin America: The challenges of transit through Darien, Panama	Alfonso J. Rodriguez-Morales (Pereira, Colombia)
	S0415	09:30	Are penitentiary systems ready for introducing vaccination programmes?Lara Tavoschi (Pisa, Italy)
	S0416	10:00	HPV and other essential vaccinations for sex workers	Debora Konopnicki (Brussels, Belgium) Co-organised with: ESCMID Vaccine Study Group (EVASG)
	SY153	08:30 - 10:30	Hall 13 2-hour Symposium Breaking new ground in febrile neutropaenia management Chairs	Murat Akova (Ankara, Türkiye) Stefan Schwartz (Berlin, Germany) rescue old-time microscopy ?A. Aupaix* (Hornu, Belgium), L. Filippin, I. Mansoor, M. Chemais, D. Martiny, V.Y. Miendje Deyi, M. Deffontaine, C. Deckers, V. Verbelen, J. Brauner
	E0828	Improving vector surveillance: evaluating a real-time PCR assay for Leishmania DNA detection in sandflies	H. Alonso-Ezcurra* (Zaragoza, Spain), M.P. Peris, I. Ruiz-Arrondo, J.A. Castillo, D. Martínez- Durán, S. Delacour, I. Ruiz-Zarzuela, I. De Blas, C. Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H. Alonso
	E0829	Assessment of a new immunochromatographic assay for serological diagnosis of amoebic liver abscess	R. Fleury* (Besançon, France), M.P. Brenier-Pinchart, P. Tirard-Collet, F. Gabriel, E. Pretot, F. Touafek, A. Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont, A. Moreno-Sabater, F. Grenouillet
	E0830	Human piroplasmosis: diagnostic lessons from a national parasitology reference laboratory in South Afric	a.C. Sriruttan-Nel* (Johannesburg, South Africa), J. Frean
	EF115	08:30 - 09:30	Arena 3 e	Poster Flash Session New genomic methods in clinical microbiology Chair Natacha Couto (Oxford, United Kingdom)
	E0831	Prediction of antimicrobial minimum inhibitory concentration from Escherichia coli whole genome sequence data using machine learning	A. Gerada* (Liverpool, United Kingdom), N. Harper, Y. Zhong, A. Howard, P.L. Green, W. Hope
	E0832	Dynamically Optimized Reference Adaptive Sampling (DORAS) to streamline bacterial Multi-Locus Sequence Typing	A. Ramette* (Bern, Switzerland), L. Borcard, M.A. Terrazos Miani, S. Gempeler, S. Neuenschwander
	E0833	Prediction of antibiotic resistance in Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae from genomic data using machine learning and deep learning approaches	E. Denakpo* (Gif-Sur-Yvette, France), N. Dias, F. Jay, B. Iorga
	E0834	Machine learning pipeline accelerates identification of diagnostic targets for Neisseria gonorrhoeae	A. Verich* (Sydney, Australia), T. Applegate, D. Bauer, P. Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany
	E0835	Reliable bacterial genomic genotyping from Oxford Nanopore Technologies data – the ONT cg	MLST Polisher	N. Scherff* (Muenster, Germany), J. Rothgänger, D. Harmsen
	E0836	Developing a core genome MLST (cg	MLST) for Mycoplasma pneumoniae	C. Dixon* (Cardiff, United Kingdom), R. Mamede, M. Ramirez, H. Milton, P.M. Meyer Sauteur, G. Greub, N. Couto, M.L. Beeton
	E0837	Voyager: real-time taxonomic characterization of long-read mixed-species sequencing samples in sorted motif distance space	S. Branders* (Hamar, Norway), M. Grabherr, R. Ahmad
	E0838	VCP: a signature protein-based tool for accurate and rapid profiling of human gut virome	J. Li* (Shenzhen, China), F. Yang, L. Xiong, X. Feng, H. Zhong
	E0839	Genomic Data-Driven Machine Learning for Predicting Antimicrobial Resistance in ESCAPEE Pathogens	A. Skoulakis* (Lamia, Greece), K. Daniilidis, S. Digenis, A. Hatzigeorgiou CGR	08:30 - 10:30	Hall 1 Special Session Clinical Grand Round Experts Nina Khanna (Basel, Switzerland) Dimitrios P. Kontoyiannis (Houston, Tx, United States) Lior Nesher (Beersheba, Israel) David L. Paterson (Singapore, Singapore) 2-hour Symposium Using mathematical and epidemiological models to identify the drivers of AMR Chairs	Marc J.M. Bonten (Utrecht, Netherlands) Sarah Tschudin Sutter (Basel, Switzerland)
	S0421	08:30	Quantifying the drivers of antiviral resistance: what does it take to prevent resistance evolution?Roger Kouyos (Zürich, Switzerland)
	S0422	09:00	Inferring the determinants of AMR dynamics across bacterial pathogens	Lulla Opatowski (Paris, France)
	S0423	09:30	Modelling the evolution of resistance	Erida Gjini (Lisbon, Portugal)
	S0424	10:00	Assessing the associations of microbiome and sociodemographic dynamics on AMRKatariina Pärnänen (Helsinki, Finland)
	EW157	08:30 - 10:30	Hall 15 Educational Session Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases Chairs	Ana Alastruey-Izquierdo (Madrid, Spain) Rita Oladele (Lagos, Nigeria)
	W0433	08:30	Advances and gaps in the diagnosis and treatment of histoplasmosis	Diego Rodrigues Falci (Porto Alegre, Brazil)
	W0434	08:50	Paracoccidioidomycosis: an update on diagnostic challenges	Beatriz L. Gomez (Bogota, Colombia)
	W0435	09:10	What is new in Talaromycosis	Brown Lottie (London, United Kingdom)
	W0436	09:30	Mycetoma: treatment challenges of a unique neglected tropical disease	Borna Nyaoke-Anoke (Nairobi, Kenya)
	EW155	08:30 - 10:30	Hall 2 Educational Session An update on arboviral disease challenges Chairs	Misa Korva (Ljubljana, Slovenia) Anna Papa-Konidari (Thessaloniki, Greece)
	W0425	08:30	The global epidemiology of arboviral diseases	Chantal B.E.M. Reusken (Bilthoven, Netherlands)
	W0426	08:50	Arboviral diseases transmitted by mosquitoes	Luisa Barzon (Padua, Italy)
	W0427	09:10	Aboviral diseases transmitted by ticks	Joanna Maria Zajkowska (Białystok, Poland)
	W0428	09:30	Arboviral diseases transmitted by sandflies	Rémi Charrel (Marseille, France) Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Infectiologists
	SY150	08:30 - 10:30	Hall 3 2-hour Symposium Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges Chairs	Lindsey Ann Edwards (London, United Kingdom) Ed J. Kuijper (Leiden, Netherlands)
	S0405	08:30	How can we recognise and deal with adverse events of Faecal Microbiota Transplantation?Serena Porcari (Roma, Italy)
	S0406	09:00	What to check? – An attempt at evidence-based donor screening	Elisabeth Terveer (Leiden, 
	E0848	Efficacy of dimercaptosuccinic acid in combination with imipenem in a murine model of experimental sepsis due to metallo-ß-lactamase-producing Pseudomonas aeruginos	a.S. Herrera-Espejo* (Seville, Spain), M. Bouvier, J. Findlay, L. Ceballos- Romero, J. Pachón, J.M. Cisneros, M.E. Pachón- Ibáñez, P. Nordmann
	EF117	09:30 - 10:30	Arena 4 e	Poster Flash Session C. diff challenges: insights into treatment, monitoring, and infection prevention Chair Kerrie Davies (Leeds, United Kingdom)
	E0849	Epidemiology, risk factors, and outcomes of nosocomial Clostridioides difficile infections: a cohort study in a tertiary hospita	l.L. Ruiz Salazar* (Madrid, Spain), T. Mata Forte
	E0850	Long-read or short-read sequencing in Clostridioides difficile infection surveillance?M. Brajerová* (Prague, Czech Republic), M. Brajerova, P. Kinross, P. Drevinek, M. Krutova
	E0851	“Beyond C. difficile Colitis”: Exploring the Role of Fidaxomicin in preventing concomitant and secondary bloodstream infections in patients with Clostridioides difficile coliti	s.D.F. Bavaro* (Milan, Italy), D. Schumann, A. Cilli, L. Diella, D. Barbanotti, D. Mondatore, F. Medioli, M. Casana, A. Belati, L. Bussini, V. Cento, R. Epis, M. Bartoletti
	E0853	Comparison of bezlotoxumab versus nobezlotoxumab on recurrence in high-risk patients with Clostridioides difficile infection	C. Arena* (Detroit, United States), A. Abed, R. Kenney, A. Shallal, S. Davis, M. Veve
	E0854	Exploring bacterial contributors to C. difficile colonization resistance: comparative effects of vancomycin and fidaxomicin in humanised mice	E. Montenegro-Borbolla* (Lausanne, Switzerland), L. Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery
	E0855	An optimised vancomycin dosing regimen is effective against C. difficile, reduces gut microbiota impact and prevents recurrent C. difficile infection in a human in vitro gut mode	l.J. Freeman* (Leeds, United Kingdom), C. Normington, E. Clark, K. Bentley, J. Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M. Wilcox, K. Davies
	E0856	Cost and resource utilization of fidaxomicin in risk patients with recurrent or refractory Clostridioides difficile infection	M. Engelhard* (Cologne, Germany), I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff
	E0857	Impact of a cohorting intervention on the incidence of hospital-acquired Clostridioides difficile infection (CDI): an interrupted time series analysis	C.D. Moschopoulos* (Athens, Greece), M. Tsakona, S. Grigoropoulou, P. Kazakou, M. Kostoula, I. Kliani, C. Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras, D. Kavatha
	ME165	11:00 - 12:00	Hall 12 Meet-the-Expert How to use citizen science for public health
	M0450	11:00	Anna Noel-Storr (Leamington Spa, United Kingdom)
	M0451	11:12	Jani Sormunen (Turku, Finland) Co-organised with: European Centre for Disease Prevention and Control (ECDC)
	SY164	11:00 - 12:00	Hall 15 female participants (EAGLE-J)Y. Kayama* (Tokyo, Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Mozzicato, S. Ura
	E0889	11:36	Efficacy of Ceftolozane/Tazobactam v	s. Ceftazidime/Avibactam in the Treatment of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa: a multicentric retrospective study from the SUSANA cohor	t.A. Bitti* (Sassari, Italy), A. De Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S. Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Socio, P. Morelli, P. Bonfanti, G. Madeddu
	E0890	11:42	Experience of dalbavancin use for unlicensed indications in a UK tertiary infectious diseases setting	C. Darlow* (Liverpool, United Kingdom), J. Parsons, D. Lucy, N. Wong
	E0891	11:48	Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcareassociated and hospital-acquired gram-negative bacterial bloodstream Infections (BSI) : Hierarchical composite endpoint analysis with DOOR and generalised pairwise comparisons	M. Hardy* (Maroochydore, Australia), D.L. Paterson, M. Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N. Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, V. Thamlikitkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris
	EF124	11:00 - 12:00	Arena 3 e	Poster Flash Session Thinking outside the box in urinary tract infection Chair Özlem Kurt Azap (Ankara, Türkiye)
	E0892	Targeted NGS: a promising approach for pathogen detection of urinary tract infection	W. Gao* (Beijing, China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B. Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang
	E0893	Turnaround time of just four hours from sample collection to informed decision-making for complicated urinary tract infections in a urology ward, using culture-independent metagenomics	A.B. Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. Asadi, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner, R. Ahmad
	E0894	Identification of Microorganism Types in Urinary Tract Infections Using Machine Learning and Flow Cytometry	E. Flores* (Alicante, Spain), I. Gutierrez, R. Torrreblanca, A. Blasco, R. Carbonell, M. Lopez- Garrigós
	E0895	A New Approach In Diagnosis Of Urinary Tract Infections	B. Dinc* (Ankara, Türkiye), F. Kırca, S. Kazcı, Ö. Uslu, N. Çöplü
	E0896	Diagnosis of urinary tract infections: from machine learning to clinical practice	E. Flores* (Alicante, Spain), R. Torrreblanca, I. Gutierrez, R. Carbonell, L.G. Maite, A. Blasco
	E0897	Strategic testing optimisation practices for urinary tract infections (STOP-UTI): findings from LMIC hospital setting	S. Sarika* (Tamil Nadu, India), B. Rithik Dharan
	E0898	Rapid culture-independent mass spectrometry based proteomics methods for improving urinary tract infection diagnostics	S. El-Ali* (Gothenburg, Sweden), L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E. Moore
	E0899	Unraveling the complexity: Corynebacterium diversity and antimicrobial resistance hub in the urinary tract ecosystem	E. Cappelli* (Porto, Portugal), A. Morais, T. Ribeiro, L. Peixe
	E0900	Active surveillance in the diagnosis of sexually transmitted infections: performing PCR in negative urine cultures	A. Castellano Verdasco* (Lleida, Spain), 
	SY162	11:00 - 12:00	Hall 11 1-hour Symposium Antimicrobial stewardship across the lifespan from paediatrics to geriatrics Chairs	Lucy Catteau (Brussels, Belgium) Priya Nori (New York, United States)
	S0444	11:00	Antimicrobial Stewardship in paediatrics across different settings	Taylor Morrisette (Charleston, United States)
	S0445	11:30	Stewardship in geriatrics: an exceedingly important target	Dafna Yahav (Ramat-Gan, Israel)
	ME166	11:00 - 12:00	Hall 13 Meet-the-Expert Implementing AI in microbiological diagnostics: practical steps and quality control
	M0452	11:00	Oliver Nolte (Zürich, Switzerland)
	M0453	11:12	Jennifer Dien Bard (Los Angeles, United States) Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)
	SY163	11:00 - 12:00	Hall 14 1-hour Symposium People-centred approach to strengthening the AMR response at primary care Chairs	Benedikt Huttner (Geneva, Switzerland) Mirfin Mpundu (Lusaka, Zambia)
	S0446	11:00	Implementation of WHO’s people-centred interventions	Nienke Van De san	De Bruinsma (Geneva, Switzerland)
	S0447	11:30	Opportunities for strengthening AMR interventions in primary healthcare	Sholpan Kaliyeva (Karaganda City, Kazakhstan) Co-organised with: World Health Organisation (WHO)
	OS122	11:00 - 12:00	Hall 16 1-hour Oral Session Serious games - a serious business Chairs	Christian Kraef (Copenhagen, Denmark) Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)
	O0878	The development process, impact and implementation of an educational VR-module in infection prevention and control for medical students and healthcare workers in The Netherland	s.A. Tostmann* (Nijmegen, Netherlands), O. Coenen- Bouwman, B. Schippers, F. Luk, M. Graner, F. Van Hoek, N. Stikkelbroeck, M. Dronkers
	O0879	Impact of Professional Background on Performance in To	REIMC: A Gamified Medical Knowledge Platform	A. Blanco-Di Matteo* (Pamplona, Spain), M. Morante Ruiz, M. Riesgo Magaña, M. Martín García
	O0880	Serious games and storytelling to enhance adolescents' capabilities for decision-making regarding meningococcal vaccination: a monocenter study	T. Morris* (Saint-Etienne, France), S. Essalim, K. Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho- Nevers, A. Gagneux-Brunon
	O0881	‘The Sepsis Olympics': Raising awareness of the Sepsis 6 care bundle in an Irish Hospital through a clinical challenge gam	e.C. Uhomoibhi* (Dublin, Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra
	O0882	Improvement of learners' confidence in antibiotic Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. Russo, P. Mc Gann
	O0861	Factors that affect plasmid transfer in multispecies biofilms	H.Y. Liu* (Norwich, United Kingdom), M. Yasir, E. Trampari, G. Langridge, M. Webber
	O0862	Identification of the czc metal efflux operon on a new plasmid type in a Pseudomonas aeruginosa clinical isolate belonging to ST357 O11A. Valcek* (Brussels, Belgium), D.I. Costescu Strachinaru, P. Soentjens, A. Stoefs, C. Van Der Henst
	OS119	11:00 - 12:00	Hall 7 1-hour Case Session Looking inside endovascular infections Chairs	Claus Moser (Copenhagen, Denmark) Matthaios Papadimitriou Olivgeris (Sion, Switzerland)
	O0863	A Case of Persistent Legionella micdadei Aortitis with Endocarditis: Diagnostic and Therapeutic Challenges	V. Zwart* (Breda, Netherlands), E. Kayabasi, H. De Groot, R. Bentvelsen
	O0864	Management and Prognosis of Vascular Endograft Infections: Case Series	N. Scarpulla* (Napoli, Italy), F. Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. Gallo, E. Durante-Mangoni
	O0865	Fungal frenzy: handling an uncommon etiology in prosthetic valve endocarditis	I. Cafarella* (Naples, Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino, A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante- Mangoni
	O0866	Successful Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus sp	p.: Experience from Seven Cases in a Referral Center	F. Frondizi* (Rome, Italy), G.M. Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. Taddei, G. Scoppettuolo, C. Torti
	O0867	Clinical Features and Outcomes of Gram-Negative Bacterial Endocarditis: A Case Series from a University Hospital	G. Oliva* (Rome, Italy), F. Giovannenze, G.M. Leanza, F. Frondizi, M. Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. Scoppettuolo, C. Torti
	OS120	11:00 - 12:00	Hall 8 1-hour Oral Session Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial Virulence Chairs	Giovanni Delogu (Rome, Italy) Simon Foster (Sheffield, United Kingdom)
	O0868	Bacteria and host responses in both mice and human lung organoid model revealed the role of a novel plasmid pvirhs1 in hypervirulent Carbapenemresistant Klebsiella pneumoniae	Y. Zhang* (Shanghai, China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang
	O0869	Presence and role of hypervirulence-associated markers in Klebsiella pneumoniae groups based on LD50 value in mouse septic model	A. Avdeeva* (Saint-Petersburg, Russian Federation), D. Kandina, E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Sopova, V. Lomonosova, V. Galushka, A. Afinogenova, V. Shapovalova, O. Sulian, I. Ageevets, V. Ageevets, S. Sidorenko
	O0870	Meta-transcriptomic Insights into Host-Pathogen Interactions in Necrotizing Soft Tissue Infections Using Differential Analysis	T. Vashist* (Chandigarh, India), N. Rana, D. Nair, A. Angrup, V. Sharma, C. Tandup, P. Ray, A. Arora
	O0871	Unveiling the hidden virulence of Acinetobacter baumannii: how the lipooligosaccharide core modulates immune responses and enhances interferon-β production	Y.T. Lee* (Taipei, Taiwan, Jakab, Á. Sonnevend, Á. Tóth
	E0944	Genomic multicentre surveillance of VIM-producing Enterobacterales shows spread driven by bacterial clones and plasmids in Germany from 2015 to 2021A. Wendel* (Cologne, Germany), J. Sattler, B. Bader, J. Müller, A. Hamprecht, S. Peter
	E0945	Three distinct routes of virulence-resistance convergence in ST-395 K. pneumoniae from Eastern Europe over the last decad	e.A. Sapre* (Silver Spring, United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R. Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M. Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J. Bennett, P. Mc Gann, M. Martin, F. Lebreton
	E0946	Carbapenemases in Germany in 2024: Report of the German National Reference Centre for Multidrugresistant Gram-negative Bacteria	N. Pfennigwerth* (Bochum, Germany), S. Möller, J. Eisfeld, F. Pankok, A. Anders, S. Gatermann
	E0947	Unravelling divergent genomic modes of transmission of Carbapenemase-Producing Organisms in a single hospital in Singapore between 2019 and 2022V. Koh* (Singapore, Singapore), Z.Q. Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakki, P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, S. Vasoo, K. Marimuthu, O.T. Ng
	E0948	2011-2017 vs 2018-2024: comparison of carbapenem non-susceptibility trends among bloodstream Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa isolates from Greek hospitals: data from the Electronic System for the AMR surveillance-WHONET-Greece	M. Polemis* (Vari, Greece), A. Vatopoulos, K. Tryfinopoulou
	EF132	13:30 - 14:30	Arena 2 e	Poster Flash Session Difficult-to-treat cases in the immunocompromised Chair Nicolas Mueller (Zurich, Switzerland)
	E0949	A case of IRIS nocardiosis	S.K. Dlamini* (Cape Town, South Africa), P. Namale, P. Arnab
	E0951	Concurrent invasive disseminated Nocardia farcinica and Candida infections in a patient undergoing longterm glucocorticoid therapy for autoimmune thrombocytopenia: A case report	N. Zhang* (Bengbu, China)
	E0952	Subcutaneous paeohyphomycosis due to Alternaria infectoria in an immunosuppressed renal transplant recipient: successful multidisciplinary management	E. Vetsiou* (London, United Kingdom), E. Rudd, S. Rai, K. Ahmed, S. Rao-Merugumala, A. Wasif, C. Shaw, A. Abdolrasouli, M. Arias
	E0953	Lung nodules in a patient with breast cancer history… Not everything is cance	r.E. Muñoa Hernández* (Chiapas, Mexico), E. Muñoa
	E0954	Treatment of fulminant Clostridioides difficile infection using bacteria-free stool supernatant in adult hematological patients during chemotherapyinduced aplasia	B.G. Szabo* (Budapest, Hungary), D. Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko
	E0955	Eradication of multidrug resistant Pseudomonas aeruginosa pneumonia in acute lymphoblastic leukemia patient with broad host-range phage	P. Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I. Ferrés, A. Galiana, F. Grill, G. Iraola
	E0956	An Emerging fungal pathogen in immunocompromised hosts: A rare case of subcutaneous abscess caused by Chondrostereum purpureum	P. Kitjacharoenchai* (Bangkok, Thailand), A. Thammahong, J. Vanichanan
	E0957	Unveiling a Rare Simultaneous Central Nervous System infection in an Immunocompromised Patient from Mexico	E. Sienra Iracheta* (Tlalpan, Mexico), A. Magallanes Lopez, J.P. Venzor Castellanos, M.J. Corredor Nassar, A.P. Rodriguez Zulueta P. Kristian
	EF134	13:30 - 14:30	Arena 4 e	Poster Flash Session Infection Controller's Daily Chair Cansu Cimen (Oldenburg, Germany)
	E0967	Mortality and length of stay associated with antimicrobial-susceptible and resistant hospitalonset bloodstream infections at a tertiary referral hospital in Melbourne, Australia	A. Stewardson* (Melbourne, Victoria, Australia), S.J. Curtis, S.L. Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley, A.C. Cheng, D.W. Spelman, A.Y. Peleg
	E0968	MRSA on the rise in neonatal care departments	E. Herkes* (Amsterdam, Netherlands), A. Schoffelen, R. Zwittink, J. Kluytmans, D. Notermans
	E0969	Risk factors for OXA-carbapenemase-producing Enterobacteriaceae acquisition in Israel: a retrospective case control study	M. Amar* (Haifa, Israel), R. Najjar-Debbiny, G. Weber, R. Yasin, A. Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked- Mishan, O. Barnett-Griness
	E0970	Experience providing a rapid, reactive nanopore isolate sequencing service for bacterial outbreak investigation for hospitals in London, UK	S. Raharison* (Nice, France), A. Alcolea-Medina, L.B. Snell, M. Tan, G. Humayun, R. Chang, D. Ward, V. Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. Goldenberg, J. Edgeworth, J. Otter
	E0971	Duration of colonization and time to de-isolation in patients with extended-spectrum beta-lactamase producing non-Escherichia coli Enterobacterales	J. Männer* (S	t.Gallen, Switzerland), V. Steinacher, T. Dörr, M. Schlegel, P. Kohler
	E0972	A tale of three cities: The comparative longitudinal epidemiology of vancomycin-resistant Enterococcus faecium from bloodstream infections at three tertiary care hospitals in Bavaria, Germany	A. Rath* (Regensburg, Germany), B. Neumann, V. Rauschenberger, B. Kieninger, A. Eichner, J. Steinmann, S. Kampmeier, W. Schneider- Brachert
	E0973	Molecular epidemiology and transmission dynamics of vancomycin-resistant Enterococcus faecium in Belgian hospitals (2022-2023)S. De Koster* (Edegem, Belgium), S. Van Kleef-Van Koeveringe, H. Jansens, S. Vandamme, T. Demuyser, M. Vanden Driessche, Y. Glupczynski, S. Malhotra-Kumar, V. Matheeussen
	E0974	Increasing Prevalence of Linezolid-resistant Enterococci: Outbreak or Overuse?R. Traynor* (Cork, Ireland), G. Brennan, I. O Callaghan, E. Keily, E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A. Doherty, C. Hickey
	E0975	Continuous 2-year surveillance for airborne fungi at hospitals in the same city: Impact of season, construction, a construction accident and HEPAfiltered/ positive pressure rooms	M.H. Nguyen* (Pittsburgh, United States), C. Clancy, Z. Wilkins, Y. Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann, A. Ayres, S. Graham
	EW174	13:30 - 15:30	Hall 11 Educational Session Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia Chairs	Fusun Can (Istanbul, Türkiye) Jeroen Schouten (Nijmegen, Netherlands)
	W0481	13:30	Artificial Intelligence to predict VAPMiia Jansson (Oulu, Finland)
	W0482	13:50	Metagenomic approach to VAP diagnosis	Jacques 
	O0938	Combined use of (1,3)-β-D-glucan and PCR in oral wash for Pneumocystis jirovecii pneumonia diagnosis in non-HIV population	A. Falcó Roget* (Mataró, Spain), A. Falcó-Roget, A. Albasanz-Puig, A.B. Pérez, S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len, I. Ruiz-Camps, M.T. Martín-Gómez
	O0939	Iron levels in bronchoalveolar lavage fluid of hematological patients with suspected invasive pulmonary aspergillosis and their association with 12- week mortality: a retrospective cohort study	H. Lamberink* (Amsterdam, Netherlands), J. Heijmans, A. Wagemakers, K. Van Dijk
	SY168	13:30 - 15:30	Hall 2 2-hour Symposium Staphylococcus aureus: its expansion dynamics and interactions with its pals Chair Barbara C. Kahl (Münster, Germany)
	S0457	13:30	S. aureus and its special relationship to S. epidermidis Andreas Peschel (Tübingen, Germany)
	S0458	14:00	Computational and in vitro evaluation of probiotic treatments for nasal S. aureus decolonization	Silvio Daniel Brugger (Zurich, Switzerland)
	S0459	14:30	Clonal population expansion of S. aureus occurs due to escape from a finite number of intraphagocyte niches	Simon Foster (Sheffield, United Kingdom)
	S0460	15:00	How bacteriophages and pathogenicity islands drive the evolution of S. aureus John Chen (Singapore, Singapore) Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)
	EW172	13:30 - 15:30	Hall 3 Educational Session Beyond the gift of life: viral infection during pregnancy Chairs	Gülsen Özkaya Sahin (Lund, Sweden) Simona Ruta (Bucharest, Romania)
	W0473	13:30	Hepatitis B during pregnancy: diagnosis, management and outcome	Tba
	W0474	13:50	RSV and Influenza during pregnancy: management and outcome	Monika Redlberger-Fritz (Vienna, Austria)
	W0475	14:10	Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guideline	Marianne Leruez-Ville (Paris, France)
	W0476	14:30	Novel methods of vaccine administration to newborns	Tba Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of Sub	Saharan Africa (GHASSA)
	SY169	13:30 - 15:30	Hall 4 2-hour Symposium Molecular epidemiology, resistance mechanisms and management of Gramnegative bacteria Chairs	Agnes Maria Sonnevend (Pécs, Hungary) Kyriaki Xanthopoulou (Cologne, Germany)
	S0461	13:30	Globally emerging resistance patterns of Enterobacterales	Sasheela Ponnampalavanar (Kuala Lumpur, Malaysia)
	S0462	14:00	Non-fermenters still important globally: a review of spread and resistance	Anupa Thampy (Vellore, India)
	S0463	14:30	Innovative rapid diagnostic methodologies for Gramnegative pathogens	Laurent Dortet (Le Kremlin- 
	O0932	Regulation of Novel Genes and Their Downstream Functions in the AI-2-Mediated Quorum Sensing System of Klebsiella pneumoniae	X. Chu* (Beijing, China), Q. Yang
	O0933	Exploring structural differences in biofilms of smooth and rough Mycobacterium abscessus clinical strains through confocal laser scanning microscopy	C. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, M.C. Muñoz-Egea
	O0934	Antibacterial and biofilm eradication of mupirocinloaded nano-emulsions	Z. Najmi* (Novara, Italy), A.C. Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Rimondini, D. Dupin
	OS126	13:30 - 15:30	Hall 8 2-hour Oral Session Emerging viruses, diverse threats Chairs	Luisa Barzon (Padua, Italy) Karin Stiasny (Vienna, Austria)
	O0910	Epidemiological and clinical features of mpox during the clade Ib outbreak in South-Kivu, Democratic Republic of the Congo: a prospective cohort study	I. Brosius* (Antwerp, Belgium), E. Hasivirwe Vakaniaki, S. Sabiti Nundu, L. Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P. Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, Y. Mujula, A. Tsoumanis, C. Van Dijck, A. Alengo, L. Mutimba-Mambo, F. Mweshi Kumbana, J. Babingwa Muunga, D. Mazambi Mambo, J. Wakilongo Zangilwa, S. Bilembo Kitwanda, S. Houben, N. Hoff, J.C. Makangara-Cigolo, E. Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. Kindrachuck, N. Low, P. Katoto, E. Bwenge Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka, S. Ahuka-Mundeke, K. Vercauteren, T. Wawina- Bokalanga, J.J. Muyembe-Tamfum
	O0911	Tracing the origin, spread and molecular evolution of Dengue type 1 cases occurred in Northern Italy in 2023G. Romano* (Pavia, Italy), G. Ferrari, A.M.G. Pitrolo, F. Rovida, A. Piralla, F. Baldanti
	O0912	Dengue Country Risk Estimation: Vector Suitability and Imported Activity 2024.M. Torres Portillo* (Toronto, Canada), K. Williams, R. Lababidi, A. Thomas, K. Khan
	O0913	Rat HEV in humans in Germany: presence but low detection rate, a screening study 2022 - 2023L. Mueller* (Berlin, Germany), M.L. Schmidt, T. Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J. Jansen, J. Melchert, T. Mauno, C. Drosten, R. Johne, V.M. Corman
	O0914	Emergence of new enterovirus D68 lineage in Europe in 2023 associated with distinct amino acid substitutions in VP1 protein	A. Hirvonen* (Vantaa, Finland), C.K. Johannesen, P. Simmonds, T.K. Fischer, H. Harvala, K.S.M. Benschop
	O0915	Health-economic impacts of chikungunya vaccination in 34 countries	J. Zhou* (Oxford, United Kingdom), N. Salant, D. Smith, D. Hollingsworth, K. Pouwels, S. Radoykova, J. Lord, K. French
	O0916	Clinical importance of a new tick-borne flaviviridae virus, Alongshan Virus: retrospective serologic and molecular study in Switzerland	F. Tagini* (Lausanne, Switzerland), O. Opota, A. Eggermann, A. Coste, G. Greub
	O0917	From Trade Routes to Transmission Routes: Risk Assessment of Japanese Encephalitis Outbreak in Pakistan under China-Pakistan Economic Corridor Using One Health Approach	S. Ahmad* (Tampere, Finland)
	O0918	Building a screening protocol for the detection of Orthobunyavirus oropoucheense infection	G. Gagliardi* (Milan, Italy), D. Mileto, A. Mancon, L. Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli, A. Lombardi, A. Dolci
	O0919	Substantial viral diversity in bats and rodents from East Africa: insights into conservation, recombination, and co-circulation	D. Wang* (Shenzhen, China) OS128	13:30 - 14:30	Hall 9 1-hour Oral Session AI Aiding AMS Chairs	Marlieke De Kraker (Geneva, Switzerland) Bhanu Sinha (Groningen, Netherlands)
	O0925	Using natural language processing to understand free-text antibiotic prescriptions	A. Martin* (Middlesbrough, United Kingdom), L. Christopher
	O0926	Enhancing Antimicrobial Stewardship Through Collaboration Between an Intelligent System and Infectious Disease Experts	H.M. Wei* (Taichung, Taiwan, China), Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P. Hwang
	O0927	Augmented Intelligence in Infectious Diseases (AI2D) as an antimicrobial stewardship tool for early antibiotic discontinuation in suspected lower respiratory tract infections	J.L. Lim* (Singapore, Singapore), P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan, S.Y. Thien, S.L.S. Tang, L.X.T. Lee, Y.C.D. Yii, P.Y. Zhou, Y. Wang, S.J. Chung,L.H.A. Kwa
	O0928	Virtual antimicrobial stewardship ward rounds: predicting antibiotic course stopping decisions in hospitals using machine learning	K. Yuan* (Oxford, United Kingdom), J. Wei, C.H. Yoon, Q. Gu, W. Walker, T. Zhu, D. Eyre
	O0929	Prospective evaluation of a machine learning-based decision support system for intravenous-to-oral antibiotic switchin	g.W. Bolton* (London, United Kingdom), R. Wilson, P. Georgiou, A. Holmes, T.M. Rawson, M. Gilchrist